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GENERAL INTRODUCTION 
 
1.1 MCD definition and impact  
Malformations of cortical development (MCD) are a group of disorders characterized by a 
congenital abnormal structure of the cerebral cortex. In general, malformations are defined 
as structural abnormalities caused by a disturbance in cell organization or function within 
a tissue type. When a disturbance results in an abnormal structure of the cerebral cortex 
we call this: malformations of cortical development. MCD are heterogeneous as a group, as 
they include several different structural abnormalities, and they have a diverse array of 
causes, both genetic and environmental.  
 
A patient with a MCD may present to a physician with different neurological symptoms. 
These signs and symptoms depend on the regions of the brain that are affected, on the 
severity of the malformation, and on how much the affected regions still have residual 
neurological functions or whether normal brain areas can compensate for loss of functions 
(plasticity). As MCD are cortical malformations, functions meant here are the cerebral 
cortical functions, such as the motor function of the limbs, language development and 
visual functions. For example, a child may present with a spastic hemiparesis if only one 
hemisphere is affected, with drooling and a speech disorder if both perisylvian areas are 
affected, or with severe psychomotor delay when the entire cortex is abnormal. Intellectual 
development can range from normal to severe mental retardation. As abnormalities of the 
cortex increase the risk of epilepsy, many MCD patients will present with epilepsy or 
develop epilepsy later in life.1 Seizures can be the only clinical feature, and then the focal 
nature of the epilepsy based on the seizure semiology or the EEG may suggest the presence 
of a MCD. Although the treating physician may suspect a cortical malformation in some 
cases, it is impossible to determine the nature of the abnormality based on the clinical 
features alone. To diagnose a MCD imaging of the brain is essential, preferably by MRI 
scan. This means that any patient with congenital neurological deficits and/or epilepsy 
without an established cause should be evaluated by MRI to exclude/diagnose a MCD. 
 
The prevalence and incidence of MCDs are not easy to estimate. Without a brain MRI, one 
cannot say which patients are affected and even then some MCD are missed if not 
specifically looked for. In a population based cohort of 96 American children with 
congenital hemiparesis, 18% had a MCD as the underlying abnormality.2 In this population 
the prevalence of congenital hemiparesis was 5:10.000. In most patients with epilepsy a 
brain MRI is performed, so MCD have been reasonably well investigated in this group. 
Prevalence figures are reported from 5-10% in unselected groups to 5-20% in patients with 
intractable epilepsy, depending on age and selection of the cohort.3-7 Epilepsy is generally 
reported between 0.5 and 1% of the population. Even with this limited information, it is 
clear that MCD are not rare and the morbidity associated with MCD is significant.  
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1.2 MCD subtypes 
Malformations of cortical development can be classified into several subgroups, based on 
the MRI. The revised Barkovich classification is most widely accepted, and is based on the 
proposed underlying mechanisms with a mixture of genetic and imaging criteria.8 
Although this classification is not ideal due to these mixed criteria and the fact that not all 
patients fit in this model, it is useful to guide the diagnostic process and to group patients 
with a similar disease. Lissencephaly was the first type of MCD that was recognized as a 
cause of severe developmental disability over 50 years ago.9 At the time a definite 
diagnosis could only be made by examination of the brain post-mortally. The advent of 
neuroimaging possibilities, in particular CT scanning in the seventies and MRI scanning in 
the eighties of the 20th century, enabled physicians to diagnose cortical abnormalities 
during life. Lissencephaly, being the ‘first MCD’, is also the subtype best described and 
understood. The brain MRI shows specific features of a thickened cortex with reduced or no 
gyration with a predilection for the occipital regions and EEGs show typical high voltage 
beta activity. Clinically, about all patients have epilepsy and psychomotor delay. The 
severity correlates with the severity of cortical involvement on MRI [this thesis, chapter 
3.1]. 
 
At the same time much progress was made in the possibilities of genetic research. Over the 
last decades this has led to insights into the causes of malformations of cortical 
development. For some cortical malformations, e.g. lissencephaly, much is now known 
about pathogenesis and inheritance. In others, causes are yet to be discovered, and 
appropriate clinical and radiological syndrome classification will provide the basis for 
future research. An etiological diagnosis is the goal, as this offers parents the best 
information on the cause, prognosis, and recurrence risk and the option of prenatal 
diagnosis in a next child. Genetic counseling is important for parents of an affected child, 
but also for patients themselves especially in those types of cortical malformations that 
may show a variable phenotype in families, e.g. in filamin A related heterotopia. 
 
In the forthcoming years, classification, etiological diagnoses, and clinical follow-up will 
provide possibilities for the development of improved treatment for these children and 
adults. At the moment no specific treatments are available and care is focused on treating 
the complications of cortical malformations, such as epilepsy and cerebral palsy. For some 
patients with intractable epilepsy, surgery can be successful, and for those the recognition 
of the cortical malformations responsible for their seizures is of vital importance. Finally, 
careful observation of patients with abnormalities of cortical development can aid 
understanding of, and research into, the processes of human brain development. 
 
To reach for these goals the first priority lies in the recognition and description of patients 
with MCD. Cortical malformations are not always easy to recognize on brain CT or MRI, or 
their relationship with other problems is not noted. Correct interpretation can lead to a 
molecularly confirmed or syndrome diagnosis, and to improved care for the individual 
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patient. On a group level, correct interpretation will improve the knowledge of known 
phenotypes and allow recognition of new phenotypes. 
 
In general, malformations of cortical development are caused by an interruption of normal 
cortical development due to a lack of normal gene expression, the production of abnormal 
protein or a disruptive factor such as ischemia or an infection. Many genes and proteins 
are involved in the development of the human brain and we are just beginning to 
understand their function and interaction. For the understanding of the clinical 
manifestations and underlying causes, basic knowledge about prenatal brain development 
is helpful. This allows timing of the underlying insult, but also more understanding of the 
pathophysiological process and of the classification of the MCD.  
 
This introduction will focus on global understanding of cortical development, classification 
of malformations and known causes. It will not go into details on the development of the 
cerebellum, mesencephalon and midline structures. First the normal cortical development 
is briefly discussed to enable a more thorough description of the MCD subtypes in the later 
paragraphs. 
 
2.1 Normal development of the cerebral cortex 
In humans the formation of the cortex is completed around birth. At that time, the human 
brain contains around 1x1011 neurons. To reach this number, one can calculate that on 
average new neurons are being generated at the rate of about 250,000 per minute during 
the nine months of gestation.10 The newborn brain weighs approximately 350-400 grams, 
while in adulthood this has grown to 1300-1400 grams. After birth, further brain 
development is focused on myelination and synaptic network formation and organization. 
It is said that there are more synapses in the cerebral cortex than there are stars in the 
galaxy (around 1x1015 synapses).11 Also, the generation of glial cells continues during the 
first year. Some neural precursors remain and retain the ability to generate neurons on a 
modest scale. 12 
 
The development of the cerebral cortex during the nine months of gestation is a 
complicated and intricate process, and it can be best understood by dividing it in three 
steps. These are overlapping stages of proliferation and differentiation, migration and 
organization. The normal six-layered structure of the neocortex is strictly organized. There 
are two main types of neurons in the cortex: excitatory glutamatergic cortical neurons and 
locally projecting GABA-ergic inhibitory interneurons. Both groups have a large number of 
subtypes that can be differentiated morphologically, electrophysiologically or molecularly, 
however for the understanding of current insights in the organization of the cortex it is 
most informative to focus on these main groups. 
 
2.2 Early embryonic phase of the prosencephalon  
By the fourth week of embryonic development the neural tube has closed and on the 
anterior or rostral side of the embryo three vesicles form, the prosencephalon, the 
General Introduction 
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mesencephalon and the rhombencephalon. The most caudal vesicles, the mesencephalon 
and the rhombencephalon, will give rise to the midbrain and the cerebellum. The most 
distal vesicle, the prosencephalon cleaves horizontally to separate the optic vesicle and 
olfactory bulbs, transversely to separate the diencephalon from the telencephalon and 
sagitally to divide the telencephalon into two ventricles (see figure 1). The telencephalon is 
the precursor of the cerebrum and the two ventricles are lined with the cells that will 
populate the brain and form the hemispheres. Many genes and proteins are crucial during 
this development, the most important being the cholesterol dependent Sonic hedgehog 
protein that is secreted by the prechordal mesoderm and induces a cascade of activation of 
other genes leading to the correct dorsoventral patterning.  
 
 
 
Figure 1: schematic representation of the early prosencephalon, including the eye-buds, mesencephalon 
and rhombencephalon. 
 
2.3 Proliferation 
The ventricular surface contains the germinal zones with the progenitor cells that will give 
rise to all neurons and glial cells. The most important time for the generation of neurons 
and glial cells is during the 2nd tot 4th month of gestation. Initially, proliferation takes place 
in the ventricular zone, close to the ventricular surface. In this first proliferative phase, 
progenitor cells divide symmetrically. This means that each mitosis creates two equal 
daughter progenitor cells. This symmetric mitosis follows a specific pattern in which a 
progenitor cell starts its mitosis in the periphery of the ventricular zone, then migrates to 
the ventricular surface, divides into two daughter cells and then both these progenitor cells 
migrate back to the periphery.13 The significance of this back-and-forth pattern is not 
completely understood, but it is probable that the progenitor cells need to maintain contact 
with the ventricular surface. The number of cell-cycles that occurs during the first period of 
symmetric division determines the total number of cortical neurons, and therefore the size 
of the brain. The growth in this phase is what differentiates the size of human brains from 
that of primates.  
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During the third month of gestation the number of progenitor cells stabilizes and the 
second phase of proliferation starts. The progenitor cells are now recognizable as radial 
glial cells that are oriented perpendicular to the ventricular surface. Their radial extension 
spans the entire neocortical wall and maintains contact with both the ventricular and pial 
surfaces. The radial glial cells begin to divide asymmetrically, thereby producing one 
progenitor cell and one postmitotic neuron. These newborn neurons migrate to their 
destination in the cortex by using the radial extension of the radial glial cells as a guide in 
the migration to their destination (see figure 2).  
In addition, the radial glial cells generate a secondary population of progenitor cells called 
intermediate progenitor cells. The intermediate progenitor cells migrate to the overlying 
area where they form the second germinal zone, called the subventricular zone. Here they 
generate more neurons for the upper cortical layers and appear to do so by symmetric 
division. The progenitor cells of the subventricular zone also produce part of the 
interneurons in humans. Another group of interneurons is produced in the ganglionic 
eminences, the future basal ganglia, and these will migrate tangentially.14 
Finally the radial glial cells differentiate into astrocytes or ependymal cells. They probably 
also produce oligodendrocytes. Some remain postnatally as astrocytic stem cells that retain 
the ability to generate neurons and glia. By 20-24 weeks of gestation the total number of 
neurons is complete. Glial multiplication and differentiation mainly takes place from 
approximately 5 months of gestation to at least one year postnatally. 
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Figure 2: Subsequent stages of proliferation. The radial glial cells extend from the ventricular surface 
(VZ) to the outer, pial surface (pia). The neural progenitor cells show a cell-cycle dependent oscillation 
and move towards the VZ in preparation of mitosis. Symmetric division (symm) results in two equal 
progenitor cells and this process is repeated. Asymmetric divisions (asymm) create post-mitotic neurons 
that first appear multipolar, and then convert to a bipolar appearance with a migratory process 
wrapped around the glial extension and an axon trailing behind.  
 
S: S-phase in cell cycle; duplication of chromosomes, G2: G2-phase in cell cycle; preparation for division, M: 
mitosis, symm: symmetric division, asymm: asymmetric division. 
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Important genetic pathways involved in the division of neural progenitors are the Notch 
receptor pathway, the ErB receptor pathway (ligand neuregulin) and the fibroblast growth 
factor receptor.15.16,17 Beta-catenin signaling is important in the decision to differentiate or 
proliferate, and in the timing of migration.18 
 
2.4 Migration 
During the process of proliferation, postmitotic neurons already start their migration to 
their target area in the cortex. The neurons use the guidance of the radial glial cell by 
attaching to the radial fiber, moving outward and disengaging at the correct location.  
This process is highly organized. Radial glial cells that border each other in the ventricular 
zone produce neurons that will border each other in the neocortex. A group of radial glial 
cells born to a single progenitor cell is called a proliferative unit. Radial glial cells each 
produce a proliferative unit that migrate along their radial extension to the cortex, each 
passing through those gone before to finally form the six-layered cortex in an inside-out 
fashion. The target layer and the order of these neurons therefore depend on the time of 
their origin. In other words, a proliferative unit gives rise to an ontogenetic column (see 
figure 3).19,20 The first wave of symmetric division determines the number of proliferative 
units and the second wave of asymmetric division determined the size of the ontogenetic 
column. Also, the number of asymmetric divisions determines the number of neurons 
created in each radial column and therefore the thickness of the cortical layer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: cortical organization based on the proliferation of neural progenitors at the ventricular surface 
(‘proliferative units’) producing postmitotic neurons in organized inside-out columns. 
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To migrate, neurons wrap a thin protrusion around the glial fiber and glide along in 
outward direction by forming and releasing neuron-glial adhesion. In this movement the 
neuronal centrosome enters the leading process first, followed by the cell soma. This is 
regulated by the PAR complex.21 Different organelles move along the microtubule 
cytoskeleton and this is organized by cytoplasmic dynein with co-factors LIS1 and 
doublecortin. The motor behind neuronal movement is formed by actin-myosin 
contractility.21 
 
Neurons produced in the subventricular zone migrate later than those generated in the 
ventricular zone, but follow the same pattern. Most radially migrating neurons are 
destined to become excitatory glutamatergic cortical projection neurons.20 
  
Interneurons are the main inhibitory neurons in the brain and show a different migration 
pattern. In the rodent these GABA-ergic interneurons arise from the medial, lateral and 
caudal ganglionic eminences and migrate tangentially to their destination (see figure 4). In 
humans however, a large proportion interneurons are generated in the subventricular 
zone.22 Most research has been done on interneurons of the olfactory system en 
hippocampus as these systems are being populated by new neurons even during 
adulthood.12 Cortical interneurons do not use a radial glial fiber to guide their path, but are 
guided by chemical cues. They are polarized cells that display a leading process and a 
shorter trailing process. The leading process continuously branches out, and the branch 
best oriented towards the guidance cues in the environment becomes stabilized.23  
 
 
Figure 4: schematic coronal section of the embryonic neocortex, illustrating radial migration (A, straight 
arrows) to the cortex, as opposed to tangential migration (B, curved arrows) from the medial and lateral 
ganglionic eminence (MGE and LGE). VZ = ventricular zone. 
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At the same time, between 9 and 20 weeks, the midline structures of the brain are formed: 
the corpus callosum, septum pellicidum, optic chiasm and hypothalamus. The corpus 
callosum is formed by cortical axons from the cingulate cortex that cross the midline 
attracted by specialized glial cells that express chemoattractants (of the Netrin family). 
They first form the rostrum, then the genu and lastly the posterior splenium. Disturbances 
of callosal development influence the final gyral pattern, especially that of the medial 
surface of the cortex (cingulate gyrus). 
 
Gyration is largely a passive process driven by proliferation and migration. The human 
brain has a much larger surface area than a rodent brain, while the thickness of the cortical 
layer is only mildly larger. This follows from the increased number of symmetric cell 
divisions in the first phase of proliferation, resulting in a much greater number of 
ontogenic columns. Folding the cortex into gyri enables this larger surface area to fit in as 
small a volume as possible. This does not explain the fairly stereotypical form of the brain 
with recognizable sulci such as the calcarine sulcus or sylvian fissure. This pattern 
probably depends on tension by tracts of axonal cortico-cortical connections that are 
present from around the time of the intermediate zone onwards.24 
At birth a human infant brain has the approximate same number of neurons it will have in 
adulthood. Further growth in volume results from glial cell proliferation and myelination. 
Finally the cortex will be 3.5-4 mm thick. The full gyration pattern emerges in the last part 
of gestation (after 35 weeks) and one should realize that it is not finished in preterm 
infants. 25,26,27 
  
Table 1 and figure 5 (reprinted with permission, copyright Radiology 1996)25:  
Gyration stages I-V can be determined by scoring the development of sulci and gyri in different areas of 
the brain: gyration is first seen in the central sulcus, occipital medial (or calcarine) sulcus, followed by 
occipital, parietal and temporal-posterior regions and lastly in the temporal-anterior and frontal areas. 
The figure showed the stages of gyration: 1; no to shallow sulci, round gyri, 2: gyri broader than 
deepness of sulci, 3: equal broadness and deepness and gyri take on square aspect, 4: sulci are deeper 
than gyri are broad, square gyri, 5 branching into secondary and tertiary gyri.  
 
 
 PCA (wk) Central 
sulcus,  
Occipit med 
Occipital, 
Parietal,  
Temp-posterior 
Frontal,  
Temp-
anterior 
 
I 
 
 
30-32 
 
3 
 
2-2.5 
 
1 
II 
 
32-34 4 2.5-3 2-2,5 
III 
 
34-37 5 3-4 2.5-3 
IV 
 
37-40 5 4-4.5 3.5-4 
V 
 
>41 5 5 4.5-5 
PCA: postconceptional age 
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postnatal
3-4 wks: neural tube closure
2-3 mo: prosencephalon development
3-4 mo: proliferation
3-5 mo: migration
5 mo-postnatally: organization
Birth to end of puberty: myelination
Prenatal development
2.5 Organization 
From the fifth month of gestation to well into puberty further organization of the cortex 
consists of differentiation of neurons and glial cells, orientation and alignment of cortical 
neurons, sprouting of axons and dendrites, formation of synapses, selective elimination of 
cells and synapses and myelination. Some controversy exists as to whether postmitotic 
neurons are equipotent and assume their network function based on the environment 
they migrate into (tabula rasa hypothesis) or that they are genetically programmed to a 
specific function (the protomap hypothesis). The latter hypothesis has gathered some 
convincing experimental support.24,28 Primordial cortical areas can assume their function 
by making the appropriate connections; for example the future somatosensory cortex 
needs to attract input from the ventroposterolateral nuclei of the thalamus.  
 
Further differentiation of the cortex is orchestrated by the interplay between gradients of 
different molecules, the expression of different genes and the interaction between 
neurons. Different patterning centers secrete different families of signaling molecules. The 
list of molecules and genes involved is extensive and growing by the month, so it is not 
feasible to go into detail. Examples of important signaling molecules are fibroblast growth 
factor secreted by the anterior cortex, Wnts or bone morphogenetic protein by the 
posteromedial border, and epidermal growth factors by the lateral areas.24 These gradients 
stimulate or suppress expression of important genes in the surrounding areas resulting in 
expansion and specialization of the different cortical areas.27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: timeline of human cortical development, peak times. X-axis represents months of gestation. 
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3. Malformations of cortical development 
At all stages of cortical development trouble may arise, and abnormal development can 
result in abnormal anatomy. The gold standard of the diagnosis is microscopic 
neuropathology, but improvements in neuroimaging techniques enable the diagnosis of 
many malformations of cortical development during life. The investigation of choice to 
visualize the central nervous system is MRI imaging, while ultrasound may give a good 
indication in neonates as well. Subtle abnormalities on MRI can be difficult to interpret in 
the neonatal period due to the high water content of the brain, and a repeat MRI in the 
second year of life may be necessary to reach a definite diagnosis. The appearance of the 
cortex also changes on MRI during the first years of life due to myelination, and MCD can 
become apparent on follow-up.28,29  
The phenotype of the different malformations of cortical development depends on the 
stage of development that is disturbed. Disruption of neurulation resulting in neural tube 
defects can be located on the caudal or rostral side. Neural tube defects (dysraphism) are 
not subject of this thesis; however they can coincide with malformations of cortical 
development such as polymicrogyria or periventricular nodular heterotopia. This is not 
considered truly coincidental, but may be a consequence of a factor that disrupts both the 
process of neurulation as well as cortical development, or may be secondary to the 
concurrent hydrocephalus.30,31 Disorders of prosencephalic cleavage, notably holo-
prosencephaly or commissural developmental anomalies, are not discussed. 
 
The current classification of MCD is based on a mixture of MRI, clinical and genetic 
criteria.8 It has changed over the recent years, and will have to be adapted to increasing 
knowledge on developmental processes and genetic factors. Also, not all patients fit neatly 
into the classification system; e.g. different types of MCD may occur in one patient, 
microlissencephaly fits both the categories of proliferation and migration disorders, and 
cortical dysplasia can be classified as a proliferation disorder when abnormal cells are 
thought to be present or a migration disorder if not. 
 
The classification system in broadly based on the following categories:8 
1. Malformations due to abnormal neuronal and glial proliferation or apoptosis 
1.1 Decreased proliferation/increased apoptosis: Microcephaly with/without 
normal cortex. 
1.2 Increased proliferation/decreased apoptosis: Megalencephaly with/without 
normal cortex. 
1.3 Abnormal proliferation (abnormal cell types) 
2. Malformations due to abnormal neuronal migration 
2.1 Lissencephaly/subcortical band heterotopia spectrum 
2.2 Cobblestone complex  
2.3 Heterotopia 
3. Malformations due to abnormal cortical organization (including late neuronal 
migration) 
3.1 Polymicrogyria and schizencephaly 
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These categories are described in more detail below.  
 
Classification of the type of MCD based on MRI imaging is the first step towards finding the 
causative mechanism in a particular patient. This should be followed by family history, 
clinical history (including pregnancy and delivery), physical, dysmorphological, and 
neurological examination. Detailed classification is needed to guide genetic analysis as 
mutations in genes known to be involved in MCDs generally result in specific 
(neuroimaging) patterns.1 
 
Causes of disruption of normal cortical development can be both environmental as genetic. 
The list of known causes is extensive and can be found in tables in the appendix. 
In general causes can be: 
 Monogenetic: These can be autosomal dominant (e.g. LIS1), autosomal recessive (e.g. 
ARFGEF2), and X-linked (e.g. FLNA). 
 Chromosomal abnormalities: Chromosomal rearrangements can cause MCD as part of 
the phenotype. Most well known is Miller-Dieker syndrome, where LIS1 and the 
surrounding genes on chromosome 17p are deleted causing complete lissencephaly 
with specific facial dysmorphism. In 22q11 microdeletion (velocardiofacial syndrome) 
polymicrogyria frequently occurs. For other microdeletion syndromes malformations of 
cortical development are less frequent, but are sometimes described. Associated 
phenotypical features may lead to specific suspicions (such as in cases of del 5q35, 5p- 
syndrome, 1p- syndrome etc). 
 Syndromal associations: a large number of syndromes associated with MCD and with 
unknown underlying cause have been described. 
 Metabolic disorders: Most well known are peroxisomal disorders in the Zellweger 
syndrome spectrum, but others have been described, such as congenital disorders of 
glycosylation and organic acidurias. 
 Infectious (prenatal): mainly associated with polymicrogyria. 
 Prenatal insults otherwise: e.g. prenatal ischemia can cause polymicrogyria. 
 
In the tables in the appendix causes are reported if the description of the MCD and the 
neuroimaging are clear, and if the MCD has been reported in more than one case. Reports 
of MCDs in aborted fetuses before gestational age of 30 weeks are disregarded as gyration 
is insufficient at that age to definitely classify an abnormality. 
 
3.1 Disorders of proliferation 
 
3.1.1 Microcephaly with simplified gyration (MSG) 
MRI features of MSG 
Fewer glia and/or neurons result in a small brain (microcephaly). This is generally 
associated with a more or less simplified gyral pattern. Gyration is less complex and the 
number of gyri is reduced. There is a continuum between normal gyration and a simplified 
pattern however, and a clear distinction is not always possible. It is more informative to 
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look at the complexity of the sulci formation, which can give an indication of the maturity 
of the gyral pattern. A useful measurement for this can be found in vd Knaap et al (see 
figure 5).25 An even simpler, but still reliable measure of severity is to use a visual rating 
scale. This visual gyration score is defined in a 3-point rating scale, based on the 
classification of normal gyration during early brain development: (1) a normal pattern, 
where gyri and sulci are branched; (2) a simplified pattern, where the width of the gyri is 
equal to the depth of the sulci; and (3) a severely simplified pattern with shallow gyri and 
sulci.32 In MSG there are no other malformations of the brain, except for aspecific 
abnormalities such as mild dilatation of the ventricles or a small pons or cerebellum.  
 
Clinical features of MSG 
In children with autosomal recessive microcephaly with simplified gyral pattern, head 
circumference is more than 3 SD below the mean. Children are generally mentally 
retarded, but show no specific neurological abnormalities such as epilepsy or spasticity. 
Syndromal variants of MSG, such as Amish lethal microcephaly or Nijmegen breakage 
syndrome usually do show more severe neurological deficits and a reduced life expectancy. 
 
Causes of MSG 
MSG can be a consequence of fewer proliferative cell cycles in early development, or of loss 
of progenitor cells or neurons by apoptosis. Classic microcephaly with simplified gyral 
pattern is also known as ‘microcephalia vera’, and several causative genes have been 
identified that are all involved in mitosis organization (see appendix). Mutations cause a 
reduction in the number of times that neuroblasts are able to divide, and therefore a 
reduction in the resulting total number of neurons and glial cells. MSG can also result from 
a loss of neuroblasts due to cell death, for example in DNA-repair disorders. In these cases 
the phenotype is more severe (see appendix). 
 
Pathology of MSG 
No specific microscopic abnormalities are found in patients with classic microcephaly with 
simplified gyral pattern.33 
 
3.1.2 Megalencephaly 
The opposite of MSG occurs in megalencephaly (large brain, more than 3 SD above normal). 
Increased proliferation of neurons or glial cells or an impairment of apoptosis can result in 
a large brain. Examples of megalencephaly are diseases that affect growth regulation 
pathways, such as tuberous sclerosis complex and neurofibromatosis type 1. This needs to 
be differentiated from macrocephaly (large head) caused by hydrocephalus, enlargement 
of the bony skull, subdural hematoma or effusion, storage disorders or 
leukencephalopathies. These disorders are not included in the scope of this thesis. 
Megalencephaly can also be seen combined with other congenital malformations, e.g. in 
megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome (see also 
chapter 6.2).34 
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These categories are described in more detail below.  
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causative mechanism in a particular patient. This should be followed by family history, 
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mutations in genes known to be involved in MCDs generally result in specific 
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Causes of disruption of normal cortical development can be both environmental as genetic. 
The list of known causes is extensive and can be found in tables in the appendix. 
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 Monogenetic: These can be autosomal dominant (e.g. LIS1), autosomal recessive (e.g. 
ARFGEF2), and X-linked (e.g. FLNA). 
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3.1 Disorders of proliferation 
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associated with a more or less simplified gyral pattern. Gyration is less complex and the 
number of gyri is reduced. There is a continuum between normal gyration and a simplified 
pattern however, and a clear distinction is not always possible. It is more informative to 
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look at the complexity of the sulci formation, which can give an indication of the maturity 
of the gyral pattern. A useful measurement for this can be found in vd Knaap et al (see 
figure 5).25 An even simpler, but still reliable measure of severity is to use a visual rating 
scale. This visual gyration score is defined in a 3-point rating scale, based on the 
classification of normal gyration during early brain development: (1) a normal pattern, 
where gyri and sulci are branched; (2) a simplified pattern, where the width of the gyri is 
equal to the depth of the sulci; and (3) a severely simplified pattern with shallow gyri and 
sulci.32 In MSG there are no other malformations of the brain, except for aspecific 
abnormalities such as mild dilatation of the ventricles or a small pons or cerebellum.  
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a loss of neuroblasts due to cell death, for example in DNA-repair disorders. In these cases 
the phenotype is more severe (see appendix). 
 
Pathology of MSG 
No specific microscopic abnormalities are found in patients with classic microcephaly with 
simplified gyral pattern.33 
 
3.1.2 Megalencephaly 
The opposite of MSG occurs in megalencephaly (large brain, more than 3 SD above normal). 
Increased proliferation of neurons or glial cells or an impairment of apoptosis can result in 
a large brain. Examples of megalencephaly are diseases that affect growth regulation 
pathways, such as tuberous sclerosis complex and neurofibromatosis type 1. This needs to 
be differentiated from macrocephaly (large head) caused by hydrocephalus, enlargement 
of the bony skull, subdural hematoma or effusion, storage disorders or 
leukencephalopathies. These disorders are not included in the scope of this thesis. 
Megalencephaly can also be seen combined with other congenital malformations, e.g. in 
megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome (see also 
chapter 6.2).34 
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3.1.3 Disorders of differentiation 
Local abnormalities of the cellular structure of the cortex are called focal cortical 
dysplasias. Cortical dysplasias are thought to either result from abnormal maturation or 
differentiation of neurons or from abnormal migration (based on ‘migration lines’ of 
neuronal tissue in the white matter proximal to the dysplasia).35 Cortical dysplasias 
consisting of purely heterotopic ‘normal’ neurons (type 1 cortical dysplasia) should be 
considered ‘true’ migration disorders, but are also included in this paragraph for the sake of 
clarity. 36 
 
Clinical features of cortical dysplasia 
Cortical dysplasias are highly epileptogenic, and are rigorously sought for in children with 
intractable focal epilepsy, as they are the most frequent cause of focal refractory seizures in 
this age group.36,37 This may have resulted in detection bias, as non-epileptogenic cortical 
dysplasias are less likely to be found. Epilepsy surgery has a high chance of success in 
patients with cortical dysplasia, but higher in type II than in type I cortical dysplasia (see 
below).38,39 Generally, small isolated cortical dysplasias do not result in other neurological 
deficits; however cortical dysplasias are also seen in the context of diseases such as 
tuberous sclerosis complex and hemimegalencephaly. 
 
MRI features of cortical dysplasia 
MRI features can be subtle. Some cortical dysplasias are only found by histopathological 
investigations after epilepsy surgery; ‘MRI-negative cortical dysplasias’. Hopefully, these 
patients will benefit from improving MRI techniques. Clues to look for are focal cortical 
thickening, blurred gray-white matter junction, and related ‘migration lines’. These are 
gray matter lines in the subcortical white matter.  If these are visible and extend to the 
lateral ventricle, the abnormality is called a transmantle dysplasia. MRI features 
suggestive of a type II cortical dysplasia (with abnormal neurons) are increased cortical 
thickness, transmantle signs, and FLAIR or T2 weighted signal change.37 Migration lines 
and the gray-white matter junction are best appreciated on T1 weighted imaging. T2 
weighted images or FLAIR images show associated white matter hyperintensity or gliosis. 
Hippocampal atrophy and signal change are suggestive of type I cortical dysplasia.37 
Cortical dysplasias can also be part of a larger cortical malformation in hemi-
megalencephaly. Low-grade developmental tumors, the DNET (dysembryoplastic 
neuroepithelial tumor), ganglioglioma, and gangliocytoma are considered to be (related to) 
cortical dysplasias as they are probably the result of abnormal proliferation/ 
differentiation. These tumors may have a solid mass, cysts, calcifications, and may 
enhance with gadolinium. 
 
Causes of cortical dysplasia 
One of the most important causes of focal cortical dysplasia due to abnormal proliferation 
is tuberous sclerosis complex. Growth regulation is impaired in this neurocutaneous 
disease, not only leading to increased number of neurons, but also the formation of 
abnormally large neurons that form the characteristic cortical ‘tubers’ or hamartomas of 
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the disease. It is a multi-organ disease and is not further explored in this thesis. 
Hemimegalencephaly is found sporadically or in association with hypomelanosis of Ito, 
Proteus syndrome, Klippel-Trenaunay, tuberous sclerosis complex, or linear naevus 
sebaceous. These syndromes are not included in the tables in the appendix. 
 
Pathology of cortical dysplasia 
Histopathologically, cortical dysplasias are graded by the Palmini grading system (see table 
2).36,39 Dysmorphic neurons are misshapen cells with abnormal orientation, size, 
cytoskeletal structure, and atypical dendritic processes. Balloon cells are abnormal cells 
with pale, eosinophilic cytoplasm and eccentric nucleus or nuclei, as some are 
multinucleated. They are usually larger than astrocytes and can have neural or glial 
immunohistochemical characteristics. Giant neurons are large neurons (compared with 
layer V pyramidal neurons) with central nuclei, but have a pyramidal morphology and are 
not dysmorphic. Ectopic neurons or heterotopias are microscopic or macroscopic clusters of 
normal appearing neurons that are not in their normal place, e.g. in the white matter.  
 
Table 2: Palmini histopathologic grading system for cortical dysplasia.36,39  
Grade  Severity Histopathologic description  
mMCD* 
         A 
         B 
Very mild Normal cortex with excess ectopic neurons 
Only in or adjacent to the molecular layer (layer I) or 
In the subcortical white matter outside of layer I. 
 
Type I  
 
         IA 
         IB 
Mild Cortical disorganization and dyslamination without abnormal 
dysmorphic–cytomegalic neurons or balloon cells.  
Type IA is cortical disorganization with no other abnormalities. 
Type IB is cortical disorganization with immature or hypertrophic but not 
dysmorphic neurons. 
 
Type II  
 
 
         IIA 
         IIB 
Severe  Cortical disorganization and dyslamination with abnormal dysmorphic–
cytomegalic neurons and balloon cells. Sometimes referred to as Taylor’s 
type cortical dysplasia.  
Type IIA contains dysmorphic–cytomegalic neurons without balloon cells.  
Type IIB contains balloon cells  
* mMCD, mild malformation of cortical development.    
 
3.2 Disorders of migration 
A complete inability to migrate results in a smooth cortex with a histopathologically 
inverted and thickened cortex; type 1 lissencephaly. Less severe migration disturbances 
that affect all or a subset of neurons give a milder MRI pattern in the same spectrum: 
pachygyria or subcortical band heterotopia.  Another type of disorder of migration is seen 
in cobblestone lissencephalies, where neurons do start their radial migration, but fail to 
detach at the appropriate place and pass through the pial membranes. This can be due to 
abnormal membrane function due to deficient o-glycosylation. Neurons move on onto the 
cortex creating a cobblestone-like aspect of the surface.  Cobblestone lissencephaly was 
previously called type II lissencephaly, and is often seen in association with congenital 
muscular dystrophy and eye abnormalities. A third type of migration disorder is 
periventricular nodular heterotopia. Clusters of gray matter line the ventricles consisting 
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cytoskeletal structure, and atypical dendritic processes. Balloon cells are abnormal cells 
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multinucleated. They are usually larger than astrocytes and can have neural or glial 
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layer V pyramidal neurons) with central nuclei, but have a pyramidal morphology and are 
not dysmorphic. Ectopic neurons or heterotopias are microscopic or macroscopic clusters of 
normal appearing neurons that are not in their normal place, e.g. in the white matter.  
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Grade  Severity Histopathologic description  
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3.2 Disorders of migration 
A complete inability to migrate results in a smooth cortex with a histopathologically 
inverted and thickened cortex; type 1 lissencephaly. Less severe migration disturbances 
that affect all or a subset of neurons give a milder MRI pattern in the same spectrum: 
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abnormal membrane function due to deficient o-glycosylation. Neurons move on onto the 
cortex creating a cobblestone-like aspect of the surface.  Cobblestone lissencephaly was 
previously called type II lissencephaly, and is often seen in association with congenital 
muscular dystrophy and eye abnormalities. A third type of migration disorder is 
periventricular nodular heterotopia. Clusters of gray matter line the ventricles consisting 
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of groups of neurons that failed to start migration. The overlying cortex may have a normal 
or abnormal appearance. 
 
3.2.1 Lissencephaly 
MRI features 
In the lissencephaly-pachygyria-subcortical band heterotopia spectrum, MRI features can 
distinguish well between the different types of lissencephaly and give direction to 
additional genetic tests. In type 1 or classic lissencephaly the cortex is smooth and 
thickened (>10mm) with a cell sparse zone.40 Lack of opercularization results in a typical 
‘figure of eight’-configuration (figure 7). Milder types of lissencephaly show thickened gyri 
(pachygyria) or fairly normal gyri with a band of gray matter below, the subcortical band 
heterotopia, consisting of neurons arrested during migration. Taking note of which areas 
of the brain are most affected aids investigations into the cause. This also goes for 
associated abnormalities of the corpus callosum or cerebellum. Type 1 lissencephaly affects 
mainly the cortex, more severely in the occipital than the frontal lobes. Its severity can be 
graded into six categories, grade 1 being most severe (see table 3 and figure 7). 
 
Table 3: classic lissencephaly grades 1-6 
Grade MRI features 
grade 1 complete agyria 
grade 2 agyria with few shallow anterior sulci 
grade 3 posterior agyria and anterior pachygyria 
grade 4 diffuse pachygyria posterior>anterior 
grade 5 mixed pachygyria and subcortical band heterotopia 
grade 6  subcortical band heterotopia only 
 
 
Figure 7: classic lissencephaly grades 1-6, note ‘figure-of-eight’ configuration in grade 1 lissencephaly. 
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Non-classic lissencephalies are type II lissencephaly or cobblestone lissencephaly (see also 
3.2.2), and lissencephalies associated with abnormalities of the cerebellum or corpus 
callosum. Lissencephaly with cerebellar hypoplasia can be subdivided into types a-f (table 
4). Naturally, not all patients always fit neatly into these categories, e.g. those patients 
with focal pachygyria. 
 
Table 4: Lissencephaly with cerebellar hypoplasia (LCH) types.41 
LCH types MRI features 
Type a Vermis hypoplasia, lissencephaly/pachygyria with p>a or a>p gradient 
Type b Cerebellar hypoplasia with abnormal foliation, pachygyria a>p, cortex 5-10 mm, 
malformed hippocampus 
Type c Severe cerebellar and brainstem hypoplasia with diffuse agyria/pachygyria, severe 
microcephaly 
Type d Moderate cerebellar hypoplasia, microcephaly, agyria-pachygyria cortex 10-20 mm 
Type e Moderate vermis hypoplasia, frontal agyria, occipital simplified gyral pattern 
Type f Absent corpus callosum, microcephaly, agyria/pachygyria, mild brainstem hypoplasia 
p = posterior, a = anterior 
 
Clinical feature of lissencephaly 
Lissencephaly type I was the earliest recognized MCD, and consequently much is known 
about the clinical features. Signs and symptoms are very diverse and range from normal 
intelligence to severe mental retardation. There is a relationship between the severity of 
the lissencephaly/pachygyria grading based on neuroimaging and outcome with respect to 
the severity of psychomotor retardation, motor symptoms and epilepsy.40 Most to all 
patients have epilepsy. Lissencephaly type I is associated with facial dysmorphic features 
when part of the Miller-Dieker syndrome. This syndrome is caused by a microdeletion of 
17p13.3 including the LIS1 gene and the 14-3-3 gene (also known as the YWHAE gene). 
These patients show bitemporal hollowing, small jaw, short nose with upturned nares, 
long upper lip with thin vermillion border and a flattened midface with vertical furrowing 
of the forehead, but these dysmorphic features may be subtle or absent. It is also associated 
with cardiac malformation, genital anomalies in boys, sacral dimple and clinodactyly 
(OMIM 247200). Interestingly, deletion of YWHAE without affecting the LIS1-gene results in 
craniofacial dysmorphic features, growth restriction, and on MRI of the brain some 
gliosis.42 In a single patient periventricular nodular heterotopia have been reported.43 
 
Causes of lissencephaly 
In 1993 the first gene involved in malformations of cortical development was identified 
when mutations in LIS1 on chromosome 17p were found to be responsible for autosomal 
dominant type I lissencephaly.44 Since then several more genes have been found, 
summarized in the appendix. Lissencephaly type I results from a failure to complete radial 
migration (along radial glial fibers) of excitatory glutamatergic pyramidal neurons. If the 
clinical phenotype with facial dysmorphic features suggests Miller-Dieker syndrome, then 
FISH investigation of the 17p13.3 region should be the initial test. In classic lissencephaly 
with a posterior to anterior gradient LIS1 mutations are very likely, and current advise is to 
order MLPA testing first, as intragenic and submicroscopic deletions are common, followed 
as needed by gene sequencing.45 Lissencephaly with a reversely oriented gradient (anterior 
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to posterior) is found in mutations in DCX, and DCX mutations are also specific for 
subcortical band heterotopia in females. Deletions are commonly found.46 The severity is 
not only determined by the type of mutation, but also by the result of X-inactivation in 
girls. In boys mutations in DCX are a rare cause of lissencephaly.47 In animal models DCX 
mutations are not only associated with problems in radial migration of excitatory neurons, 
but also in GABA-ergic interneurons and neuronal maturation. This may be relevant to 
understand the epilepsy in these patients.48,49 In patients with pachygyria combined with 
cerebellar hypoplasia, mutations in RELN, VLDLR or TUBA1A are more likely (see 
appendix).50,51 In TUBA1A related lissencephaly, the pachygyria shows a predilection for the 
perisylvian regions which does not fit into the classic grading system.51 TUBA1A  mutations 
are specifically found in patients with lissencephaly (perisylvian) with cerebellar and/or 
brainstem hypoplasia and corpus callosum abnormalities (LCH type c or f). However, also 
in approximately 5% of classic lissencephaly patients TUBA1A mutations can be found. 
Phenotypes similar to LIS1 phenotypes are related to the TUBA1A R402C mutation.51 Very 
rarely lissencephaly with callosal agenesis and abnormal genitalia in boys is caused by 
mutations in X-linked ARX.52 This homeobox gene causes a diverse array of phenotypes 
when disturbed, from mental retardation to various types of epilepsy or malformation of 
cortical development. It affects GABA-ergic interneuron migration primarily. 
 
Pathology of lissencephaly 
The histopathology of LIS1-related lissencephaly shows a typical 4 layered inverted cortex 
instead of the normal 6-layered pattern, most prominently in the occipital cortex. The 4-
layered lissencephaly is characterized by a molecular layer (layer I) containing Cajal-
Retzius cells, a pyramidal cell layer, a cell-sparse layer that is myelinated in patients older 
than 2 years and can be visible on MRI (layer III), and a thick layer of disorganized neurons 
(layer IV). Sometimes the boundary between the grey and white matter can be blurred by 
vertical clusters of axons. Microscopic white matter heterotopia are seen in some patients 
with documented LIS1 mutations, but these are unlikely to be visible on MRI.53 
In two published cases of lissencephaly based on DCX mutations, a vaguely 4-layered 
lissencephalic cortex in the frontal lobes was described, but it was not like the typical 
cortex associated with LIS1 mutations. Layer I contained Cajal-Retzius neurons and was 
indistinguishable from LIS1 related lissencephaly. Layer II contained pyramidal neurons 
but was relatively thin with only a few pyramidal neurons. In one of the 2 cases examined, 
there was a relatively well-formed layer III with sparse myelination. In both cases, this 
layer contained more neurons than in brains with LIS1 mutations. Layer IV was thickened, 
but also contained more pyramidal neurons than were found in LIS1 brains. At the junction 
between the grey and white matter there was a transition between the lissencephalic 
cortex to multiple small nodules of subcortical heterotopia that made up the subcortical 
band. The two lissencephalic brains with DCX mutations showed a transition to relatively 
normal 6-layered cortex ventrally and diffusely disorganized cortex occipitally.53 
In two published cases of ARX mutation related lissencephaly histopathology showed a 3-
layered cortex. There was a hypercellularity of the molecular layer that consisted of 
primarily small- to medium-sized neurons. Immediately below this layer was a relative 
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increase in pyramidal cells followed by a thick layer of small- and medium-sized neurons, 
including pyramidal neurons of various sizes. No hypocellular or myelinated layer was 
detected.53 
In severe forms of TUBA1A related lissencephaly in four prenatally diagnosed patients 
various abnormalities were seen. Consistently observed were developmental anomalies in 
cerebral gyration (complete agyria usually without an identifiable Sylvian fissure and 
thinner cortical plate), the corpus callosum, hippocampus, cerebellum and brainstem, with 
various degrees of severity. Dystrophic axonal tracts with aberrant pathways were seen in 
the periventricular white matter suggesting abnormal axonal guidance. In one case of 35 
weeks gestational age the cortex was abnormally thick and similar to the four-layered 
cortex of classical lissencephaly. Labelling studies suggested that migration abnormalities 
involved projection neurons as well as interneurons. The ventricles were at most only 
slightly enlarged. The white matter was poorly developed and the periventricular areas 
contained heterotopic immature neurons, which are rarely observed in classical 
lissencephaly. The cerebellum and brainstem were consistently affected with a variable 
degree of hypoplasia with heterotopic cells in the cerebellar hemispheres and olivary 
heterotopia in the medulla.54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: simplified representation of lissencephaly pathology.  
A: normal cortex, with six layers (I: molecular layer, II: external granular layer, III: external pyramidal 
layer, IV: internal granular cell layer, V: internal pyramidal layer, VI, fusiform or multiform layer).   
B: LIS1 related lissencephaly, C: DCX related lissencephaly, D: ARX related lissencephaly. 
 
3.2.2 Cobblestone lissencephalies 
MRI features of cobblestone lissencephaly 
The MRI imaging of cobblestone or type II lissencephaly can be similar to type 1 
lissencephaly in terms of agyria or pachygyria. In high quality imaging the uneven aspect 
of the cortex can be visible. Projections of white matter into the cortex result in an irregular 
gray-white matter junction. This can be better appreciated after the neonatal period. The 
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to posterior) is found in mutations in DCX, and DCX mutations are also specific for 
subcortical band heterotopia in females. Deletions are commonly found.46 The severity is 
not only determined by the type of mutation, but also by the result of X-inactivation in 
girls. In boys mutations in DCX are a rare cause of lissencephaly.47 In animal models DCX 
mutations are not only associated with problems in radial migration of excitatory neurons, 
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various degrees of severity. Dystrophic axonal tracts with aberrant pathways were seen in 
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irregularity of the gray-white matter junction can appear similar to that seen in 
polymicrogyria, and mild cobblestone phenotypes and polymicrogyria may be 
indistinguishable on MRI.55 
 
Clinical features of cobblestone lissencephaly 
Cobblestone lissencephalies are typically seen in the context of three congenital muscular 
dystrophy syndromes: muscle-eye-brain disease, Fukuyama-muscular dystrophy and 
Walker-Warburg syndrome. Children with Walker Warburg syndrome are most severely 
affected of this group. They all have retinal anomalies and muscular dystrophy with 
elevated creatine kinase. Milder variants of muscle-eye-brain disease may show (near) 
normal mental development, limb-girdle muscular dystrophy and less severe eye 
abnormalities. 
 
Causes of cobblestone lissencephaly 
Cobblestone lissencephalies result from an overmigration of radially migrating neurons. 
Normally the glia limitans ‘limits’ further migration and defects result in migration of 
neurons into the subarachnoid space. Up until 2009, all genes found in cobblestone 
lissencephaly with muscular dystrophy and eye abnormalities caused defective O-
glycosylation of alpha-dystroglycans (see appendix). Once this pattern was discovered, 
other genes in this pathway were quickly found and the extent of the phenotype described. 
Recently mutations in TUBB2B were found to cause an MRI pattern of asymmetric 
polymicrogyria, however neuropathology was compatible with cobblestone 
lissencephaly.56 TUBB2B is involved in microtubule function and patients do not show 
muscular dystrophy or eye abnormalities. Other genes unrelated to O-glycosylation, have 
also been implicated in animal models.57,58 
 
Pathology of cobblestone lissencephaly 
In the cortex ectopic clusters of neurons are seen. There are projections of white matter 
with fibrovascular tissue between the clusters. In the white matter ectopic neurons can be 
found. Migrating neurons seem to have moved through the glia limitans onto the outer 
cortex creating an uneven surface.56 This can be difficult to see on MRI. 
 
3.2.3 Heterotopia 
MRI features of heterotopia 
Heterotopia are formed of neurons that have not migrated to their destination in the 
cortex. As they are otherwise normal neurons, they have all characteristics of gray matter 
on MRI. This distinguishes heterotopia from other periventricular abnormalities such as 
calcifications in congenital infections and subependymal noduli in tuberous sclerosis 
complex. Heterotopia can be unilateral or bilateral, and isolated versus continuous. 
Bilateral continuous periventricular heterotopia with an otherwise normal brain, except 
for an enlarged retrocerebellar space, is the classical phenotype of FLNA mutations. 
Distinctly different types of heterotopia are those found in the cerebral white matter. The 
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typical subcortical band heterotopia is considered to be part of the lissencephaly-
pachygyria continuum and is discussed in section 3.2.1. 
 
Clinical features of heterotopia 
Clinical features are very diverse, may give no neurological complaints and can be a chance 
finding. Psychomotor development may be completely normal or delayed. Periventricular 
nodular heterotopias give a high risk of epilepsy, but seizures may be delayed until 
adulthood. Associated congenital anomalies may give a clue to the underlying cause, e.g. 
cardiac malformations are associated with FLNA mutations.  
 
Causes of heterotopia 
The most common monogenetic cause are loss-of-function mutations in X-linked FLNA.59,60 
This causes bilateral periventricular nodular heterotopia, but also cardiac malformations in 
the outflow tract and Ehlers-Danlos like skin and joint anomalies. Rarely bilateral PNH are 
caused by autosomal recessive mutations in ARFGEF2, also associated with microcephaly, 
severe mental retardation, movement disorder and epilepsy.61 There are many syndromes 
associated with periventricular heterotopia (see appendix). For subcortical heterotopia or 
heterotopia in the white matter, no specific causes are known so far. 
 
 
Figure 9: examples of MRI patterns of heterotopia. A: T1-weighted transversal image showing bilateral 
continuous periventricular nodular heterotopia in a patient with a FLNA mutation. B: T1-weighted 
coronal image showing bilateral, almost continuous periventricular nodular heterotopia in a patient 
with autosomal recessive ARFGEF2 mutations. C: T1-weighted coronal image showing a unilateral, 
isolated periventricular nodular heterotopia (arrow) without known cause. D: T1-weighted coronal 
image showing extensive bilateral continuous periventricular and white matter heterotopia without 
known cause. E: T1-weighted transversal image showing bilateral subcortical heterotopia without 
known cause. F: T2-weighted transversal image showing bilateral isolated periventricular nodular 
heterotopia in a patient with a meningomyelocele, Arnold Chiari malformation and hydrocephalus. 
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cortex. As they are otherwise normal neurons, they have all characteristics of gray matter 
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typical subcortical band heterotopia is considered to be part of the lissencephaly-
pachygyria continuum and is discussed in section 3.2.1. 
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Clinical features are very diverse, may give no neurological complaints and can be a chance 
finding. Psychomotor development may be completely normal or delayed. Periventricular 
nodular heterotopias give a high risk of epilepsy, but seizures may be delayed until 
adulthood. Associated congenital anomalies may give a clue to the underlying cause, e.g. 
cardiac malformations are associated with FLNA mutations.  
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This causes bilateral periventricular nodular heterotopia, but also cardiac malformations in 
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caused by autosomal recessive mutations in ARFGEF2, also associated with microcephaly, 
severe mental retardation, movement disorder and epilepsy.61 There are many syndromes 
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Pathology of heterotopia 
In bilateral periventricular nodular heterotopia due to FLNA mutations the heterotopia 
contains normal appearing neurons. Apart from the heterotopia, glomeroid vascular 
abnormalities have been reported in autopsy material.62,63 Interestingly, nodular 
heterotopia show an intrinsic laminal specificity that is similar to that of the cortex .64 This 
suggests that the neurons in the heterotopia fail to migrate, but do attempt to differentiate 
normally. PET studies also suggest that neurons in heterotopic gray matter participate in 
neural networks and brain function.65,66 
 
3.3 Disorder of cortical organization:  
Polymicrogyria is the most heterogeneous malformation of cortical development, both in 
appearance as in causes. It can be seen as an isolated malformation, but also in 
combination with periventricular nodular heterotopia or other brain malformations such 
as corpus callosum agenesis or cerebellar abnormalities. 
 
3.3.1 Polymicrogyria 
MRI features of polymicrogyria 
Polymicrogyria is probably the most common MCD and also probably the most difficult 
malformation to recognize on MRI imaging. This is partly due to the marked change in its 
appearance during the first years of life, and partly to its heterogeneous nature. In 
newborns the cortex is thin and due to a lack of myelination the gray-white matter border 
is harder to appreciate. In these infants the polymicrogyric cortex shows numerous, very 
small ripples. After myelination the polymicrogyric cortex appears thickened with an 
unclear white-matter junction. If the resolution of the imaging allows, it can be 
appreciated that this ‘fuzziness’ results from the small undulations of the cortex. The 
surface of the cortex may appear lumpy-bumpy or may seem smooth due to fusion of the 
upper layer of the cortex across adjacent microgyri. Not surprisingly, the compaction of 
small gyri can be easily mistaken for a thickened cortex (pachygyria).  This is a common 
mistake in interpreting MCD on MRI and a high level of suspicion is necessary.1,67 When in 
doubt, repeat MRIs after the age of 18 months can be very useful as myelination changes 
the appearance of polymicrogyria (see figure 10).68 
Polymicrogyria can also manifest as schizencephaly, which are clefts in the neocortex 
reaching the ventricle lined with PMG. Polymicrogyria can be difficult to distinguish 
radiologically from cobblestone malformation. 
PMG subtypes can be recognized based on differences in topography, such as diffuse or 
generalized, frontal, posterior, mesial parieto-occipital, multilobar, and perisylvian forms. 
The perisylvian form accounts for 60–70% of patients, with all other forms less commonly 
seen.69 The severity of perisylvian polymicrogyria may be graded using the system by 
Leventer,  separately grading the left and right hemisphere if applicable (see table 5).70 
Other PMG subtypes cannot be graded with this system. 
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Figure 10: example of changing aspect of polymicrogyria over time in a boy with psychomotor 
retardation and spastic tetraplegia. A) upper panel T1 weighted and lower panel T2 weighted 
transversal MRI images at the age of three weeks, and B) the same images at the age of 29 months. Note 
the difficulty in recognizing the irregular gray-white matter junction in the early MRI. Also note the 
advanced myelination in the abnormal perisylvian regions, which can be an early indication of a cortical 
malformation. 
 
Table 5: grading of perisylvian polymicrogyria severity 
Grade MRI features 
Grade 1  Entire perisylvian region extending to other brain regions including one or both poles 
Grade 2 Entire perisylvian region extending to other brain regions but not involving either pole 
Grade 3  Entire perisylvian region 
Grade 4  Posterior perisylvian region 
 
Clinical features of polymicrogyria 
Bilateral perisylvian polymicrogyria results in the so-called perisylvian syndrome. Motor 
function of the oral musculature is impaired, resulting in speech delay, dysarthria and 
dysphagia. This clinical syndrome has also been described as Worster-Drought syndrome, 
however also children without PMG can have this syndrome.71 PMG can be unilateral or 
bilateral. In unilateral cases clinical features resemble cerebral palsy, with a congenital 
spastic hemiparesis. Epilepsy is common, but not obligatory.1 
 
Causes of polymicrogyria 
Polymicrogyria is the probably the MCD with the most heterogeneous causative 
mechanisms. Several non-genetic causes have been described, such as congenital 
cytomegalovirus infection or prenatal ischemia.72-75 Several genes and microdeletion 
syndromes have been associated with PMG, but each seems to be responsible for only a 
small group of patients (see appendix). The most important established genetic cause is the 
22q11 microdeletion syndrome.70 
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Bilateral perisylvian polymicrogyria results in the so-called perisylvian syndrome. Motor 
function of the oral musculature is impaired, resulting in speech delay, dysarthria and 
dysphagia. This clinical syndrome has also been described as Worster-Drought syndrome, 
however also children without PMG can have this syndrome.71 PMG can be unilateral or 
bilateral. In unilateral cases clinical features resemble cerebral palsy, with a congenital 
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Polymicrogyria is the probably the MCD with the most heterogeneous causative 
mechanisms. Several non-genetic causes have been described, such as congenital 
cytomegalovirus infection or prenatal ischemia.72-75 Several genes and microdeletion 
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Pathology of polymicrogyria 
PMG is characterized by an excessively folded cortical ribbon of miniature, individually 
thin gyri, which may be fused together or piled on top of each other. Predilection areas are 
around the insula and the central fissure. The normal 6-layered cortex can be reduced to 
four layers or no clear layers may be seen at all. The four layers consist of a molecular layer 
and two layers of neurons separated by an intermediate layer of few cells.76 Pathology can 
be the only way to distinguish PMG from cobblestone complex, as brain MRI may be 
ambiguous. 77 
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4. Scope of the thesis 
During the last decade (pediatric) neurologists have benefited from increasing possibilities 
in imaging the human cerebral cortex. This is based on advancements in neuroimaging 
techniques, but also on the possibility of improving image quality by scanning young 
children under general anaesthesia. We have now recognized that malformations of 
cortical development (MCD) can explain epilepsy and neurological deficit in many 
patients. Genetic research in these patients has been able to identify several involved 
genes already; however the underlying cause of these malformations has remained elusive 
in many patients.  
 
The aims of the studies described in this thesis are to establish the yield of etiological 
diagnosis in patients with MCD by detailed clinical and radiological description, 
classification, and by genetic testing, to describe the natural history of patients with MCD, 
and to describe new phenotypes and syndromes. 
 
To achieve this aim a cohort of patients with malformations of cortical development has 
been recruited from 2001 onwards. This consisted of retrospectively ascertained patients 
that were re-evaluated and patients that were newly referred. All patients were 
periodically seen for evaluation of the history, and a neurological and dysmorphological 
exam. Brain MRIs were performed according to a standard protocol. This cohort of over 200 
patients with different types of MCD forms the basis of the studies of this thesis. The 
cohort mainly consists of, but is not limited to, children. 
 
In chapter two our cohort of patients with MCD is described and we show in how many 
patients an etiological diagnosis can be currently made by combining clinical, radiological, 
and genetic classification, with syndrome identification, family study, and diagnostic 
molecular testing. 
 
In chapter three we describe new insights in the natural history of patients with different 
MCDs with known causes, in particular mutations in LIS1 and FLNA. 
 
In chapter four we discuss new phenotypes resulting from description of our cohort, in 
particular a new phenotype associated with ARFGEF2 mutations and a group of patients 
with microcephaly with simplified gyral pattern with early onset diabetes. 
 
In chapter five we describe the association of MCD and metabolic disease in a case of 
malonyl-CoA decarboxylase deficiency. 
 
In chapter six we discuss syndromal associations observed in our patients. This involves a 
group of patients with periventricular nodular hetertopia and limb deficiency and patients 
with MPPH-MCD (megalencephaly, polydactyly, PMG, hydrocephalus syndrome, also 
known as macrocephaly capillary malformation). 
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Pathology of polymicrogyria 
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ABSTRACT 
 
Background:  
Malformations of cortical development (MCDs) are a major source of handicap. Much 
progress in understanding the genetic causes has been made recently. The number of 
affected children in whom a molecularly confirmed diagnosis can be made is unclear. 
Objective:  
To evaluate the etiology of MCDs in children and the effect of a combined radiological, 
clinical, and syndrome classification. 
Design:  
A case series of 113 children with a radiological diagnosis of MCD from January 1, 1992, to 
January 1, 2006. 
Setting:  
The Erasmus MC–Sophia Children’s Hospital, a secondary and tertiary referral center.  
Patients:  
Patients with MCD underwent a complete radiological, clinical, and neurological 
assessment and testing for known genes involved in the pathogenesis of MCD as 
appropriate for their phenotype. 
Results:  
We established an etiological diagnosis in 45 of 113 cases (40%). For 21 patients (19%), this 
included molecular and/or genetic confirmation (Miller-Dieker syndrome; LIS1, DCX, FLNA, 
EIF2AK3, or KIAA1279 mutations; or an inborn error of metabolism). In 17 (15%), a 
syndrome with an unknown genetic defect was diagnosed. In 7 patients (6%), we found 
evidence of a gestational insult. Of the remaining 68 patients, 34 patients probably have a 
yet-unknown genetic disorder based on the presence of multiple congenital anomalies (15 
patients), a family history with multiple affected persons (12 patients), or consanguineous 
parents (7 patients). 
Conclusions:  
In our cohort, combining diagnostic molecular testing with clinical, radiological, and 
genetic classification; syndrome identification; and family study provided a diagnosis in 
40% of the cases of MCD. This contributes to the possibility of prenatal diagnosis and 
improved patient treatment and disease management. 
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CORTICAL BRAIN MALFORMATIONS 
Effect of Clinical, Neuroradiological, and Modern Genetic Classification 
 
Malformations of cortical development (MCDs) are a major source of mental retardation, 
motor dysfunction, and epilepsy in children. Up to 10% of children with epilepsy are 
estimated to have an MCD, and the percentage is greater in those with intractable 
epilepsy.1 Not all patients with MCD develop epilepsy, however, and the level of motor and 
mental handicap varies. In recent years, much progress has been made in understanding 
the genetic and molecular basis of cortical development. Several essential genes have been 
identified (table 1). Also, MCDs have been described in patients with known syndromes 
such as the Adams-Oliver, Delleman, MICRO, and Kabuki make-up syndromes.2-6 
Illustratively, the London Medical Dysmorphology Database includes 46 syndromes with 
MCD as a requirement and 232 with MCD as a possible feature. 
Accurate classification is important for patient care and for improving insight into 
different phenotypes and causes. The 2005 classification system for MCD distinguishes 
disorders of cell proliferation, migration, and cortical organization and is useful for guiding 
the diagnostic approach in individual patients.7 This approach starts with a detailed brain 
magnetic resonance imaging (MRI) study, combined with medical and family history and a 
pediatric and neurological examination. Affected relatives, parental consanguinity, 
dysmorphic features, and typical MCD patterns can suggest genetic causes. Complications 
during pregnancy or congenital infections can be compatible with a fetal insult. Internal 
organ dysfunction and a progressive course may suggest a metabolic disease.8  
Apart from monogenetic mutations, chromosomal anomalies should be looked for. Some 
microdeletions can cause distinctive MCD, particularly interstitial deletions of 
chromosome 17p in lissencephaly, duplications of 5p in nodular heterotopia, and 
microdeletions of 22q11 in polymicrogyria (PMG).9-11 
The aims of the present study were to evaluate the effect of clinical, radiological, and 
genetic test results on etiological diagnosis in a series of consecutive cases of MCD in a 
university children’s hospital; to describe the relationship between diagnosis and clinical 
features; and to evaluate the consequences of an etiological diagnosis for disease 
management and genetic counseling. 
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METHODS 
 
Patient population 
The medical records of children with MCD referred to the Department of Pediatric 
Neurology or the Department of Clinical Genetics at the Erasmus Medical Center were 
retrospectively collected from January 1, 1992, through December 31, 2001, and 
prospectively from January 1, 2002, to January 1, 2006. We stopped inclusion when we 
started to recruit referrals actively. Information on the retrospective group was collected 
using the radiology reports as documented in the medical correspondence database of the 
Erasmus Medical Center–Sophia Children’s Hospital using the terms simplified gyral 
pattern, lissencephaly, pachygyria, polymicrogyria, heterotopia, cortical dysplasia, and 
migration disorder. All patients with available neuroimaging studies were included. All 
neuroimaging findings (MRI and computed tomography) were reevaluated by a pediatric 
neurologist (I.F.M.d.C.), a clinical geneticist (G.M.S.M.), and a pediatric neuroradiologist 
(M.H.L.). From 1992 to 2005, we included the most recent MRI study if a diagnosis of MCD 
was made when the patient was younger than 16 years. Consensus was required and 
patients were classified into 4 groups on the basis of MRI criteria.7,12 None of the patients 
had a molecularly confirmed diagnosis. 
We excluded patients with neoplasms, tuberous sclerosis, and neurofibromatosis 1. We 
excluded those with hydranencephaly and holoprosencephaly, unless associated with 
obvious MCD such as periventricular nodular heterotopia. We excluded patients with 
infratentorial abnormalities only and patients with a normal cortex and microcephaly or 
macrocephaly. 
 
Clinical evaluation 
If possible, patients were examined at the multidisciplinary outpatient clinic. Epilepsy was 
diagnosed when seizures were present and electroencephalographic findings were 
abnormal. The level of mental retardation was defined as mild (IQ, 70-80), moderate (IQ, 
50-69), or severe (IQ, <50), based on age-appropriate neurodevelopmental testing, 
performed by the school or by our clinic. 
 
RESULTS 
 
Patient classification 
Diagnosis was confirmed retrospectively in 48 patients, with 65 patients added 
prospectively, resulting in a case series of 113 patients (55 boys and 58 girls). They were 
classified into 4 groups on the basis of MRI findings. Further classification was based on 
results of the physical examination and genetic and metabolic tests (Table 2 and Figure 1). 
In the retrospective search, 76 children were found to have a documented diagnosis of 
MCD. Thirteen were excluded because of missing brain imaging studies. In 15, the 
diagnosis was reversed. In the remaining 48 cases, an MCD was confirmed, although the 
classification was revised in 11 patients. In 6, a diagnosis of pachygyria was changed to 
PMG. The opposite change was made in 1 case. In 2 cases, a diagnosis of lissencephaly was 
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METHODS 
 
Patient population 
The medical records of children with MCD referred to the Department of Pediatric 
Neurology or the Department of Clinical Genetics at the Erasmus Medical Center were 
retrospectively collected from January 1, 1992, through December 31, 2001, and 
prospectively from January 1, 2002, to January 1, 2006. We stopped inclusion when we 
started to recruit referrals actively. Information on the retrospective group was collected 
using the radiology reports as documented in the medical correspondence database of the 
Erasmus Medical Center–Sophia Children’s Hospital using the terms simplified gyral 
pattern, lissencephaly, pachygyria, polymicrogyria, heterotopia, cortical dysplasia, and 
migration disorder. All patients with available neuroimaging studies were included. All 
neuroimaging findings (MRI and computed tomography) were reevaluated by a pediatric 
neurologist (I.F.M.d.C.), a clinical geneticist (G.M.S.M.), and a pediatric neuroradiologist 
(M.H.L.). From 1992 to 2005, we included the most recent MRI study if a diagnosis of MCD 
was made when the patient was younger than 16 years. Consensus was required and 
patients were classified into 4 groups on the basis of MRI criteria.7,12 None of the patients 
had a molecularly confirmed diagnosis. 
We excluded patients with neoplasms, tuberous sclerosis, and neurofibromatosis 1. We 
excluded those with hydranencephaly and holoprosencephaly, unless associated with 
obvious MCD such as periventricular nodular heterotopia. We excluded patients with 
infratentorial abnormalities only and patients with a normal cortex and microcephaly or 
macrocephaly. 
 
Clinical evaluation 
If possible, patients were examined at the multidisciplinary outpatient clinic. Epilepsy was 
diagnosed when seizures were present and electroencephalographic findings were 
abnormal. The level of mental retardation was defined as mild (IQ, 70-80), moderate (IQ, 
50-69), or severe (IQ, <50), based on age-appropriate neurodevelopmental testing, 
performed by the school or by our clinic. 
 
RESULTS 
 
Patient classification 
Diagnosis was confirmed retrospectively in 48 patients, with 65 patients added 
prospectively, resulting in a case series of 113 patients (55 boys and 58 girls). They were 
classified into 4 groups on the basis of MRI findings. Further classification was based on 
results of the physical examination and genetic and metabolic tests (Table 2 and Figure 1). 
In the retrospective search, 76 children were found to have a documented diagnosis of 
MCD. Thirteen were excluded because of missing brain imaging studies. In 15, the 
diagnosis was reversed. In the remaining 48 cases, an MCD was confirmed, although the 
classification was revised in 11 patients. In 6, a diagnosis of pachygyria was changed to 
PMG. The opposite change was made in 1 case. In 2 cases, a diagnosis of lissencephaly was 
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revised to simplified gyral pattern (SGP). A presumed cortical dysplasia was found to be 
PMG in 2 cases. 
 
Table 2. Classification of patients 
Group 
No. 
Description (subgroup) No. of 
Patients 
1 Disorders of proliferation, congenital microcephalies  11 
2  Disorders of migration, lissencephaly/heterotopia (all)  
 Agyria, pachygyria, subcortical band heterotopia (A)  24 
 Cobblestone-type lissencephaly (B)  2 
 Periventricular nodular heterotopia (C)  14 
 Periventricular nodular heterotopia with PMG (D)  11 
3 Disorders of cortical organization, PMG (all)  
  PMG and schizencephaly (A)  48 
 Transmantle dysplasia (B)  1 
4 MCDs secondary to inborn errors of metabolism   2 
All   113 
 
 
Figure 1. Flowchart of diagnostic results 
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Epidemiological findings 
In the 10 years of retrospective analysis, we found 48 cases; in the 4 years of prospective 
analysis, 65 cases. This change may be owing to increased alertness and/or the quantity 
and quality of brain imaging. In addition, the number of first-patient visits increased 
greatly. At the time of the study, patients were not referred to us preferentially. Per year, 
1700 to 2000 new patients were referred to the pediatric neurology outpatient clinic, 
making the incidence of MCD in our population approximately 8 cases for every 1000 new 
patients.  
 
Clinical Overview 
Before or during follow-up, 68 patients (60%) developed epilepsy. Significantly fewer 
patients with PMG had epilepsy than in the other groups (Table 3). They may develop 
epilepsy at an older age. Mental retardation was present in 106 of 113 patients, although 
the degree was mild in 27. The severity of mental retardation was correlated with the 
presence of epilepsy and its age at onset (P=.001). If a first seizure happened before 9 
months of age (median age at onset), most of these patients (31 of 35 [91%]) showed 
moderate to severe mental retardation, whereas this was found in 17 (57%) of the 30 
patients who developed seizures later in life. This probably reflects the severity of the 
underlying brain malformation. All 22 children who presented with neonatal seizures or 
infantile spasms developed severe mental retardation, and 8 died during infancy. Overall, 
17 children died during follow up. Neurological motor problems were common, including a 
spastic tetraparesis in 26 children, a spastic hemiparesis in 19, and severe hypotonia in 18. 
A range of congenital major and minor anomalies was seen.  
 
Table 3. Clinical features of epilepsy and mental retardation 
Group 
No. 
Subgroup No. of 
patients 
Moderate/severe mental 
retardation, no. (%) 
Epilepsy, 
No. (%) 
Median age at onset 
of epilepsy, y 
All  Overall 113 79 (70) 68 (60)  0.8 
   1 Microcephaly 11 9 (82) 6 (55) 0.2 
   2A Pachygyria 24 19 (79) 19 (79) 1.8 
   2C PNH 14 8 (57) 10 (71) 2.9 
   2D PNH with PMG 11 7 (64) 9 (82) 0.8 
   3 PMG 48 32 (67) 20 (42)* 1.6 
Abbreviations: PMG, polymicrogyria; PNH, periventricular nodular heterotopia. *p= .001, 2 test. 
 
Genetic Overview 
The standard karyotype was normal in all patients who underwent testing unless 
otherwise specified. Further genetic analysis is described per group (Figure 1 and Table 4).  
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Groups 
Congenital microcephalies with MCD 
We found 11 cases of congenital microcephalies with MCD (group 1), including 7 with SGP 
and 4 with agyria or pachygyria. Two unrelated patients had SGP and diabetes mellitus. In 
patient 1, the cause was Wolcott-Rallison syndrome; in the other, this cause was excluded. 
Three of the remaining patients with SGP had consanguineous parents. Two patients with 
SGP had mild or no mental retardation and normal motor skills (e.g., Figure 2A). None had 
evidence of a gestational insult. 
Patients with SGP are candidates for testing of the MCPH loci (Table 1), but tests are 
currently not available. The patient with Wolcott-Rallison syndrome had a homozygote 
missense mutation in EIF2AK3 and was included in a previously published report.13 In 3 of 
the 4 patients with agyria or pachygyria, interstitial deletions in 17p13.3 and LIS1 
mutations were excluded; for the remaining patient, no DNA was available. 
 
Lissencephaly, pachygyria, and subcortical band heterotopia spectrum 
Twenty-four patients were diagnosed as having syndromes or diseases that fell within the 
spectrum of lissencephaly, pachygyria, and subcortical band heterotopia (group 2A) (Table 
4). In 16 of these patients, a genetic syndrome was diagnosed. Five had Miller-Dieker 
syndrome with typical facial features, severe mental retardation, and epilepsy (Figure 3A). 
Four patients with pachygyria and moderate or severe mental retardation had a LIS1 
mutation (Figure 3B). Two patients with milder retardation and MRI abnormalities had a 
somatic mosaic LIS1 mutation (Figure 3C).14 Two girls with subcortical band heterotopia 
and epilepsy had a DCX mutation (Figure 3D). One girl was diagnosed as having Baraitser-
Winter syndrome (patient 25) (Figure 2B).15 Patient 26 had a muscle-eye-brain type disease 
with muscular dystrophy, elevated levels of creatine kinase, and visual impairment. His 
MRI did not show a cobblestone-type lissencephaly, but rather occipital pachygyria with 
nonprogressive leukodystrophy (Figure 2C). Arguably, this patient could be classified as 
belonging to group 2B. One boy was diagnosed as having FG syndrome on the basis of 
dysmorphic features and urogenital abnormalities.16 He is undergoing testing for the 
R916W mutation in the HOPA gene (OMIM 300188).17 
Of the 8 patients with unknown etiology, 1 pedigree shows an affected mother and son, 
suggesting an autosomal dominant or X-linked inheritance, but the mutation analysis 
results of LIS1, DCX, and ARX were normal. One patient had a brother with 
microlissencephaly in group 1. There was no consanguinity in group 2A. Most of the 
patients had severe psychomotor retardation with or without epilepsy (16 of 24), whereas 
only 5 patients had normal development or a mild mental deficit. The 5 patients with 
Miller-Dieker syndrome had an interstitial deletion of 17p13.3 confirmed by fluorescence 
in situ hybridization analysis. Sequencing of LIS1 was performed in 12 patients and 
showed pathological mutations in 4, including 2 nonsense mutations (W261X and G147X), 
1 frameshift mutation (c.162delA), and 1 intron mutation (900+1G>C; IVS8+1G>C). In 2 
patients, a somatic mosaicism was found (mosaic 162delA and R113X). Analysis of DCX 
was performed in 8 patients. In 2, a nonsense mutation was found (R303X and R272X). No 
mutations were found in 2 patients in whom ARX and RELN were tested. None of the 
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patients fit the typical phenotype of X-linked lissencephaly with abnormal genitalia for 
ARX or of pachygyria, cerebellar anomalies, and lymphedema for RELN (Appendix). In 
patient 25, results of microscopic analysis of a muscle biopsy were normal, and mutations 
in FCMD (OMIM 607440) and FKRP (OMIM 606596) were excluded. 
 
Cobblestone-type lissencephalies 
Two patients with cobblestone-type lissencephalies (group 2B) had Walker-Warburg 
syndrome (Table 4). Both died in infancy (Figure 2D). No muscle biopsy material was 
preserved for histochemical analysis of -dystroglycans.18 Mutations in POMT1 and 
POMGnT1 were excluded in both patients. Further genetic analysis will be performed when 
methods become available.  
 
Nodular heterotopia  
We found 14 patients with nodular heterotopia without cortical abnormalities (group 2C) 
(Table 4). One patient with a history of maternal cocaine abuse during pregnancy, mild 
retardation, epilepsy, and diffuse bilateral periventricular nodular heterotopia (BPNH) had 
an FLNA mutation (patient 38, Figure 3E).19 We assumed there was an autosomal recessive 
syndrome in 3 siblings with microcephaly, BPNH, and cerebellar atrophy without FLNA or 
ARFGEF2 mutations. One patient had a syndrome with an occipital meningocele and BPNH, 
a combination reported previously.20 Patient 41 died in infancy of a severe cardiac anomaly 
and BPNH with enlarged ventricles. In another boy, maternal alcohol abuse during 
pregnancy was documented, but alcohol has not been clearly linked to BPNH in humans. 
Overall, symptoms ranged from drug-responsive epilepsy with normal or near-normal 
mental and motor development to epilepsy with severe handicap.  
Testing of FLNA was performed in 10 patients in group 2C.19 A pathogenic frameshift 
mutation (7104delG) was found in patient 40. In patient 41, a previously unreported 
missense change in exon 20 was found, but it was not possible to perform additional tests 
to prove pathogenicity. For 2 patients, no DNA was available. Testing of ARFGEF2 was 
performed in 3 patients, with normal results.21 
 
Heterotopia with overlying PMG 
In 11 patients with heterotopia combined with overlying PMG (group 2D), 7 presented 
with severe psychomotor retardation, whereas 4 showed normal or near-normal mental 
development independent of epilepsy or the extent of MRI abnormalities (Table 4). We 
diagnosed frontonasal dysplasia in a patient with a frontal encephalocele and facial 
asymmetry. Considering the overlap with craniofrontonasal dysplasia, mutations in EFNB1 
were excluded (OMIM 300035). One girl had a large Xq chromosome deletion (patient 53). 
In 2 patients, there was parental consanguinity. A standard karyotype of patient 53 
showed a deletion of Xq21qter, including the FLNA and DCX loci. This finding was excluded 
in her parents. It was not possible to conduct X chromosome inactivation studies to 
analyze the relevance. 
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Figure 2. Magnetic resonance images of key patients with a definite diagnosis without known molecular 
defects. All images are T1-weighted, except where indicated. A, T2-weighted image of patient 2, a boy 
aged 29 months with a simplified gyral pattern and high clinical function. A reduced number of gyri, 
shallow sulci, and normal cortical thickness are seen. B, Patient 25, a girl aged 6 months with Baraitser-
Winter syndrome. The cortex in the frontal lobes is thickened. C, Patient 26, a boy aged 6 years with a 
muscle-eye-brain–type syndrome. Smooth gyration in the occipital lobes is evident. D, Patient 36, a 
newborn boy with Walker-Warburg syndrome. Gyration is absent and the ventricles are enlarged. E, 
Patient 68, a boy aged 3 years with Adams-Oliver syndrome. Periventricular heterotopic nodules of gray 
matter and irregularity of the gyral pattern suggest polymicrogyria (PMG). F, Patient 71, a boy aged 5 
years with merosin-negative muscular dystrophy. Irregular gyration is seen in the frontoparietal regions, 
most pronounced around the sylvian fissure, suggestive of PMG. 
 
PMG and schizencephaly 
We established a causative diagnosis in 20 of 48 cases with PMG and schizencephaly 
(group 3A) (Table 4). Four patients belonged to a pedigree with Goldberg-Shprintzen 
syndrome.22 Ten cases were diagnosed as having a syndrome or a monogenetic disorder 
associated with PMG. One patient fulfilled criteria for Adams-Oliver syndrome (Figure 2E), 
another for Sturge-Weber syndrome, another for Aicardi syndrome, and another for Joubert 
syndrome. 2,7,23,24 Patient 67 had a muscle-eye-brain type disease with schizencephaly, 
congenital cataracts, and muscular dystrophy. Patient 71 was diagnosed as having a 
merosin-negative muscular dystrophy (Figure 2F). Three patients, 2 of whom are from the 
same pedigree, were found to have a syndrome consisting of megalencephaly, perisylvian 
PMG, postaxial polydactyly, and hydrocephalus.25 In an additional 7 patients, there was 
documented evidence of a gestational insult that could have caused PMG. Congenital 
cytomegalovirus infection was excluded in 9 patients with unexplained PMG; in 2 
additional patients, this infection could not be excluded. We suspected a genetic cause in 6 
patients with multiple congenital abnormalities and in 4 with consanguineous parents or 
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multiple affected family members. In 11 of 48 patients, we found no clues to an underlying 
cause. 
In all patients examined after 2001, microdeletions at the 22q11 locus were excluded. 
Analysis of KIAA1279 in patients with Goldberg-Shprintzen syndrome was performed as 
described by Brooks et al.22 Testing for mutations in GPR56 was performed in 13 cases of 
bilateral perisylvian PMG, with negative results. Mutations in AHI1 (OMIM 608894), 
associated with Joubert syndrome, were excluded in patient 72. In patient 67, analysis of -
dystroglycans in muscle biopsy specimens was ongoing at last follow-up. In patient 71, 
LAMA2 (OMIM 156225) analysis was not available at the time of diagnosis. 
 
 
 
Figure 3: Magnetic resonance images of key patients with a definite diagnosis with a known molecular 
defect. A, Axial T1-weighted image of patient 13, a girl aged 5 months, with Miller-Dieker syndrome. The 
cortex is smooth and thickened with a slight posterior-to-anterior gradient. B, Coronal T2-weighted 
image of patient 18, a girl aged 6 years, with a LIS1 mutation. The cortex is smooth and thickened with 
relative sparing of the temporal lobe. C, Axial T1-weighted image of patient 21, a boy aged 14 months, 
with a mosaic LIS1 mutation. A less severe phenotype is seen, but still with a reduced number of gyri and 
cortical thickening. D, Coronal T2-weighted image of patient 23, a girl aged 6 years, with a DCX 
mutation. A thick band of subcortical gray matter (“double cortex”) is seen. E, Axial T2-weighted image 
of patient 38, a girl aged 5 weeks, with an FLNA mutation. A bilateral periventricular ribbon of 
heterotopic nodules is evident. F, Axial T1-weighted image of patient 113, a girl aged 1 week, with 
Zellweger syndrome. Irregular and small gyri, suggestive of diffuse polymicrogyria, and partial agenesis 
of the corpus callosum are seen. 
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Metabolic causes 
Metabolic causes were found in 2 patients (group 4) diagnosed as having Zellweger 
syndrome and malonylcoenzyme A decarboxylase deficiency, an inborn metabolic disease 
(Table 4). Polymicrogyria is associated with Zellweger syndrome, but diffuse severe PMG 
with cerebellar abnormalities is rare (Figure 3F).26 To our knowledge, pachygyria and 
nodular heterotopia have not been described in previous reports of malonyl-coenzyme A 
decarboxylase deficiency.27 
Peroxisomal fatty acid oxidation in fibroblasts and a mutation in PEX10 (OMIM 602859) 
confirmed the diagnosis in patient 113. Malonyl-coenzyme A decarboxylase in fibroblasts 
of patient 112 was deficient, and MLYCD (OMIM 606761) analysis showed absence of a 
transcript.27  
 
COMMENT 
This study of a large consecutive group of patients with MCD shows the effect of 
combining radiological, clinical, and molecular analysis. After radiological classification, 
analysis for associated congenital anomalies and dysmorphic features, and genetic tests, a 
definite diagnosis of the underlying cause was found in 38 cases (34%). For 21 patients 
(19%), this included molecular and/or genetic confirmation, and in 17 (15%), this was a 
syndrome diagnosis with an unknown genetic defect. In another 7 patients, we found 
evidence of a gestational insult, for a total of 45 etiological diagnoses (40%). These results 
improved patient care and gave parents opportunities for reproductive choices and 
prenatal diagnosis. Some smaller studies have been published, most of which focus on a 
specific MCD subgroup.12,19,28-30 One cohort study of similar size reviewed radiological and 
clinical findings, without syndrome diagnoses or molecular diagnostic testing.31 
 
Neuroradiological Data 
Our retrospective revision of all neuroimaging studies showed that 26 of 63 patients (41%) 
had received previous misdiagnoses. A quality MRI of the brain and a skilled 
neuroradiologist are essential for a correct classification and the choice of diagnostic tests. 
The 2005 MCD classification is useful, although some patients remain hard to classify, 
especially those with combinations of heterotopia and abnormal cortex.7,12 
 
Laboratory and Molecular Data  
For some MCD phenotypes such as Walker-Warburg syndrome, genetic heterogeneity is 
wide, making molecular confirmation difficult.18 In others such as microcephaly with SGP, 
tests for known genes are not routinely available. Telomere multiplex ligation-dependent 
probe amplification is also becoming available to assist in diagnosis. More extensive 
testing can further increase the number of molecularly confirmed diagnoses. As expected 
from previous observations, genetic causes were most often confirmed in our patients with 
lissencephaly or pachygyria.29,32 Mutations in LIS1 or DCX explained the lissencephaly and 
pachygyria in more than half of our patients. The genetic causes of PMG are still largely 
elusive. Mutations in GPR56 and KIAA1279 only explain a small percentage of PMG 
cases.22,33 We tested GPR56 in 13 patients with bilateral frontoparietal PMG, but found no 
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mutations. None of these patients had the typical pons hypoplasia and white matter 
abnormalities, further confirming the specificity of the  phenotype associated with GPR56 
mutations.30 
 
Implications for Clinical Care 
In our cohort, most patients were diagnosed as having MCDs when they developed 
seizures. Patients with PMG have a lower incidence of epilepsy, and motor dysfunction 
often prompted medical attention. The overall risk of psychomotor retardation is high, but 
34 of our 113 patients had an IQ greater than 70. Epilepsy is a negative prognostic factor, 
particularly infantile spasms or neonatal seizures. In 1 patient with BPNH, we found a 
pathogenic FLNA mutation, whereas her developmental delay previously was accredited to 
prenatal exposure to cocaine. This supports the predictive power of a specific radiological 
pattern for genetic testing. We did not find mutations in patients whose MRI pattern was 
not typical for the gene tested. We recommend careful classification before ordering 
genetic tests. 
 
Future Perspective  
Nine patients in our cohort fit a known syndrome with an unknown genetic cause. 
Another 15 patients presented with an apparently unique syndrome, meaning a 
combination of multiple anomalies likely to result from an underlying genetic cause. 
Furthermore, a genetic cause is likely in patients with affected family members with or 
without consanguinity (12 patients) or in patients with consanguineous parents only (7 
patients). These 3 groups are candidates for whole-genome analysis by means of new 
techniques designed to discover other genes involved in brain development. This approach 
has been successful in cohorts of patients with congenital malformations and mental 
retardation.34 In addition, consanguineous families with multiple affected members can be 
explored by improved linkage techniques. 
 
CONCLUSIONS 
Our cohort represents a heterogeneous group but closely follows clinical practice, where 
most patients are referred with an unclassified MCD. We show that classification based on 
radiological, clinical genetic, and neurological examinations combined with genetic testing 
can yield important information about monogenetic, syndromal, and metabolic causes and 
can lead to improvement of patient care and genetic counseling. This requires a 
multidisciplinary team specialized in neuroradiology, pediatric neurology, and genetics. 
Even then, the underlying cause remains elusive in more than 50% of patients, and the 
suspicion of an underlying genetic cause remains in many of our unclassified cases. This 
encourages exploitation of new genome-wide techniques. 
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ABSTRACT 
 
All patients with classic or type 1 lissencephaly born between 1972 and 1990 in the 
Netherlands were at the time enrolled in an observational study. We attempted to contact 
these 24 patients again to obtain long-term follow-up and survival information. Eleven 
patients were alive. All patients showed severe mental retardation, intractable epilepsy 
and complete dependence on care. Life expectancy showed a significant correlation to the 
severity of the lissencephaly on neuroimaging.  
Molecular analysis of the LIS1-gene was not possible at the time of the original study and 
was now requested by eight parents. This revealed a pathogenic mutation or large deletion 
of LIS1 in seven patients.  
Our study provides information about the long-term course of lissencephaly, the 
relationship between lissencephaly severity and prognosis, and shows that renewed 
attention to genetic counseling remains valued by families of a patient with a severe 
congenital neurological disease. 
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LONG TERM FOLLOW-UP OF LISSENCEPHALY 
 
INTRODUCTION 
Lissencephaly type 1 (‘smooth brain’) has long been recognized as a cause of severe mental 
retardation. In lissencephaly type 1 the cerebral cortex lacks the characteristic gyri and 
sulci and is thicker than normal, either throughout the cortex or more severely in the 
posterior than the anterior regions. The advance of neuroimaging techniques enabled the 
diagnosis of lissencephaly during life, and sparked more research into its causes. 
Improving techniques for genetic studies yielded a first answer when (partial) monosomy 
of chromosome 17 was found in patients with lissencephaly and typical facial dysmorphic 
features (Miller-Dieker syndrome).1 The identification of 17p13.3 as the region involved in 
Miller-Dieker syndrome in 1989 changed genetic counseling and made prenatal testing 
possible in some cases.2 Ten years later the LIS1 gene (also called the PAFAH1B1 gene) was 
identified in this region, which causes autosomal dominant lissencephaly or pachygyria 
with a posterior to anterior gradient.3 Several other genetic causes were later found in the 
lissencephaly, pachygyria and subcortical bandheterotopia (SBH) spectrum. DCX causes X-
linked lissencephaly or SBH with an anterior to posterior gradient.4  Autosomal recessive 
lissencephaly associated with cerebellar and brainstem abnormalities is caused by RELN 
mutations.5 In the RELN pathway, another gene called VLDLR can cause a similar but milder 
phenotype.6 Mutations in ARX can cause X-linked lissencephaly, but there is a wide 
variation in phenotypes associated with mutations in this gene.7 Mutations in TUBA1A 
cause autosomal dominant lissencephaly, often with cerebellar and callosal 
malformation.8 
Most cases of type 1 lissencephaly are explained by mutations in LIS1, DCX or by 17p13.3 
haploinsufficiency. Clinical signs reported are epilepsy, mental retardation and spasticity. 
Not much has been published on the follow-up of lissencephaly patients or their life 
expectancy. Groups of patients are described in general terms and follow-up is reported to 
early childhood and only in a few cases until adulthood.9-13 To improve knowledge about 
the natural course of lissencephaly type 1 and provide better prognostic information for 
parents, we attempted to contact all lissencephaly patients born between 1972-1990 
identified in a nation-wide study done in the Netherlands who, if alive, would now be 
adults.11,14-16 This is the largest reported cohort of consecutive patients in the literature. At 
the time of the original study, parents had given informed consent for DNA to be stored 
and to be used if and when further genetic testing would become feasible. 
 
METHODS 
During the original study of de Rijk-van Andel 24 type 1 lissencephaly patients born in the 
Netherlands in the period 1972-1990 were included.11,14-16 At the end of the original follow-
up in 1990, 17 patients were still alive. Between 2006 and 2008, we attempted to contact 
these 17 patients. If possible, the patient was examined at our clinic, and if not an 
interview was done by telephone with the parents or caretaker. All original brain imaging 
(CT scans and MRI scans if available) was reevaluated and lissencephaly was graded 
according to the following lissencephaly patterning scale: grade 1: complete agyria, grade 
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ABSTRACT 
 
All patients with classic or type 1 lissencephaly born between 1972 and 1990 in the 
Netherlands were at the time enrolled in an observational study. We attempted to contact 
these 24 patients again to obtain long-term follow-up and survival information. Eleven 
patients were alive. All patients showed severe mental retardation, intractable epilepsy 
and complete dependence on care. Life expectancy showed a significant correlation to the 
severity of the lissencephaly on neuroimaging.  
Molecular analysis of the LIS1-gene was not possible at the time of the original study and 
was now requested by eight parents. This revealed a pathogenic mutation or large deletion 
of LIS1 in seven patients.  
Our study provides information about the long-term course of lissencephaly, the 
relationship between lissencephaly severity and prognosis, and shows that renewed 
attention to genetic counseling remains valued by families of a patient with a severe 
congenital neurological disease. 
Long term follow-up of Lissencephaly 
69 
LONG TERM FOLLOW-UP OF LISSENCEPHALY 
 
INTRODUCTION 
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adults.11,14-16 This is the largest reported cohort of consecutive patients in the literature. At 
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and to be used if and when further genetic testing would become feasible. 
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During the original study of de Rijk-van Andel 24 type 1 lissencephaly patients born in the 
Netherlands in the period 1972-1990 were included.11,14-16 At the end of the original follow-
up in 1990, 17 patients were still alive. Between 2006 and 2008, we attempted to contact 
these 17 patients. If possible, the patient was examined at our clinic, and if not an 
interview was done by telephone with the parents or caretaker. All original brain imaging 
(CT scans and MRI scans if available) was reevaluated and lissencephaly was graded 
according to the following lissencephaly patterning scale: grade 1: complete agyria, grade 
de Wit_DEF.indd   69 02-08-10   16:32
de Wit (all).ps Front - 35     T1 -    Black CyanMagenta Yellow
Chapter 3.1 
70 
2: agyria with few shallow anterior sulci, grade 3: posterior agyria and anterior pachygyria, 
grade 4: diffuse pachygyria posterior>anterior, grade 5: mixed pachygyria and subcortical 
band heterotopia (SBH), grade 6 SBH only.17 If the patient had died, age and cause of death 
were recorded. At the time of the original study, DNA from leukocytes of patients alive at 
diagnosis was stored with the parents’ informed consent. If genetic analysis had not 
previously been done, we offered the parents the option testing for 17p13.3 deletion, 
sequence analysis of LIS1 and DCX where appropriate for the phenotype and MLPA analysis 
for deletions in/of these genes. Repeating neuroimaging studies or EEG was considered not 
justified as it would not benefit the patients. 
 
RESULTS 
Diagnosis 
In two patients lissencephaly was diagnosed at autopsy and grading was done based on 
the autopsy report, for all other patients neuroimaging was available. Lissencephaly 
grading was done based on brain CT (examples in figure 1). Both CT and MRI had been 
made in five patients, and grading based on MRI was the same as on CT. The majority had a 
grade 1 or 2 lissencephaly (33% and 46%). Five patients had a grade 3 or 4 lissencephaly 
(see table).  
 
 
 
Figure 1: examples of CT scans and grading. Grade 1 (patient 24, female, CT scan made at the age of 9 
months) shows complete agyria, ‘figure of eight’-configuration due to lack of opercularization and 
thickened cortex. Also note the cavum septum pellicidum. Grade 2 (patient 17, male, CT scan made at 
the age of 4.5 months). Note the few shallow sulci in the frontal lobes and some opercularization. Grade 
3 (patient 4, male, CT scan made at the age of 1 yr). Note diffuse course gyri and shallow sulci 
predominantly in the anterior regions and the further opercularization of the insular region. 
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Survival 
During the original study period 7 patients (29%) died at ages between 0 and 9 years (table, 
figure 2 and 3). One patient was lost to follow-up and we have been informed that she died 
but we could not recover the age or cause of death (pat 5 in table). All other parents agreed 
to visit the clinic or gave information over the telephone. Five patients had died after 1990, 
between the ages of 3 and 19. The cause of death was either status epilepticus or 
pneumonia. Eleven patients (46%) are alive, now aged 18 to 27 years (see survival curves in 
figure 2). There is a significant association between survival and the severity of the 
lissencephaly (Log-Rank test p=0.002).  
 
Clinical signs (table) 
All patients show severe psychomotor retardation. In 15 cases parents report having (had) 
some contact with their child, in nine there is or has never been any contact. In one patient 
contact was lost at the onset of seizures. All have intractable epilepsy with age of onset 
between a few days to 2 years old (average 6 months). Five patients presented with 
seizures in the neonatal period, 17 with infantile spasms and two with multifocal epilepsy 
(at age 6 months and age 2 years). There is no significant correlation between age of onset 
of seizures and survival. In two patients seizures are reasonably controlled by anti-
epileptic drugs, in the others seizures remain frequent (daily to weekly). The EEGs have 
been described before and show typical generalized fast activity with high amplitude 
and/or high amplitude sharp- and slow-wave complexes in almost all cases.16 None of the 
patients ever had a normal EEG. Two patients had shown some motor development to 
head balance, clapping hands and belly crawling, but had lost these milestones later in life 
during periods of infectious disease and seizures. All patients show axial hypotonia, and 
four patients have a severe scoliosis. Spasticity is mild, but more prominent in three 
patients. All but one of the parents said that having a child with lissencephaly has a severe 
and negative impact on their family and their quality of life, but that their child seems 
content most of the time and does not suffer. One mother states that she feels that her 
child does not have any quality of life.  
 
Genetic analysis 
During the original study, of all patients alive at the time of inclusion (18/24) DNA had 
been stored with informed consent. At the time microscopic high resolution chromosome 
banding was done in all patients and in one patient had shown a probable chromosome 
17p13.3 deletion consistent with Miller-Dieker lissencephaly syndrome (pat 7). This was 
confirmed with FISH analysis and this patient died during the original study period. At the 
current follow-up, we found that since 1990 in three more patients a diagnosis had been 
made of Miller-Dieker syndrome due to a deletion at chromosome 17p13.3 (pat 13, 20, and 
24). One of these had since died. For 13 patients without a molecularly confirmed diagnosis 
DNA was still stored. 
Five patients had died after 1990. Parents of one of these patients parents wanted further 
testing to aid reproductive choices in the sisters of the patient and a heterozygous LIS1 
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mutation (c.334insA) was detected (pat 23). Parents of two patients wanted to leave the 
decision to their other children; one couple did not have other children. 
Eleven patients are alive now (46%). In two a chromosome 17p13.3 had been diagnosed 
after 1990. Of the remaining nine patients, seven families requested further genetic testing 
to confirm the diagnosis and to aid reproductive choices in the siblings of the patients. Two 
families preferred not to have any more medical tests. 
 
Direct sequence analysis of the coding exons and exon intron boundaries showed 
heterozygosity for a frameshift, nonsense or splice site mutation in the LIS1 gene in four 
patients (see table). MLPA analysis showed an intragenic LIS1 deletion in one patient 
spanning at least the 6 most 3’ exons, whereas another patient had a total LIS1 deletion 
possibly further extending into the Miller Dieker region. In one patient LIS1 sequencing 
and MLPA testing of the LIS1 gene were normal (pat 8). Additional sequence analysis of 
TUBA1A was also normal. When a gene defect had been found, parents and siblings were 
invited for genetic counseling. In parents that were tested, mutations were absent (two 
couples). When mutations were found in the patients, most parents expressed that they 
were pleased that any doubts about influences during pregnancy and recurrence risks had 
now been dispelled. 
 
 
Figure 2: flowchart of follow-up results 
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Discussion 
Our cohort study confirms that children with type 1 lissencephaly have a severe mental 
and motor retardation and that the epilepsy is intractable in all cases. Epilepsy treatment is 
still important, because seizures can lead to loss of skills or death as also demonstrated in 
this cohort. Life expectancy is limited but with supportive care focused on the prevention 
of infectious complications and scoliosis many of these children can reach adulthood. All 
patients in this cohort have severe lissencephaly phenotypes, as milder phenotypes such 
as subcortical band heterotopia were not recognized during life in 1980-1990 due to the 
limitations of neuroimaging. In general, the phenotype may be as mild as having epilepsy 
with normal mental development.18 We show that life expectancy is related to the severity 
of the lissencephaly on neuroimaging, with a significantly worse outcome for complete 
agyria as compared to the milder diffuse pachygyria. Location of the mutation in the LIS1-
gene have been postulated not to directly predict disease severity.19,20 However, LIS1 
missense mutations are though to result in a milder phenotype.18  Also, the severity of the 
effect of the mutation on the LIS1-protein does have a relationship with the severity of the 
lissencephaly grading on neuroimaging.13,21,22 In our cohort all mutations found in LIS1 are 
nonsense mutations or intragenic deletion, and we did not find any missense mutations. 
We had no indication of somatic mosaicism in our cohort, although this can never be ruled 
out entirely. Possibly, our findings are caused by selection bias toward the more severe 
phenotype due to the neuroimaging possibilities of that time, indirectly supporting the 
notion that missense mutations generally result in milder phenotypes.  
With the techniques available at the time of the original study only microscopic 
chromosome deletions could be detected by high resolution chromosome banding and a 
deletion of 17p was found in one patient then. After 1990 a deletion of chromosome 
17p13.3 had been found in three more patients. When we offered parents further genetic 
analysis using current techniques, the majority welcomed this, and in 8 out of 14 patients 
genetic testing confirmed the clinical diagnosis. These results confirm the high predictive 
value of classic lissencephaly on neuroimaging for mutation in LIS1. In one patient we 
were unable to confirm a genetic cause with all available options, including TUBA1A 
analysis (pat 8).  Possibly she has a LIS1 dysfunction that could not be proven with our 
methods (MLPA and sequencing) or the available material (DNA isolated from leukocytes). 
Our study shows the importance of the interpretation and classification of neuroimaging 
for prognosis and counseling of parents of a child with a severe congenital neurological 
disease. It also reminds us that genetic studies are still valued by parents and siblings of 
adult disabled patients to understand the cause and to answer any lingering doubts about 
recurrence risk. 
 
Acknowledgments: 
Dr. D. Pilz, Department of Medical Genetics, Cardiff University School of Medicine, UK, 
tested patient 8 for TUBA1A mutation. 
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ABSTRACT 
 
Filamin A is an important gene involved in the development of the brain, heart, connective 
tissue and blood vessels. A case is presented illustrating the challenge in recognising 
patients with filamin A mutations. The patient, a 71-year-old woman, was known to have 
heart valve disease and bilateral periventricular nodular heterotopia when she died of a 
subarachnoid haemorrhage. Autopsy showed typical cerebral bilateral periventricular 
heterotopia and vascular abnormalities. 
Postmortally, the diagnosis of a filamin A mutation was confirmed. Recognition during life 
may prevent cardiovascular problems and provide possibilities for genetic counselling. 
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FILAMIN A MUTATION, A COMMON CAUSE FOR PERIVENTRICULAR 
HETEROTOPIA, ANEURYSMS AND CARDIAC DEFECTS 
 
Filamin A (FLNA) is an important gene involved in the development of the brain, heart, 
connective tissues and blood vessels. Patients with FLNA mutations may develop 
symptoms at any age. We present a case that shows distinctive features of a FLNA 
mutation, which was only recognised at the time of her death. 
 
CASE REPORT 
A 71-year-old woman presented with an acute loss of consciousness. Brain CT showed a 
subarachnoid haemorrhage, leukoaraiosis and bilateral periventricular nodular 
heterotopia (BPNH) (fig 1). CT angiography confirmed several fusiform aneurysms 
inaccessible for coiling or surgery. The patient had cardiac problems from the age of 24 
years with palpitations, chest pains and fatigue. At 32 years a severe aortic valve 
insufficiency was treated by valve replacement. Progressive heart failure led to heart 
transplantation at the age of 56 years. A VVIR-pacemaker was implanted because of 
symptomatic ventricular arrests. One year before admission she had developed temporary 
cognitive problems during a urinary tract infection. The consulting neurologist had 
ordered a brain CT (figure 1) as MRI was impossible with the pacemaker. 
This showed fusiform aneurysms of the right internal carotid artery and both medial 
cerebral arteries, BPNH and leukoaraiosis. The patient had graduated normal primary 
school and was a housewife and mother of a healthy son. Her mother had died of heart 
failure at the age of 69 years. Her father died at the age of 72 years of a heart attack. The 
patient had a healthy twin brother and a sister, both childless. Despite optimal ICU 
support, the patient died of a rebleed 13 days later. Her husband consented to autopsy. 
 
 
Figure 1: Brain imaging studies. (A) CT scan showing blood in the subarachnoid spaces and an aneurysm 
of the right middle cerebral artery. (B, C) Earlier CT scan showing mildly enlarged lateral ventricles with 
bilateral periventricular nodules of grey matter. The white matter shows bilateral hypodense areas 
suggestive of leukoaraiosis. 
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Brain pathology 
There was a subarachnoidal haemorrhage due to a ruptured aneurysm of the left internal 
carotic artery. The vessels of the circle of Willis showed severe atherosclerosis. There were 
extensive hypertensive microvascular changes. There were subependymal proliferations 
consistent with ependymitis granularis (i.e. proliferation of ependyma, usually due to 
longstanding hydrocephalus). The cerebellum, pons and mesencephalon appeared normal. 
There were numerous periventricular nodular heterotopia along the walls of both the 
lateral ventricles extending into the parahippocampal area (fig 2). These consisted of 
neuronal cells and glia with a mature morphology. A discrete cortical malformation 
consisting of an unclear white to grey matter junction was seen in the right temporal 
region, but otherwise the cortex appeared normal. In the grey and white matter of both 
hemispheres, including the heterotopia, capillary proliferations were present. Many of 
these vessels displayed a glomeruloid-like architecture, and were present individually and 
in groups. The capillary lumina were lined by CD31 and CD34 positive cells, parts of which 
also stained for smooth muscle actin. The distribution of the proliferated microvasculature 
seemed random without concentration areas. These ‘glomeruloid microvascular 
anomalies’ have been described in a patient with a FLNA mutation, but not in other 
diseases.1 
 
Figure 2: Microscopic findings in the brain at autopsy. (A, B) Kluver staining of heterotopia. (C) CFAP 
staining of heterotopia. (D) Area of temporal cortex dysplasia. (E, F) CD34 and CD31 staining of 
glomeruloid capillary proliferations. 
 
Genetic analysis 
Direct sequence analysis of the 48 coding exons and exon–intron boundaries of the FLNA 
gene showed a new pathogenic frameshift mutation 3045del5 in exon 21, not present in 
100 controls. This mutation affects the C terminus binding site and/or the ability of the 
protein to dimerise and will probably produce instable mRNA that will be degraded by the 
nonsense mediated decay system. 
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DISCUSSION 
In this patient, a common cause for the cardiac valvular disease, cerebral cortical 
malformation and arterial aneurysms, was suspected and confirmed at post mortem. 
BPNH usually presents with epilepsy, but surprisingly our patient never had seizures. In 
BPNH, neuronal progenitors fail to migrate to the cortex during prenatal brain 
development. In 1998 mutations in the X-linked FLNA, encoding the filamin A protein, 
were found in female BPNH patients.2 In males, loss of function mutations are often fatal, 
but milder mutations cause a phenotype similar to females.3 Many patients have 
additional cardiac abnormalities, particularly aortic or mitral valve disease.4 Other 
associated abnormalities include persistent ductus arteriosus, aortic root aneurysm and 
idiopathic thrombocytopenia.2,4-6 A subgroup of BPNH patients caused by FLNA mutations 
show additional features of joint hypermobility and aortic aneurysms, similar to Ehlers 
Danlos syndrome.7 One of these patients survived a subarachnoid haemorrhage.8 Recently, 
in three families, X-linked mitral valvular dysplasia with varying degrees of aortic valve 
insufficiency was found to be caused by FLNA mutations.9 In these families, there was no 
evidence of neurological disease, although no brain imaging was done. All of the clinical 
signs described above are associated with loss of function mutations. Skewing of X-
chromosome inactivation level in females, and the severity of the mutation in both sexes, 
determine the phenotypic variation. Gain of function FLNA mutations cause another 
phenotype with skeletal dysplasia (frontometaphyseal dysplasia, Melnick–Needles 
syndrome or oto-palato-digital syndrome type I and II).10 These syndromes are also 
associated with cardiac defects. Filamin A is the non-muscle isoform of filamin and is 
widely expressed. Two filamin A proteins associate to form a flexible V-shaped 
homodimer. This dimer crosslinks two F-actin filaments, creating a three dimensional 
network inside the cell. The C-terminal side can link to different membrane proteins, 
thereby anchoring the cytoskeleton to the cell membrane. The mechanism leading to BPNH 
has not been fully elucidated. Filamin A is needed for cell migration.11,12 Still, the motility of 
many cell types in subjects with defective filamin A does not seem to be affected, both in 
humans and in mice.13 Filamin A also has an important function in the formation of 
intercellular junctions and the anchoring of the cell to the extracellular matrix. Flna 
knockout mice show cardiac and vascular developmental disorders and midline 
abnormalities.14 Vascular endothelial cells in Flna null mice show defective cell–cell 
contacts and adherens junctions resulting in abnormal angiogenesis with disorganised 
blood vessels with aberrant branching.12 Our patient showed that vascular aneurysms can 
be associated with FLNA mutations in the absence of other Ehlers Danlos type symptoms. 
 
CONCLUSION 
In patients with FLNA mutations, neurological, cardiovascular or orthopaedic symptoms 
may dominate the phenotype. Recognition may lead to prevention of complications and 
also allows genetic counselling for patients and their relatives. Although periventricular 
nodular heterotopia are the clue to the diagnosis, cardiovascular symptoms may dominate 
the patient’s history. Neurologists that diagnose periventricular nodular heterotopia 
should consider referring their patients for a cardiac evaluation. 
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ABSTRACT  
 
Background 
Cardiac defects can be the presenting symptom in patients with mutations in the X-linked 
gene FLNA. Dysfunction of this gene is associated with a congenital malformation of the 
cerebral cortex, but can also lead to cardiac abnormalities, especially in the left ventricular 
outflow tract. We noticed that some patients diagnosed at the Neurogenetics Clinic had 
first presented to a cardiologist, suggesting that earlier recognition may be possible if the 
diagnosis is suspected. 
Methods and results 
From the Erasmus MC cerebral malformations database 24 patients were identified with 
cerebral bilateral periventricular nodular heterotopia (PNH) without other cerebral cortical 
malformations. In six of these patients, a pathogenic mutation in FLNA was present. Five of 
these a cardiac defect was also found in the outflow tract. Four had presented to a 
cardiologist before the cerebral abnormalities were diagnosed. 
Conclusions 
The cardiological phenotype typically consists of aortic or mitral regurgitation, coarctation 
of the aorta or other left-sided cardiac malformations. Most patients in this category will 
not have a FLNA mutation, but the presence of neurological complaints, hyperlaxity of the 
skin or joints and/or a family history with similar cardiac or neurological problems in a 
possibly X-linked pattern may alert the clinician to the possibility of a FLNA mutation. 
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COMBINED CARDIOLOGICAL AND NEUROLOGICAL ANOMALIES DUE TO 
FILAMIN A MUTATIONS 
 
INTRODUCTION 
Cardiac defects in adults are usually sporadic and rarely considered to be part of a 
hereditary syndrome. The presence of other congenital malformations or a positive family 
history should alert the clinician to the possibility of an underlying, possibly genetic 
cause.1,2 Combined neurological and cardiac disease is well recognized in neuromuscular 
disorders3; however a cardiac defect can also be the presenting symptom in patients with a 
congenital malformation of the cerebral cortex due to mutations in the X-linked gene FLNA 
(OMIM 300017). Dysfunction of this gene leads to abnormalities in outflow tract 
development, often manifesting as a mitral or aortic valve insufficiency and a cerebral 
migration disorder, characterized by clusters of grey matter along the ventricles consisting 
of neurons that failed to migrate to the cortex during prenatal development.4 Some 
mutations in FLNA can lead to craniofacial and skeletal abnormalities, including 
otopalatodigital (OPD) syndrome types 1 (OMIM 311300) and 2 (OMIM 304120), Melnick-
Needles syndrome (MNS, OMIM 309350) and frontometaphyseal dysplasia (FMD, OMIM 
305620). The filamin proteins (FLNA, FLNB and FLNC) are products of different genes and 
splice variants. Filamins stabilize F-actin networks in the cell and link them to cellular 
membranes by binding to transmembrane receptors or ion channels, thereby regulating 
cell morphology, membrane integrity and cell locomotion.5 FLNA and FLNB are widely 
expressed, while FLNC is restricted to the striated muscle. Mutations in FLNC have been 
associated with myofibrillar myopathy.6 FLNA is highly expressed in early myotubes, 
developing myofibrils and migratory neurons. During myofibril development FLNA is 
replaced by FLNB.5 There seems to be some functional redundancy of both proteins.7 
Mutations in FLNB have only been described in skeletal chondrodysplasia, like Larsen 
syndrome (OMIM 150250), spondilocarpotarsal dysostosis (OMIM 272460), 
atelosteogenesis I and III (OMIM 108720 and 108721) and boomerang dysplasia (OMIM 
112310). Among these, only Larsen syndrome occasionally presents with cardiac outflow 
tract defects and none with cerebral PNH. In this study, we evaluated patients known with 
a FLNA mutation for cardiac abnormalities. 
 
METHODS 
We used our database of patients with malformations of cortical development to 
determine how often we see a combination of cerebral periventricular nodular heterotopia 
(PNH) and cardiac abnormalities due to FLNA mutations, to describe the patient 
characteristics and to provide information for the cardiologist as to when they should be 
alert to the possibility of an associated cerebral malformation. FLNA mutations were 
identified by direct sequencing of exons and intron exon boundaries (reference sequence 
NM_01110556.1). 
 
de Wit_DEF.indd   86 02-08-10   16:32
de Wit (all).ps Back - 43     T1 -    Black CyanMagenta Yellow
Chapter 3.3 
86 
ABSTRACT  
 
Background 
Cardiac defects can be the presenting symptom in patients with mutations in the X-linked 
gene FLNA. Dysfunction of this gene is associated with a congenital malformation of the 
cerebral cortex, but can also lead to cardiac abnormalities, especially in the left ventricular 
outflow tract. We noticed that some patients diagnosed at the Neurogenetics Clinic had 
first presented to a cardiologist, suggesting that earlier recognition may be possible if the 
diagnosis is suspected. 
Methods and results 
From the Erasmus MC cerebral malformations database 24 patients were identified with 
cerebral bilateral periventricular nodular heterotopia (PNH) without other cerebral cortical 
malformations. In six of these patients, a pathogenic mutation in FLNA was present. Five of 
these a cardiac defect was also found in the outflow tract. Four had presented to a 
cardiologist before the cerebral abnormalities were diagnosed. 
Conclusions 
The cardiological phenotype typically consists of aortic or mitral regurgitation, coarctation 
of the aorta or other left-sided cardiac malformations. Most patients in this category will 
not have a FLNA mutation, but the presence of neurological complaints, hyperlaxity of the 
skin or joints and/or a family history with similar cardiac or neurological problems in a 
possibly X-linked pattern may alert the clinician to the possibility of a FLNA mutation. 
Filamin A 
87 
 
COMBINED CARDIOLOGICAL AND NEUROLOGICAL ANOMALIES DUE TO 
FILAMIN A MUTATIONS 
 
INTRODUCTION 
Cardiac defects in adults are usually sporadic and rarely considered to be part of a 
hereditary syndrome. The presence of other congenital malformations or a positive family 
history should alert the clinician to the possibility of an underlying, possibly genetic 
cause.1,2 Combined neurological and cardiac disease is well recognized in neuromuscular 
disorders3; however a cardiac defect can also be the presenting symptom in patients with a 
congenital malformation of the cerebral cortex due to mutations in the X-linked gene FLNA 
(OMIM 300017). Dysfunction of this gene leads to abnormalities in outflow tract 
development, often manifesting as a mitral or aortic valve insufficiency and a cerebral 
migration disorder, characterized by clusters of grey matter along the ventricles consisting 
of neurons that failed to migrate to the cortex during prenatal development.4 Some 
mutations in FLNA can lead to craniofacial and skeletal abnormalities, including 
otopalatodigital (OPD) syndrome types 1 (OMIM 311300) and 2 (OMIM 304120), Melnick-
Needles syndrome (MNS, OMIM 309350) and frontometaphyseal dysplasia (FMD, OMIM 
305620). The filamin proteins (FLNA, FLNB and FLNC) are products of different genes and 
splice variants. Filamins stabilize F-actin networks in the cell and link them to cellular 
membranes by binding to transmembrane receptors or ion channels, thereby regulating 
cell morphology, membrane integrity and cell locomotion.5 FLNA and FLNB are widely 
expressed, while FLNC is restricted to the striated muscle. Mutations in FLNC have been 
associated with myofibrillar myopathy.6 FLNA is highly expressed in early myotubes, 
developing myofibrils and migratory neurons. During myofibril development FLNA is 
replaced by FLNB.5 There seems to be some functional redundancy of both proteins.7 
Mutations in FLNB have only been described in skeletal chondrodysplasia, like Larsen 
syndrome (OMIM 150250), spondilocarpotarsal dysostosis (OMIM 272460), 
atelosteogenesis I and III (OMIM 108720 and 108721) and boomerang dysplasia (OMIM 
112310). Among these, only Larsen syndrome occasionally presents with cardiac outflow 
tract defects and none with cerebral PNH. In this study, we evaluated patients known with 
a FLNA mutation for cardiac abnormalities. 
 
METHODS 
We used our database of patients with malformations of cortical development to 
determine how often we see a combination of cerebral periventricular nodular heterotopia 
(PNH) and cardiac abnormalities due to FLNA mutations, to describe the patient 
characteristics and to provide information for the cardiologist as to when they should be 
alert to the possibility of an associated cerebral malformation. FLNA mutations were 
identified by direct sequencing of exons and intron exon boundaries (reference sequence 
NM_01110556.1). 
 
de Wit_DEF.indd   87 02-08-10   16:32
de Wit (all).ps Front - 44     T1 -    Black CyanMagenta Yellow
Chapter 3.3 
88 
RESULTS 
From our ongoing database of patients with malformations of cortical development, we 
identified 24 patients with bilateral PNH without other cerebral cortical malformations.8 In 
six patients this was due to a pathogenic mutation in FLNA. Five of these FLNA patients 
had a cardiac defect in the outflow tract. Details of these five patients are found in the 
table and clinical descriptions below. Four presented to a cardiologist before the diagnosis 
of the cerebral abnormalities was known. In the 18 other patients with bilateral PNH 
without other cerebral malformations pathogenic mutations in FLNA were excluded, and 
none of these had a cardiac defect as evaluated by a cardiologist. Patients with other 
malformations of cortical development were not all screened by a cardiologist, so the 
incidence of cardiac defects in this group cannot be inferred from our data. 
 
Five case reports 
1. The first patient is a boy (patient 1 in Table and Figure 2), the third child of healthy 
parents of Somalian descent. A prenatal ultrasound at 20 wks showed an unclassified 
cardiac abnormality. Pregnancy and term birth (38 wks) were uncomplicated. Birth weight 
was 2635 grams, head circumference 34 cm (normal). Cardiac ultrasound and 
catheterization showed a cardiac malformation consisting of a situs solitus, AVVA 
concordant, mono-atrium, mitral atresia, hypoplastic left ventricle, double outlet right 
ventricle, patent arterial duct, severe hypoplasia of the transverse aortic arch and 
coarctation of the aorta. Physical exam showed a normal abdomen, cryptorchidism, a 
closed palate and normal facies, apart from minor anomalies of a preauricular pit on the 
left side and mildly posteriorly rotated ears. Neurological evaluation in the neonatal period 
showed an alert infant with normal movements, reflexes and muscle tone. 
Ophthalmologic screening was normal. EEG showed no epileptiform discharges. Brain MRI 
showed wide cerebral ventricles with bilateral PNH, a normal cortex, and a bifid septum 
pellucidum, and an enlarged retrocerebellar space with normal cerebellum and brainstem. 
Thorax CT angiogram performed to classify the cardiac abnormality additionally showed 
incomplete fusion of the distal third part of the sternum. The patient died at the age of 2 
months of heart failure. Autopsy was not allowed and the family was lost to follow-up.  
Genetic testing: FLNA sequencing of DNA extracted from leukocytes showed two sequence 
changes. The missense change c.5290G>A (p.A1764T) has been reported before in a woman 
with PNH and has been described as pathogenic, although there is no definitive evidence.1 
The second missense change was found in exon 20 (c.3035C>T) resulting in a serine to 
leucine substitution at position 1012 of the protein and has not been reported before in 
PNH or in the OPD-spectrum. This is a change in rod 1 (repeat 1-15) before the hinge 1 
domain and is predicted to be a non-tolerated amino acid change in two different 
computer models. It is uncertain whether the second missense change contributes to the 
phenotype. 
2. During the first pregnancy of an unrelated healthy Dutch couple prenatal ultrasound 
and prenatal MRI had shown a girl with a possibly enlarged heart and mildly enlarged 
cerebral ventricles (patient 2 in Table and Figure 2). Delivery at term was uncomplicated. 
Birth weight was 2830 gr and head circumference 37 cm (+2SD). Postnatally, cardiac 
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ultrasound showed a secundum atrial septal defect, coarctation of the aorta and mild 
aortic regurgitation. The coarctation was surgically corrected at the age of 16 days by 
resection and end-to-end anastomosis. She showed normal to mildly delayed cognitive 
development and delayed motor development with hypotonia and severe hyperlaxity. 
Facial features show a broad forehead, prominent orbital ridges, deep set eyes with down-
slant, and a flat midface. She has never had seizures, and EEG showed no epileptiform 
discharges. Brain MRI showed bilateral PNH and an enlarged retrocerebellar cyst (Figure 1). 
At the age of 3 months she developed dyspnoea due to congenital lobar emphysema of the 
right middle pulmonary lobe with bronchomalacia. She was successfully treated with a 
pulmonary lobectomy.  
Genetic analysis: FLNA sequencing of DNA extracted from leukocytes showed a missense 
change c.220G>A in exon 2 (p.G74R). Family studies showed the mother, not the father, to 
be carrier of the same mutation. Brain MRI of the mother showed bilateral PNH, typical of 
FLNA mutations. She subsequently developed epilepsy at age 27 years. Cardiological 
evaluation, including ultrasound, of the mother was normal. The mother has hyperlaxity. 
This missense change was absent in leukocyte DNA of the maternal grandparents. These 
have no FLNA related complaints or symptoms, although brain MRI was not done. Its de 
novo occurrence in the family renders it very likely that c.220G>A, p.G74R is a pathogenic 
mutation. 
3. A woman with a normal IQ and an otherwise unremarkable history underwent aortic 
valve replacement for severe aortic valve regurgitation at age 40. Details on the pathology 
were lost.  At age 55 she was diagnosed with heart failure and one year later she 
underwent heart transplantation. Macroscopic pathology showed a dilated heart and a 
dilated aortic root. The left ventricle shows subendocardial fibrosis. At age 60 she was 
diagnosed with severe venous varicosis of the legs and at age 70 an infrarenal aortic 
aneurysm with a 4.7 cm diameter was found and treated conservatively. At age 71 
symptoms of mild cognitive decline prompted a brain CT showing bilateral PNH as a 
chance finding. Eight months later she died of a subarachnoid hemorrhage from a ruptured 
fusiform carotid aneurysm. She never had an epileptic seizure and showed no hyperlaxity 
of joints or skin.  Family history revealed that her mother had heart problems from a young 
age and died from heart failure at age 69, details could not be recovered. The patient had a 
healthy twin brother and a sister and a healthy son. The autopsy showed severe 
generalized atherosclerosis with mild dilatation of the thoracic aorta and an aneurysm of 
the abdominal aorta of 7 cm. Brain autopsy showed symmetrical bilateral PNH and 
bilateral fusiform carotid aneurysms with widespread glomeruloid microvascular changes 
in the cerebral cortex. 9 
Genetic analysis: direct sequence analysis of FLNA in DNA extracted from leukocytes 
showed a pathogenic frame shift mutation c.3045del5 in exon 21.  
4. A six-year old girl presented with a cardiac murmur and was diagnosed with a mild 
aortic stenosis (9mm gradient) and regurgitation with a normal left ventricle diameter that 
remained stable over the years (patient 4 in Table and Figure 2). She is now 46 years old 
and has a normal IQ. She had a first generalized epileptic seizure at age 28. Brain CT 
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showed bilateral PNH. Dysmorphic evaluation showed no abnormalities and no 
hyperlaxity. She has no children and one healthy brother.  
Genetic analysis: direct sequence analysis of FLNA in DNA extracted from leukocytes 
showed a pathogenic frame shift mutation c.3582delC in exon 22.  
5. A girl presented shortly after birth with cyanosis during feeding and was diagnosed with 
a ventricular septal defect and aortic regurgitation (patient 5 in Table and Figure 2). At age 
24 the ventricular septal defect was surgically corrected and she received an aortic 
bioprosthesis. At age 36 yrs she underwent a Bentall procedure. At age 40, she presented to 
a neurologist because of a complicated migraine attack with aphasia. A brain MRI showed 
bilateral PNH and an enlarged retrocerebellar space (Figure 1). Family history revealed that 
her mother died suddenly at age 57 from a rupture of the aorta. The patient has one sister 
with mild aortic regurgitation, she has been invited for counselling. The patient has a 
healthy son. 
Genetic analysis: direct sequence analysis of FLNA in DNA extracted from leukocytes 
showed a pathogenic mutation frame shift mutation c.6635delTCAG in exon 41. 
 
 
 
Figure 1: neuroimaging characteristics of a child (patient 2) in A1 and A2, and an adult (patient 5) in B1 
and B2. All are T1 weighted MRI images. Note the periventricular nodular heterotopia (denoted by 
arrows) and the enlarged retrocerebellar space (denoted by a star). 
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Figure 2: pedigrees of the described cases. FLNA mutation carriers in black, probably affected but 
deceased persons in grey. Numbers refer to the described cases. 
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Table: patient characteristics. 
Case Sex Cardiological phenotype Neurological 
phenotype 
Outcome Mutation 
1 M Mono-atrium, mitral atresia, 
hypoplastic LV, double outlet RV, 
aortic coarctation 
Normal Died age 2 months 
of heart failure 
c.5290G>A 
2 F Aortic coarctation Hypotonia Now 18 m old c.220G>A  
3 F Severe aortic valve insufficiency  Normal Died aged 71 yrs 
of subarachnoid 
haemorrhage 
c.3045del5 
4 F Mild aortic valve stenosis and 
regurgitation 
Epilepsy Now 45 yrs old c.3582delC 
5 F Severe aortic valve regurgitation  Normal Now 41 yrs old c.6635delTCAG 
 
DISCUSSION 
Five out of six patients with a pathogenic mutation in FLNA from our database show a 
combination of cardiac disease and bilateral cerebral PNH. Four patients presented to a 
cardiologist before or at the time of their neurological workup. Neurological signs were 
absent or mild at that time and the diagnosis of bilateral PNH was made later due to 
epileptic seizures (case 4), hypotonia (case 2) or during the workup of non-related 
complaints. This suggests that the cardiologist had the first opportunity to recognise these 
patients. Recently also X-linked mitral valvular dystrophy without neurological signs or 
symptoms of epilepsy was found to be caused by mutations in FLNA, however brain 
imaging was not reported.10 The cardiological phenotype is not always this specific. FLNA 
knock out mice show midline skeletal defects and early male lethality due to cardiac 
malformations in atrioventricular septal and outflow tract development.11 Human patients 
also show abnormalities in the outflow tract ranging from patent ductus arteriosus, mitral 
or aortic valvular abnormalities to coarctation of the aorta, and ascending aorta 
aneurysm.12-14 Cerebral PNH in FLNA patients is caused by impaired migration of later born 
neurons due to disrupted cell adhesion and abnormal ventricular ependymal function.15 
This shows that pathways involved in cell adhesion can both affect the neuro-epithelium 
and vascular development. Apart from cerebral and cardiovascular developmental defects 
FLNA mutations can also cause connective tissue abnormalities, and autopsy studies show 
abnormal glomeruloid microvascular proliferations in the brain.9,15 A combination of PNH 
and Ehlers-Danlos syndrome with joint hyperlaxity and aorta aneurysms caused by a 
mutation in FLNA has been described in females.16 Neurological phenotypes associated 
with PNH are diverse and range from epilepsy and normal development to patients with 
multiple congenital anomalies and mental retardation. In males mutations are often 
prenatal lethal. Less severe mutations with residual filamin A function are found in males 
with PNH. One male patient has been described with PNH and a lethal complex cardiac 
malformation, including atrial and ventricular septal defect and persistent left superior 
caval vein.12 Interestingly, gain of function mutations of FLNA are associated with 
syndromes with craniofacial and skeletal abnormalities, including otopalatodigital 
syndrome types 1 and 2, Melnick-Needles syndrome (MNS) and frontometaphyseal 
dysplasia.17 In these syndromes several male patients have been described with heart 
defects, cryptorchidism and umbilical hernia, but no PNH.17 The combination of mitral 
and/or aortic regurgitation and skeletal abnormalities with hyperlaxity is also found in 
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multiple congenital anomalies and mental retardation. In males mutations are often 
prenatal lethal. Less severe mutations with residual filamin A function are found in males 
with PNH. One male patient has been described with PNH and a lethal complex cardiac 
malformation, including atrial and ventricular septal defect and persistent left superior 
caval vein.12 Interestingly, gain of function mutations of FLNA are associated with 
syndromes with craniofacial and skeletal abnormalities, including otopalatodigital 
syndrome types 1 and 2, Melnick-Needles syndrome (MNS) and frontometaphyseal 
dysplasia.17 In these syndromes several male patients have been described with heart 
defects, cryptorchidism and umbilical hernia, but no PNH.17 The combination of mitral 
and/or aortic regurgitation and skeletal abnormalities with hyperlaxity is also found in 
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autosomal dominant Marfan syndrome (OMIM 154700), in the allelic Shprintzen-Goldberg 
syndrome (OMIM 182212) and in Loeys-Dietz syndrome type 1A and B (OMIM 609192 and 
610168). Some neuromuscular abnormalities are described in these patients, but no 
cerebral cortical developmental abnormalities. Although we did not find any cases, cardiac 
defects are reported to be associated with some other cerebral PNH phenotypes. Patients 
with Williams syndrome, caused by a microdeletion of chromosome 7q11.22-23, have 
distinctive facial dysmorphias, ‘elfin face’, and often cardiac defects, such as supravalvular 
aortic stenosis, mitral or pulmonary valve abnormalities, and atrial or ventricular septum 
defect. One case has been described with associated PNH.18 In chromosome 6q terminal 
deletion syndrome, brain MRI commonly shows hypoplasia of the corpus callosum, and a 
few patients have been described with associated PNH.19 About half of 6q terminal deletion 
patients are reported to have cardiac abnormalities, primarily ventricular or atrial septum 
defect. Distal duplications of chromosome 5 p have been associated with PNH in two 
patients, one of which also had atrial septum defect and mitral and tricuspid valve 
prolapse.20 Genetic factors related to similar cardiac malformations without PNH are being 
widely investigated, but still only few genes are known to cause a developmental defect of 
the atrioventricular septum and the outflow tract in humans.21-23 
 
CONCLUSION 
Patients with mutations in FLNA show a cardiological phenotype with aortic or mitral 
regurgitation, coarctation of the aorta or other left-sided malformations. Although patients 
with cardiac defects in this category are numerous and most will not have a FLNA 
mutation, the presence of neurological complaints, hyperlaxity of the skin or joints and/or 
a family history with similar cardiac or neurological problems in a possibly X-linked 
pattern should alert the clinician to the possibility of a FLNA mutation. Recognition will 
enable genetic testing and genetic counselling for patients and their family.  
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ABSTRACT 
 
We report a child with a severe choreadystonic movement disorder, bilateral 
periventricular nodular heterotopia (BPNH), and secondary microcephaly based on 
compound heterozygosity for two new ARFGEF2 mutations (c.2031_2038dup and 
c.3798_3802del), changing the limited knowledge about the phenotype. The brain MRI 
shows bilateral hyperintensity of the putamen, BPNH, and generalized atrophy. Loss of 
ARFGEF2 function affects vesicle trafficking, proliferation/apoptosis, and neurotransmitter 
receptor function. This can explain BPNH and microcephaly. We hypothesize that the 
movement disorder and the preferential damage to the basal ganglia, specifically to the 
putamen, may be caused by an increased sensitivity to degeneration, a dynamic 
dysfunction due to neurotransmitter receptor mislocalization or a combination of both. 
ARFGEF2 
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MOVEMENT DISORDER AND NEURONAL MIGRATION DISORDER DUE TO 
ARFGEF2 MUTATION 
 
INTRODUCTION 
In 2004 mutations in the gene ARFGEF2 encoding ADP-ribosylation factor guanine 
nucleotide exchange factor 2, were found to cause autosomal recessive bilateral 
periventricular nodular heterotopia (BPNH) in four patients from two Turkish pedigrees.1 
Clinical features reported were microcephaly, feeding difficulties, severe mental 
retardation, quadriparesis, and epilepsy. More details on the phenotype were not reported 
and since then, to our knowledge, no additional patients have been published. We discuss 
a patient with a different phenotype caused by two new ARFGEF2 mutations. 
 
CASE 
Our patient is the only child of non-consanguineous parents from Dutch descent. Prenatal 
ultrasounds showed growth retardation. She was born at 38 weeks of gestation with an 
Apgar score of 10 after 5 min, birth weight 2,790 g, and length 46 cm. Occipito-frontal 
circumference was 34.2 cm at the age of 3 weeks (−1.5 SD). During the first year 
developmental delay became apparent. She showed social smiling at 2 months and 
grasping at 5 months, and rolled over at the age of 8 months. There were excessive 
extension movements. She had persistent feeding problems, severe drooling, and frequent 
vomiting. At the age of 9 months a pediatrician noted dystonic-spastic paraplegia with 
axial hypotonia. With physical therapy she showed some progression, but did not reach 
normal milestones. At the age of 4 years feeding difficulties prompted a gastrostomy. 
Despite adequate caloric intake, growth is unsatisfactory with height progressing at 2.5 SD 
below normal. Occipito-frontal circumference growth went from the –1.5 SD to 0.5 cm 
below the –2.5 SD curve. She never had seizures. Now, at the age of 7 years, she makes eye 
contact, smiles, and understands some words. She vocalizes, but does not produce any 
words. Pupillary responses are normal. There is no nystagmus. Axial muscle tone is low 
and variable in the extremities. Muscle strength is normal. She shows a severe 
extrapyramidal movement disorder with irregular repetitive jerking movements of all 
extremities and the face (chorea) and sustained abnormal movements and posturing 
(dystonia). This is exacerbated by emotions and during infections when large proximal 
jerking movements may resemble ballism. There is no rigidity or ataxia. Tendon reflexes 
are lively and symmetric, with extensor plantar responses (Babinski sign). She can sit with 
support, but cannot stand. The movement unrest can be so severe that she becomes 
exhausted and is partially responsive to treatment with high doses of benzodiazepines.  
Brain MRI at the age of 13 months showed BPNH, myelination delay, and generalized 
atrophy, a second MRI at age 4 years and 10 months showed improved myelination, stable 
or minimally progressive generalized atrophy but also symmetric atrophy of the basal 
ganglia, specifically of the globus pallidus and the putamen with focal T2- hyperintensity 
of the putamen (Figure). In retrospect, inhomogeneous abnormalities of the putamen can 
also be seen on the first MRI and suggest early degeneration resulting in gliosis. 
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Brain MRI at the age of 13 months showed BPNH, myelination delay, and generalized 
atrophy, a second MRI at age 4 years and 10 months showed improved myelination, stable 
or minimally progressive generalized atrophy but also symmetric atrophy of the basal 
ganglia, specifically of the globus pallidus and the putamen with focal T2- hyperintensity 
of the putamen (Figure). In retrospect, inhomogeneous abnormalities of the putamen can 
also be seen on the first MRI and suggest early degeneration resulting in gliosis. 
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EEGs show delta-activity without differentiation or epileptiform activity. Metabolic testing 
of urine and plasma, including amino acids, lactate, pyruvate, and creatine kinase was 
normal. The family history is unremarkable.  
Sequence analysis of all 39 coding exons and intron–exon boundaries of the ARFGEF2 gene 
on chromosome 20 shows compound heterozygosity for two variations that have not been 
previously reported. At the DNA level c.2031_2038dup and c.3798_3802del using reference 
sequence NM_006420.2 and at protein level p.Gln680ProfsX2 and p.Phe1267-GlyfsX17, 
respectively. Both these variations lead to frame shift followed by a premature stop-codon 
and are therefore considered pathogenic mutations. Parents are heterozygote for found 
mutations. 
 
 
Figure: Brain MRI made at the age of 13 months (images A, B, and C) and at the age of 4 years and 10 
months (images D, E, and F). A and D T1-weighted images showing bilateral periventricular nodular 
heterotopia with the intensity of gray matter (black arrow in image D). B and E T2-weighted images 
showing hyperintensity of the putamen and atrophy of the putamen and globus pallidus (white arrow 
in image E). C and F Flair images, coronal view, showing bilateral hyperintensity of the putamen, more 
clearly visible on image F made at a later age (white arrow), and mild atrophy of the hippocampi. 
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DISCUSSION 
Mutations in ARFGEF2 can cause autosomal recessive bilateral periventricular nodular 
heterotopia (BPNH) with microcephaly.1 Our patient shows that a choreadystonic 
extrapyramidal movement disorder can be part of the phenotype. The movement disorder 
is reflected in MRI abnormalities of the basal ganglia, specifically of the putamen, in 
addition to generalized atrophy and BPNH. Anatomically, putamen and caudate nucleus 
form the dorsal striatum and are the major afferent center of the basal ganglia, receiving 
excitatory input from the cerebral cortex, thalamus, and brain stem. The putamen receives 
projections from the cortical motor and somatosensory areas, the midbrain, and the raphe 
nuclei. The striatum projects to the globus pallidus and substantia nigra, mainly with 
GABAergic neurons. Output is mediated by local inhibitory interneurons.2 Similar 
choreadystonic movement disorders and putamen degeneration on MRI are seen in 
Huntington’s disease, Wilson’s disease and Leigh syndrome.  
ARFGEF proteins are guanine nucleotide exchange factors (GEFs) that activate ADP-
ribosylation factors (ARFs). ARFGEF2 protein, also known as BIG2, is one of three GEFs 
expressed in the brain during the period of neural proliferation and migration with high 
expression in the cortical ventricular zone and ganglionic eminences, the future basal 
ganglia.1 ARFs regulate the formation of coated vesicles from the Golgi, trans-Golgi 
network (TGN), and endosomes. In recycling endosomes BIG2 loss of function result in 
failure to deliver proteins to the cell membrane.3-5 This was shown for the GABA(A) 
receptor, but also for the transferrin receptor and the tumor necrosis factor receptor.1,4,6,7 
Other cell surface receptors are likely to be also affected. To understand our patient’s 
phenotype, different consequences of ARFGEF2 loss of function need to be considered. The 
BPNH are similar to those seen in patients with loss-of-function mutations in the X-linked 
filamin A gene (FLNA). FLNA is the most commonly identified genetic cause for BPNH, 
found in approximately one third of patients.8 In heterozygous females BPNH is associated 
with epilepsy and/or developmental delay or may be an accidental finding. In males FLNA 
mutations are often fatal, but may result in a similar phenotype to affected females .8,9 In 
both ARFGEF2 and FLNA patients the neuroepithelium lining the ventricles is disrupted 
leading to failed migration of later-born neurons.9 The similarity may be solely due to 
failed transport of the filamin A protein to the cell membrane by BIG2 dysfunction or to a 
final common pathway disrupting vesicle trafficking.9,10 However, despite the similar brain 
phenotype, FLNA patients do not have extrapyramidal movement disorders or 
microcephaly. Speculatively, in ARFGEF2 neuronal migration may be more severely 
affected due to disruption in GABA(A) receptor function in the embryonic period, as 
GABA(A) antagonists have been shown to impair neuronal motility in rodents in vitro and 
in vivo.11,12 Microcephaly can be due to diminished neuronal proliferation and BIG2 
inhibition in vitro experiments seem to suggest this occurs.1 Increased apoptosis can also 
cause microcephaly and atrophy. Other BIG2 inhibition experiments show some signs of 
endoplasmic reticulum stress in cultured cells.13 Possibly, ER stress increases susceptibility 
to apoptosis in specific neurons. Our patient’s normal occipito-frontal circumference at 
birth shows that congenital microcephaly is not obligatory. Why the putamen should show 
a specific sensitivity for neuronal loss is unknown. Finally, ARFGEF2 is expressed 
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postnatally and neurotransmitter receptor function can be impaired by defective exosome 
function.3,6 Disruptions in the recycling of receptors also hinder dendritic arborization.9 
This may have contributed to the movement disorder. Our patient is compound 
heterozygote for two new mutations and new patients are needed to determine if a 
genotype–phenotype relation exists for ARFGEF2 mutations. BPNH caused by autosomal 
recessive ARFGEF2 mutations is more than an anatomical malformation. We suggest that 
the clinical features of the choreadystonic movement disorder, BPNH, and microcephaly of 
our patient can be understood in the light of abnormal vesicle transport resulting in 
neuroependyma disruption, decreased proliferation of neurons, and/or increased 
sensitivity to apoptosis and lifelong exosome dysfunction affecting neurotransmitter 
receptor function and neuronal development. 
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ABSTRACT 
 
Two families are presented with a child suffering from microcephaly with a simplified 
gyral pattern of the brain (SGP) and early onset insulin dependent diabetes mellitus 
(IDDM). The first patient was diagnosed postmortally with Wolcott–Rallison syndrome, 
after her younger brother developed IDDM, and a homozygous mutation in the eukaryotic 
translation initiation factor 2-alpha kinase 3 was found. The younger brother did not 
undergo magnetic resonance imaging (MRI). The patient from the second family has no 
EIF2AK3 mutation. SGP is considered to arise from decreased neuronal proliferation or 
increased apoptosis at an early stage of embryonal development, but insight into the 
pathways involved is minimal. EIF2AK3 is involved in translation initiation. It has been 
proposed that loss of function mutations reduce the ability of the cell to respond to 
endoplasmic reticulum stress, resulting in apoptosis of pancreatic Langerhans cells. Our 
findings suggest that in some cases, early onset IDDM and SGP can arise from common 
mechanisms leading to increased apoptosis. 
MSG with diabetes mellitus 
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MICROCEPHALY AND SIMPLIFIED GYRAL PATTERN OF THE BRAIN 
ASSOCIATED WITH EARLY ONSET INSULIN-DEPENDENT DIABETES MELLITUS  
 
INTRODUCTION 
In congenital microcephaly, magnetic resonance imaging (MRI) of the brain may reveal a 
relatively normal looking cortex (true microcephaly) or a diverse spectrum of brain 
malformations. One of those malformations is a simplified gyral pattern (SGP). in which 
the number of gyri and sulci is reduced, while cortex thickness is normal. This 
differentiates SGP from pachygyria or microlissencephaly with abnormally thick cortex. 
The same phenotype is also described in the literature as microcephaly with simplified 
gyration (MSG). SGP is thought to arise from decreased proliferation and/or increased 
apoptosis during embryogenesis.1 Most cases are unexplained, although four genes have 
been identified that cause primary microcephaly with mental retardation without 
significant neurological deficit and a relatively well preserved gyral pattern (MCPH1, 
ASPM, CDK5RAP2 and CENPJ). These genes are all involved in mitosis, as shown by 
premature chromosome condensation in affected cells. Mutations are thought to cause 
decreased proliferation of neuroblasts.2 As far as we know, there are no known gene 
defects that cause SGP by the mechanism of increased apoptosis. 
Persistent early onset insulin-dependent diabetes mellitus (IDDM) is rare. Neonatal onset 
persistent IDDM (with symptoms within the first 3 months of life) has an estimated 
incidence of one in 800,000 live births.3 Three main mechanisms contribute to the 
development of IDDM: defects in insulin signaling leading to insulin resistance, defects of 
insulin secretion leading to hypoinsulinaemia and impaired development or apoptosis of 
pancreatic beta-cells leading to decreased pancreatic beta-cell mass.4 One of the 
monogenetic early onset IDDM syndromes in which inappropriate apoptosis is proposed to 
be the pathological mechanism is Wolcott–Rallison syndrome (WRS, OMIM 226980). This 
syndrome is characterized by neonatal or early onset IDDM associated with multiple 
epiphyseal dysplasia and other variable clinical features and is caused by mutations in the 
eukaryotic translation initiation factor 2-alpha kinase 3 gene (EIF2AK3). In the literature, 
one patient with WRS has been described that also had a brain developmental disorder 
resembling pachygyria or SGP.5 Other monogenetic IDDM syndromes where inappropriate 
apoptosis has been proposed to be the underlying mechanism are Wolfram syndrome 
(OMIM 222300), Friedreich ataxia (OMIM 229300), thiamine-responsive megaloblastic 
anaemia (OMIM 249270) and Werner syndrome (OMIM 277700).4 
Here, we present three cases from two families with early onset IDDM, two of which also 
show a simplified gyral pattern of the cerebral cortex. In one family, Wolcott–Rallison 
syndrome is the cause of IDDM; the other shows a similar phenotype but without an 
EIF2AK3 mutation. 
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monogenetic early onset IDDM syndromes in which inappropriate apoptosis is proposed to 
be the pathological mechanism is Wolcott–Rallison syndrome (WRS, OMIM 226980). This 
syndrome is characterized by neonatal or early onset IDDM associated with multiple 
epiphyseal dysplasia and other variable clinical features and is caused by mutations in the 
eukaryotic translation initiation factor 2-alpha kinase 3 gene (EIF2AK3). In the literature, 
one patient with WRS has been described that also had a brain developmental disorder 
resembling pachygyria or SGP.5 Other monogenetic IDDM syndromes where inappropriate 
apoptosis has been proposed to be the underlying mechanism are Wolfram syndrome 
(OMIM 222300), Friedreich ataxia (OMIM 229300), thiamine-responsive megaloblastic 
anaemia (OMIM 249270) and Werner syndrome (OMIM 277700).4 
Here, we present three cases from two families with early onset IDDM, two of which also 
show a simplified gyral pattern of the cerebral cortex. In one family, Wolcott–Rallison 
syndrome is the cause of IDDM; the other shows a similar phenotype but without an 
EIF2AK3 mutation. 
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Family 1 
Case 1, a girl, was born to consanguineous Turkish parents, third degree relatives, after an 
uneventful pregnancy. At the age of 6 weeks, she was admitted with hyperglycaemia and 
diagnosed with IDDM. It was noted that her head circumference was 3 SD below the mean. 
At the age of 2.5 years, she was admitted for analysis of insufficient growth and 
psychomotor retardation. A brain MRI showed a simplified gyral pattern with normal 
cerebellum, brainstem and corpus callosum (Figure 1, upper row). Routine metabolic 
screening was normal, including thyroid function, and antibodies against Langerhans cells 
were absent. During this admission, she deteriorated into a comatose state with myoclonic 
jerks of the upper extremities. Electroencephalogram (EEG) registration revealed a status 
epilepticus which was treated with midazolam and phenytoin, later switched to valproate. 
She slowly gained consciousness over the following days but had lost some developmental 
milestones. Hand X-rays showed coneshaped proximal phalanges, osteoporosis and 
cortical sclerosis (Figure 2). Over the following years, her epilepsy proved therapy resistant 
and the IDDM difficult to control. Around the age of 3, she was not able to walk 
independently due to a spastic–ataxic tetraparesis and only spoke some words. She was 
able to make eye contact, communicate and play. Further analysis showed cochlear 
hearing loss of 60 dB on the right side and 50 dB on the left. At the age of 4.7 years, she 
developed hepatic dysfunction during a staphylococci sepsis and died. A few years later, 
Wolcott–Rallison syndrome was diagnosed in a younger brother caused by a pathogenic 
EIF2AK3 mutation. Retrospectively, we concluded that case 1 suffered from the same 
disorder.  
Case 2 is a boy, the younger brother of case 1. A few days postpartum, he was found to 
have IDDM. His head circumference was normal at 1.5 to 2 SD below the mean. His 
neurological examination was normal, but psychomotor development was delayed. At the 
age of 22 months, he has just learned to walk but does not speak any words. Liver enzymes 
were repeatedly found to be mildly elevated, and he was admitted several times for rising 
liver enzymes during mild infections. He suffers from frequent and intractable vomiting. 
Antibodies against Langerhans cells are absent and thyroid function is normal. His EEG 
shows a normal reactive background pattern with aspecific abnormal sharp waves 
bilaterally in the temporal and parieto-occipital regions. He has never had an epileptic 
seizure. The suspicion was raised of him having an autosomal recessive form of infantile 
diabetes, and in particular, considering the sister, Wolcott–Rallison syndrome. X-rays of 
hands and knees revealed hypoplastic epiphyses and mild osteopenia without any 
structural changes. Further investigations showed a homozygous pathogenic mutation in 
the EIF2AK3 gene. Parents denied permission for brain MRI. 
 
Family 2 
Case 3 is a boy, born at 40 weeks gestation to third degree related parents, originally from 
Morocco. At birth, his head circumference was 2.5 SD below the mean. Two older sisters 
were healthy with normal head circumference. At the age of 3 months, he was admitted 
with generalized seizures. An EEG showed multifocal epileptic discharges with an 
abnormal background pattern. A brain MRI showed a simplified gyral pattern with thin 
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corpus callosum and normal cerebellum and brainstem (Figure 1b). Epilepsy proved 
therapy-resistant. At the age of 8 months, he was diagnosed with IDDM, which proved 
difficult to control. Physical exam showed severe psychomotor retardation, obesity and 
small genitalia. Additional investigations showed a mild hypothyroidism with TSH, 5.26 
mU/l (reference 0.4–4.3) and FT4, 26.2 pmol/l (reference 12–26). Plasma lipids were 
elevated with cholesterol, 8.2 mmol/l (reference 2.0–5.0), triglycerides, 2.07 mmol/l 
(reference 0.30–1.30), low density lipoprotein (LDL) cholesterol, 6.11 mmol/l (reference 
<4.20) and normal high density lipoprotein (HDL)-cholesterol 1.16 mmol/l (reference 0.90–
2.75). Further analysis including routine metabolic screening in urine and plasma, 
cerebrospinal fluid (CSF) screening for IgG, neurotransmitters and lactate/pyruvate and 
ophthalmologic screening was normal. Antibodies against Langerhans cells were absent 
and liver function was normal. Skeletal X-rays were never done. He died at the age of 1.5 
years due to pneumonia. Parents refused autopsy. 
 
MATERIALS AND METHODS 
EIF2AK3 mutation screening: DNA was extracted from peripheral blood collected on 
ethylenediamine tetraacetic acid (EDTA), and mutation screening was performed by 
sequencing all the coding regions of the gene on genomic DNA for case 2 and in case 3 and 
his parents, as previously described.6 
 
RESULTS 
We identified a new homozygous mutation in case 2, corresponding to a G>A substitution 
at position 3,037 on EIF2AK3 cDNA sequence (Genbank number: NF 004836.3). This 
mutation has not been identified in 95 healthy controls nor in any of the previously 
screened WRS patients. This mutation causes a G to E missense mutation at position 957 of 
the protein (Genbank number: NP 004827.3), in the second serine/threonine kinase domain 
of the protein. Based on previous genetic and functional investigations of EIF2AK3 
mutations in WRS patients by our group and others, the mutated protein is likely to be 
nonfunctional, due to the loss of kinase activity.7,8 No mutation was identified in EIF2AK3 
in case 3 from the second family, and the implication of this gene could be excluded on the 
basis of heterozygosity of common single nucleotide polymorphisms in this gene.  
 
DISCUSSION 
Wolcott–Rallison syndrome causes IDDM and epiphyseal dysplasia with variable 
manifestations including hepatic failure and psychomotor retardation [for review, see 
reference 8]. Mental retardation is frequently reported in WRS without mention of head 
circumference or brain imaging, but the degree of brain developmental disorder may vary 
within one family as seen in cases 1 and 2. Microcephaly has been reported in a single case 
of WRS, and a loss of function mutation in EIF2AK3 was identified in this patient.7 
Later, a patient with WRS was reported to have brain atrophy with pachygyria and 
simplified gyri on MRI.6 Her head circumference was on the tenth percentile. The published 
figure is insufficient to classify the brain malformation, but cortical thickness does not 
seem to be increased, so the description could also be compatible with SGP. Our patient 
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therapy-resistant. At the age of 8 months, he was diagnosed with IDDM, which proved 
difficult to control. Physical exam showed severe psychomotor retardation, obesity and 
small genitalia. Additional investigations showed a mild hypothyroidism with TSH, 5.26 
mU/l (reference 0.4–4.3) and FT4, 26.2 pmol/l (reference 12–26). Plasma lipids were 
elevated with cholesterol, 8.2 mmol/l (reference 2.0–5.0), triglycerides, 2.07 mmol/l 
(reference 0.30–1.30), low density lipoprotein (LDL) cholesterol, 6.11 mmol/l (reference 
<4.20) and normal high density lipoprotein (HDL)-cholesterol 1.16 mmol/l (reference 0.90–
2.75). Further analysis including routine metabolic screening in urine and plasma, 
cerebrospinal fluid (CSF) screening for IgG, neurotransmitters and lactate/pyruvate and 
ophthalmologic screening was normal. Antibodies against Langerhans cells were absent 
and liver function was normal. Skeletal X-rays were never done. He died at the age of 1.5 
years due to pneumonia. Parents refused autopsy. 
 
MATERIALS AND METHODS 
EIF2AK3 mutation screening: DNA was extracted from peripheral blood collected on 
ethylenediamine tetraacetic acid (EDTA), and mutation screening was performed by 
sequencing all the coding regions of the gene on genomic DNA for case 2 and in case 3 and 
his parents, as previously described.6 
 
RESULTS 
We identified a new homozygous mutation in case 2, corresponding to a G>A substitution 
at position 3,037 on EIF2AK3 cDNA sequence (Genbank number: NF 004836.3). This 
mutation has not been identified in 95 healthy controls nor in any of the previously 
screened WRS patients. This mutation causes a G to E missense mutation at position 957 of 
the protein (Genbank number: NP 004827.3), in the second serine/threonine kinase domain 
of the protein. Based on previous genetic and functional investigations of EIF2AK3 
mutations in WRS patients by our group and others, the mutated protein is likely to be 
nonfunctional, due to the loss of kinase activity.7,8 No mutation was identified in EIF2AK3 
in case 3 from the second family, and the implication of this gene could be excluded on the 
basis of heterozygosity of common single nucleotide polymorphisms in this gene.  
 
DISCUSSION 
Wolcott–Rallison syndrome causes IDDM and epiphyseal dysplasia with variable 
manifestations including hepatic failure and psychomotor retardation [for review, see 
reference 8]. Mental retardation is frequently reported in WRS without mention of head 
circumference or brain imaging, but the degree of brain developmental disorder may vary 
within one family as seen in cases 1 and 2. Microcephaly has been reported in a single case 
of WRS, and a loss of function mutation in EIF2AK3 was identified in this patient.7 
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supports the idea that mental retardation in WRS may result from malformations of 
cortical development occurring during early gestation and that simplification of the gyral 
pattern and reduction of brain volume are variable features of the phenotype. In early 
onset IDDM, hypo- or hyperglycaemia occur only after birth so it cannot influence brain 
development during the first trimester of pregnancy. The underlying pathogenic 
mechanism is unclear. The EIF2AK3 gene codes for one of four eukaryotic EIF2alpha 
kinases (eukaryotic translation initiation factor2-alpha kinase 3, also known as murine 
PERK: pancreatic endoplasmic reticulum kinase). PERK/EIF2alpha kinase 3 regulates the 
cellular response to endoplasmic reticulum (ER) stress. When an imbalance between 
protein synthesis and processing occurs, leading to accumulation of unfolded protein in 
the ER, EIF2alpha kinase is activated and phosphorylates eukaryotic initiation factor 2 
alpha (EIF2alpha). EIF2alpha is an essential factor for protein synthesis by recruiting tRNA 
to ribosomes; its phosphorylation results in suppression of protein synthesis. EIF2AK3 is 
also involved in the next steps in the cellular response to ER stress: the second being 
removal of excess unfolded protein, and the third, ultimately, apoptosis. It has been 
proposed that loss of EIF2AK3 function leads to failure of protection against ER stress and 
uncontrolled apoptosis.9 PERK knockout mice are born with normal exocrine and endocrine 
pancreas function but develop progressive Langerhans cell apoptosis and a phenotype 
with neonatal diabetes, skeletal defects and growth retardation.10 Animal experiments 
have shown PERK to be present in the brain and to be important in the reaction to stress by 
inhibition of protein synthesis in situations of ischemia, status epilepticus and essential 
amino acids deficiency.11-13 
The EIF2alpha activity level is further regulated by the EIF2beta protein. Both proteins are 
required to allow translation initiation. Mutations in the different subunits of EIF2-beta are 
known to cause a leukodystrophy syndrome called vanishing white matter disease.14-15 It is 
unclear why the white matter of the brain is relatively more affected than the grey matter. 
Deterioration of patients with vanishing white matter disease is often triggered by head 
trauma or intercurrent infections, and uncontrolled apoptosis in response to stress is a 
likely explanation. Early neuronal apoptosis can be one of the mechanisms leading to SGP.1  
The mechanisms leading to EIF2AK3 activation are not fully understood, and moreover, it 
is unknown whether EIF2AK3 is expressed during embryonic brain development.16 
Putatively, EIF2AK3 mutations are an example of how an insufficient cellular response to 
stress during brain development in utero could lead to abnormal apoptosis. Consequently, 
a second (epigenetic or environmental) event leading to ER stress added to the genetic 
mutation might be needed to cause abnormal brain development in WRS. This coincidence 
of factors could partly account for the wide clinical heterogeneity of the neurological 
deficits in WRS.5,8 In case 3 (Family 2), the association of early onset IDDM and SGP on brain 
imaging was suggestive of WRS, by analogy of case 1, although skeletal abnormalities were 
not looked for. The medical history offers no support for any of the other previously 
mentioned monogenetic IDDM syndromes. Parental consanguinity suggests a genetic 
recessive cause, but analysis showed no mutation at the EIF2AK3 locus. This observation 
suggests that pancreatic Langerhans cell apoptosis and brain development can be linked 
through other mechanisms and that EIF2AK3 may not be the only gene associated with 
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supports the idea that mental retardation in WRS may result from malformations of 
cortical development occurring during early gestation and that simplification of the gyral 
pattern and reduction of brain volume are variable features of the phenotype. In early 
onset IDDM, hypo- or hyperglycaemia occur only after birth so it cannot influence brain 
development during the first trimester of pregnancy. The underlying pathogenic 
mechanism is unclear. The EIF2AK3 gene codes for one of four eukaryotic EIF2alpha 
kinases (eukaryotic translation initiation factor2-alpha kinase 3, also known as murine 
PERK: pancreatic endoplasmic reticulum kinase). PERK/EIF2alpha kinase 3 regulates the 
cellular response to endoplasmic reticulum (ER) stress. When an imbalance between 
protein synthesis and processing occurs, leading to accumulation of unfolded protein in 
the ER, EIF2alpha kinase is activated and phosphorylates eukaryotic initiation factor 2 
alpha (EIF2alpha). EIF2alpha is an essential factor for protein synthesis by recruiting tRNA 
to ribosomes; its phosphorylation results in suppression of protein synthesis. EIF2AK3 is 
also involved in the next steps in the cellular response to ER stress: the second being 
removal of excess unfolded protein, and the third, ultimately, apoptosis. It has been 
proposed that loss of EIF2AK3 function leads to failure of protection against ER stress and 
uncontrolled apoptosis.9 PERK knockout mice are born with normal exocrine and endocrine 
pancreas function but develop progressive Langerhans cell apoptosis and a phenotype 
with neonatal diabetes, skeletal defects and growth retardation.10 Animal experiments 
have shown PERK to be present in the brain and to be important in the reaction to stress by 
inhibition of protein synthesis in situations of ischemia, status epilepticus and essential 
amino acids deficiency.11-13 
The EIF2alpha activity level is further regulated by the EIF2beta protein. Both proteins are 
required to allow translation initiation. Mutations in the different subunits of EIF2-beta are 
known to cause a leukodystrophy syndrome called vanishing white matter disease.14-15 It is 
unclear why the white matter of the brain is relatively more affected than the grey matter. 
Deterioration of patients with vanishing white matter disease is often triggered by head 
trauma or intercurrent infections, and uncontrolled apoptosis in response to stress is a 
likely explanation. Early neuronal apoptosis can be one of the mechanisms leading to SGP.1  
The mechanisms leading to EIF2AK3 activation are not fully understood, and moreover, it 
is unknown whether EIF2AK3 is expressed during embryonic brain development.16 
Putatively, EIF2AK3 mutations are an example of how an insufficient cellular response to 
stress during brain development in utero could lead to abnormal apoptosis. Consequently, 
a second (epigenetic or environmental) event leading to ER stress added to the genetic 
mutation might be needed to cause abnormal brain development in WRS. This coincidence 
of factors could partly account for the wide clinical heterogeneity of the neurological 
deficits in WRS.5,8 In case 3 (Family 2), the association of early onset IDDM and SGP on brain 
imaging was suggestive of WRS, by analogy of case 1, although skeletal abnormalities were 
not looked for. The medical history offers no support for any of the other previously 
mentioned monogenetic IDDM syndromes. Parental consanguinity suggests a genetic 
recessive cause, but analysis showed no mutation at the EIF2AK3 locus. This observation 
suggests that pancreatic Langerhans cell apoptosis and brain development can be linked 
through other mechanisms and that EIF2AK3 may not be the only gene associated with 
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IDDM, microcephaly and SGP. Possibly, further research into mechanisms of inappropriate 
apoptosis can shed more light on the pathological mechanism of simplified gyral pattern. 
 
 
 
 
 
  
Figure 2: Hand X-ray of case 1: diffuse osteoporosis with cortical sclerosis, most pronounced in the 
metacarpals, and ‘cone-shaped’ proximal phalanges. 
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IDDM, microcephaly and SGP. Possibly, further research into mechanisms of inappropriate 
apoptosis can shed more light on the pathological mechanism of simplified gyral pattern. 
 
 
 
 
 
  
Figure 2: Hand X-ray of case 1: diffuse osteoporosis with cortical sclerosis, most pronounced in the 
metacarpals, and ‘cone-shaped’ proximal phalanges. 
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ABSTRACT 
 
Malonyl-CoA decarboxylase (MCD) deficiency is an extremely rare inborn error of 
metabolism that presents with metabolic acidosis, hypoglycemia, and/or cardiomyopathy. 
Patients also show neurological signs and symptoms that have been infrequently reported. 
We describe a girl with MCD deficiency, whose brain MRI shows white matter 
abnormalities and additionally diffuse pachygyria and periventricular heterotopia, 
consistent with a malformation of cortical development. MLYCD-gene sequence analysis 
shows normal genomic sequence but no messenger product, suggesting an abnormality of 
transcription regulation. Our patient has strikingly low appetite, which is interesting in 
the light of the proposed role of malonyl-CoA in the regulation of feeding control, but this 
remains to be confirmed in other patients. Considering the incomplete understanding of 
the role of metabolic pathways in brain development, patients with MCD deficiency 
should be evaluated with brain MRI and unexplained malformations of cortical 
development should be reason for metabolic screening. 
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BRAIN ABNORMALITIES IN A CASE OF MALONYL-CoA DECARBOXYLASE 
DEFICIENCY 
 
INTRODUCTION 
Malonyl-CoA decarboxylase (MCD) catalyzes the conversion of malonyl-CoA to acetyl-CoA 
and carbon dioxide. MCD deficiency (OMIM 248360) causes autosomal recessive malonic 
aciduria. Symptoms are psychomotor retardation, spasticity/hypotonia, seizures,  
cardiomyopathy, and episodes of metabolic acidosis. Seventeen cases have been published 
but brain pathology is poorly described (Table 1). The role and localization of MCD in the 
cell is controversial. Cytoplasmic malonyl-CoA is a potent inhibitor of mitochondrial fatty 
acid oxidation by inhibiting the mitochondrial outer membrane enzyme carnitine 
palmitoyltransferase I (CPT1). Heart and skeletal muscle contain a CPT1-isoform that is 
substantially more sensitive to inhibition by malonyl-CoA than liver CPT1, where 
cytoplasmic malonyl-CoA serves as a precursor for fatty acid synthesis.1 Both isoforms are 
encoded by different genes, CPT1B and CPT1A. A third brain-specific CPT1 protein-isoform 
with high affinity for malonyl-CoA has been described.2 
Symptoms of cardiomyopathy and metabolic acidosis triggered by stress can be explained 
by inhibition of mitochondrial -oxidation by continuous high levels of malonyl-CoA in 
cytoplasm 3 The carboxy-terminal of the MCD-protein contains a peroxisomal targeting 
sequence suggesting a peroxisomal function, but there is also a potential mitochondrial 
targeting sequence at the N-terminus and mitochondrial localization has been shown in 
rats.1,4,5 In 1999, a mutation in a 2.1-kb cDNA fragment was identified on chromosome 
16q24.3 encoding the human MCD gene MLYCD (OMIM 606761).1 Wightman et al. further 
elucidated a probable mitochondrial and peroxisomal targeting sequence in the MLYCD 
gene and several different frame-shift, stop codon, and mislocalizing mutations in MCD-
deficient patients.6 We present a patient with a malformation of cortical development and 
a MLYCD abnormality, further delineating the neurological consequences of MCD 
deficiency. 
 
CASE REPORT 
Our patient is the daughter of Moroccan third degree consanguineous parents, born at 32 
weeks by emergency c-section due to maternal pre-eclampsia. Family history shows five 
healthy children, two neonatal deaths, several early and late miscarriages. Birth weight 
was 1255 g (-1/-2 SD) with Apgars 5/9/10. A brain ultrasound at one month showed 
generalized atrophy. At nine months old she presented with feeding problems, failure to 
thrive and developmental delay. At two years growth was insufficient (height/ 
weight/head circumference -2SD), she was irritable and showed little to no language 
development. Metabolic screening showed a compensated metabolic acidosis and 
hyperammonaemia of 113 mol/L (normal <50 mol/L), elevated levels of urine malonic 
acid (1447mmol/mol creatin, reference <3mmol/mol creatin), methylmalonic acid 
(12mmol/mol creatin, reference <5mmol/mol creatin), malonylcarnitine (0.36 mol/L, 
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reference 0.02–0.08 mol/L), and propionylcarnitine (1.02 mol/L, ref 0.14–0.94 mol/L) in 
plasma. 
Brain MRI showed generalized atrophy, major white matter loss, thickened cortex, and 
nodular heterotopia. (Fig. 1) Cardiological evaluation was normal. With a low fat/high 
protein diet and carnitine supplements she gained some weight. Follow up acylcarnitine 
analysis showed invariably elevated malonylcarnitine (0.49 mol/L). At the age of 4.5 years 
she walks only with support and shows no language development. There is mild spasticity. 
Developmental level is estimated at one year. Length is at -2SD, length/weight at -1SD, OFC 
at -2.5SD and she consistently refuses food. 
 
Laboratory investigation 
A complete MCD deficiency was measured in cultured skin fibroblasts (0.96 nmol/mg/h, 
reference 10–31 nmol/mg/h). Genomic sequencing of the five MLYCD exons and flanking 
areas revealed no mutation in the patient and both parents. RT-PCR amplification of cDNA, 
followed by examination on 1% agarose gel even after cycling 40x, showed no product in 
the patient, whereas the control displayed the expected bands. Control genes showed a 
normal amplification product (Fig. 2). This abnormality has not been reported and suggests 
a mutation in a transcription regulatory site. 
 
Biochemical and molecular methods 
MCD enzyme activity was assayed in cultured skin fibroblasts according to a modification 
of the method of Scholte.7 
 
MLYCD analysis 
Genomic DNA was isolated from peripheral blood using standard protocols. The primers 
were designed to amplify the five exons including at least 50 bases of flanking genomic 
sequences based on the reference sequence of MLYCD as deposited in GenBank (Accession 
No. for the mRNA NM_012213 and for the MLYCD gene Entrez GeneID 23417). Genomic 
DNA of the patient and both the parents was isolated from leucocytes, using the Puregene 
DNA isolation kit from Gentra. 
All five exons were multiplied by PCR and sequenced including at least 50 bp up- and 
downstream intronic sequence. Exon 1 and 5, because of their size were amplified in two 
overlapping pieces. 
 
Genomic primers 
Exon 1.1 forward  GCGGGGCAGTAACCTTTAG 
Exon 1.1 reverse  CCACCGTAGAAGCTCACGA 
Exon 1.2 forward  CTACGAGCTGCGCGAGAA 
Exon 1.2 reverse  AGGGGGCAAGTGAGGACTAC 
Exon 2 forward  TGTGCTGACCACAACACAGA 
Exon 2 reverse   GAATGGAGATAGATTAGCTTTTAGCC 
Exon 3 forward  CGAATAGTATGAATAGGAGTCAGCA 
Exon 3 reverse   AAACACAAGGGGCTCTATGG 
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Exon 4 forward  CTTCTCGTCCCAGCAACAG 
Exon 4 reverse   CCCACGAGGTTCGCTGAC 
Exon 5.1 forward  CCTCTGTTGGTAACGTACCTG 
Exon 5.1 reverse  TCTGCAGGTGGAAGTTGG 
Exon 5.2 forward  GCTGCAGACTCCGCTGAT 
Exon 5.2 reverse  GCTTGGAAAGCTGCTTCAGA 
 
RT-PCR 
Total RNA was isolated from the patients and a control fibroblast cell line using the 
RNAeasy Mini Kit (Qiagen). First strand cDNA synthesis was performed with the 
SuperScript system for RT-PCR (Invitrogen) with random hexamer primers. The quality of 
the cDNA was tested by RT-PCR of two unrelated genes, ARX (Aristaless like OMIM 300382), 
and glycerol kinase (GK1 OMIM 300474), which both multiplied as expected, when 
analysed on a 1% agarose gel (see Figure 2). RT-PCR of the malonyl-CoA decarboxylase 
cDNA was performed using the following overlapping primers:  
 
RT I forward  AGTAACCTTTAGCCACACTTGG 
RT I reverse   CCACCGTAGAAGCTCACGA 
RT II forward   CTACGAGCTGCGCGAGAA 
RT II reverse   AGGGGGCAAGTGAGGACTAC 
RT III forward   AATGAATGGGGTGCTGAAAG 
RT III reverse   AAGCCATTTGGTGAAACCAG 
RT IV forward   TCGTCAAGGAGTTGCAGAGA 
RT IV reverse   TTTGAAACTGGGCCACTAGG 
RT V forward   AGACCCTCAAGCTCCTCCTC 
RT V reverse   AACTTTGGCTTTGCTTGGAA 
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Table 1 
Summary of neurological symptoms and neuroimaging findings of all malonyl CoA decarboxylase 
patients in the literature 
 
Reference S Age at 
presentation 
Metabol. 
acidosis 
PMR Epileptic 
seizures 
Head 
circumference 
Brain imaging 
Brown et al. 
[16]  
M 5 years  + Mild - Normal ND 
Haan et al. 
[17]  
M 10 months + + + (during 
crisis) 
Normal CT: normal 
Matalon et 
al. [18]  
M 7 months + + + ND ND 
Macphee et 
al. [19]  
M 9 years ND + + ND ND 
Macphee et 
al. [19]  
F 1 years + + + ND ND 
Krawinkel et 
al. [20]  
M 4 days + + - ND Brain MRI: enlarged 
extracerebral spaces 
suggesting atrophy 
Yano et al. 
[21]  
M 4 years + + + Borderline 
microcephaly 
ND 
Buyukgebiz 
et al. [22]  
F died 8 days 
old 
+ N/a N/a ND Not performed 
Ozand et al. 
[23] 
M 9 months + + + P50, decreased 
to <p5 
MRI: frontotemp 
atrophy, abnormal 
intensity putamen, 
caudate, periventricular 
white matter. 
Ozand et al. 
[23]  
M 12 days - + - P50 CT: hypodense myelin 
Ozand et al. 
[23] 
M died 5 
months 
+ + ND ND ND 
Gao et al. [5]  M died 10 
months 
ND ND - ND Not performed 
Wightman et 
al. [6] San1  
F 6 months + - + ND ND 
Wightman et 
al. [6] San2  
F 7 months - - - ND ND 
Wightman et 
al. [6] San3  
M 12 years ND + + ND CT: leftsided cerebral 
infarction. 
Wightman et 
al. [6] Rib1 
F 21 months - + - +2.5SD MRI: altered white 
matter signals frontal 
lobes 
Wightman et 
al. [6] Dou1  
M 6 day + - - Normal ND 
Our patient  F 2 years + + - -2SD MRI: white matter loss, 
pachygyria, nodular 
heterotopia 
References in brackets. ND, not described. 
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Table 1 
Summary of neurological symptoms and neuroimaging findings of all malonyl CoA decarboxylase 
patients in the literature 
 
Reference S Age at 
presentation 
Metabol. 
acidosis 
PMR Epileptic 
seizures 
Head 
circumference 
Brain imaging 
Brown et al. 
[16]  
M 5 years  + Mild - Normal ND 
Haan et al. 
[17]  
M 10 months + + + (during 
crisis) 
Normal CT: normal 
Matalon et 
al. [18]  
M 7 months + + + ND ND 
Macphee et 
al. [19]  
M 9 years ND + + ND ND 
Macphee et 
al. [19]  
F 1 years + + + ND ND 
Krawinkel et 
al. [20]  
M 4 days + + - ND Brain MRI: enlarged 
extracerebral spaces 
suggesting atrophy 
Yano et al. 
[21]  
M 4 years + + + Borderline 
microcephaly 
ND 
Buyukgebiz 
et al. [22]  
F died 8 days 
old 
+ N/a N/a ND Not performed 
Ozand et al. 
[23] 
M 9 months + + + P50, decreased 
to <p5 
MRI: frontotemp 
atrophy, abnormal 
intensity putamen, 
caudate, periventricular 
white matter. 
Ozand et al. 
[23]  
M 12 days - + - P50 CT: hypodense myelin 
Ozand et al. 
[23] 
M died 5 
months 
+ + ND ND ND 
Gao et al. [5]  M died 10 
months 
ND ND - ND Not performed 
Wightman et 
al. [6] San1  
F 6 months + - + ND ND 
Wightman et 
al. [6] San2  
F 7 months - - - ND ND 
Wightman et 
al. [6] San3  
M 12 years ND + + ND CT: leftsided cerebral 
infarction. 
Wightman et 
al. [6] Rib1 
F 21 months - + - +2.5SD MRI: altered white 
matter signals frontal 
lobes 
Wightman et 
al. [6] Dou1  
M 6 day + - - Normal ND 
Our patient  F 2 years + + - -2SD MRI: white matter loss, 
pachygyria, nodular 
heterotopia 
References in brackets. ND, not described. 
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 Figure 2: Left panel: RT-PCR products of malonyl-CoA decarboxylase cDNA in the patient and a control. 
The sequence has been divided in five different products (I–V). None of the products is amplified in the 
patient, suggesting a mutation in a transcription regulatory site. Right panel: RT-PCR of ARX (lanes 1 and 
2) and glycerol kinase (GK, lanes 3 and 4) genes from total RNA, showing normal amplification products 
in the patient. C, control; P, patient. 
 
Discussion 
Except for the cortical malformation and lack of cardiac complaints, our patient phenotype 
is similar to the 17 previously described patients. While 12 of 17 patients are 
developmentally delayed and 8 of 17 had epileptic seizures, brain imaging is only reported 
in six cases (Table 1). In three cases this is a brain CT, insufficient to rule out neuronal 
migration disorders. In two patients the imaging showed atrophy and in three altered 
white matter signals (once combined), suggesting an influence of MCD deficiency on brain 
development. In our patient, brain atrophy and periventricular white matter loss are 
striking. These cannot be explained by metabolic crises, as our patient did not have periods 
of hypoglycaemia or severe acidosis. We found pachygyria and periventricular nodular 
heterotopia consistent with a neuronal migration disorder caused by an early gestational 
insult. In both pachygyria and periventricular heterotopia there is a premature arrest of 
neuronal migration. During intrauterine development neurons are required to migrate 
along radial glial cells and detach when they reach the target layer of the cortex. 8 
Mutations in many genes cause periventricular heterotopia, lissencephaly, and subcortical 
band heterotopia. Not all cases of pachygyria/lissencephaly and nodular heterotopia are 
explained by mutations in these genes.8 Inborn errors of metabolism rarely cause 
migration disorders. Zellweger syndrome and other peroxisomal biogenesis disorders can 
present with gyral abnormalities, heterotopia, polymicrogyria-like abnormalities, 
pachygyria, and cerebellar hypoplasia. Dysregulation of the glutamatergic pathway in 
Zellweger mice has been suggested to play a role.9 If the MCD-protein also has a role in 
peroxisomal function, disturbance of this function could contribute to the observed brain 
development abnormalities. 
Malonyl CoA decarboxylase deficiency 
125 
Deficiency of the inner mitochondrial membrane enzyme CPT2 has been associated with 
cortical defects such as heterotopia and polymicrogyria.10 CPT2 has a close interaction with 
CPT1 and could therefore be influenced by malonyl-CoA levels. The brain-specific CPT1 
subunit (CPT1C) has high affinity for malonyl-CoA.2 Disturbed interaction between 
malonyl-CoA and CPT1C in our patient may have contributed to abnormal brain 
development. In mouse-brain high levels of MCD are co-expressed in regions with high 
levels of lipogenic enzymes such as the hypothalamus and cortex. It suggests an important 
but so far unrecognized role in lipid synthesis in brain. Membrane function is known the 
be important in neuronal migration and also other lipid synthesis disturbances could 
contribute to migration disorders.11,12  
One more striking symptom in our patient is her refusal to eat. Many children with inborn 
errors of metabolism suffer from failure to thrive, but her food refusal was consistent and 
unusual. It is well established that malonyl-CoA influences appetite control, apart from 
being an important factor in the balance of glucose–fatty acid metabolism. Recent studies 
in animals have demonstrated that increasing hypothalamic malonyl-CoA reduces 
appetite and feeding behavior, while starvation reduces hypothalamic malonyl-CoA 
level.13,14 Hypothalamic malonyl-CoA levels thus function as a final common signal to 
regulate food intake.15 It is possible that the feeding problems in our patient are influenced 
by high hypothalamic malonyl-CoA. 
In light of the incomplete knowledge of the influence of metabolic pathways on brain 
development patients with MCD deficiency should be evaluated with brain MRI. 
Unexplained malformations of cortical development should be reason for metabolic 
screening by urine organic acid and plasma acylcarnitine profiling in addition to 
measurement of plasma very long chain fatty acids which is routine. 
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ABSTRACT 
 
Malformations of cerebral cortical development, in particular periventricular nodular 
heterotopia (PNH), and distal transverse limb deficiency have been reported as associated 
congenital anomalies. Patients with PNH and transverse limb deficiency can be classified 
as having amniotic band sequence or Adams-Oliver syndrome (AOS). Controversy exists 
whether these should be considered separate entities. In some AOS patients, autosomal 
recessive inheritance has been shown, but in most patients causes are unknown, and both 
environmental and genetic factors have been implicated. We present three patients with 
PNH and distal transverse limb deficiency to support the hypothesis that these should be 
considered part of one group of disorders, and highlight the variable severity of the clinical 
and neuroradiological phenotype. Chromosome abnormalities were excluded by copy 
number analysis on 250K SNP microarray data. Research done on limb deficiency as on 
PNH caused by mutations in known genes, suggests the involvement of vascular 
developmental pathways. The combination of limb deficiency and PNH may have a 
common causative mechanism. Recognition and grouping of patients with this 
combination of abnormalities will help elucidating the cause. 
PNH and limb deficiency 
133 
PERIVENTRICULAR NODULAR HETEROTOPIA AND DISTAL LIMB DEFICIENCY 
A recurrent association 
  
INTRODUCTION 
Malformations of cerebral cortical development (MCD) such as periventricular nodular 
heterotopia (PNH), or polymicrogyria (PMG) can occur as an isolated malformation or in 
combination with a diverse range of congenital abnormalities.1 One reported association is 
with limb anomalies. A combination of limb deficiency and PNH has also been described in 
the amniotic band sequence (OMIM 217100) and Adams–Oliver syndrome (AOS, OMIM 
100300). Both diagnoses have even been suggested in the same patient, highlighting the 
overlapping findings.2,3 Amniotic band sequence refers to congenital disruption with distal 
limb deficiencies and constriction rings, associated with other congenital anomalies.4 It 
remains controversial whether these are caused by external constriction by amniotic 
bands or by genetic factors that cause both the congenital anomalies and the formation of 
amniotic bands. AOS is a variable syndrome of scalp defects and distal limb deficiencies. 
The severe variant with central nervous system involvement is thought to be autosomal 
recessive.3,5,6 Other patients with PNH and limb deficiencies are not classified as AOS or 
amniotic bandsequence.7 In this report we focus on malformations of cortical 
development, particularly PNH, associated with distal transverse limb deficiency and 
suggest these may have a shared pathogenesis. To support this, we present three patients 
with PNH and distal limb deficiency. 
 
PATIENTS 
Patient 1 
This boy was born to non-consanguineous parents at 32 weeks of gestation after an 
uneventful pregnancy. At birth defects of the limbs were noted and he was diagnosed with 
amniotic band sequence. The left hand is normal, but with a ring constriction at the wrist. 
Radiographs are normal. The right hand has a normal thumb. There is cutaneous 
syndactyly, partial between 2 and 3, 4 and 5, and complete between 3 and 4, and a lack of 
finger creases. There are nails present on digit 2, the fused digits 3–4 and digit 5. 
Radiographs show a normal thumb and normal metacarpals. Digits 2–5 lack phalanges. 
Digits 2 and 4 have fused phalanges, digits 3–5 hypoplastic proximal phalanges. The left 
foot shows short toes 1–3 without nails, with partial cutaneous syndactyly of toes 1 and 2, 
and complete syndactyly of toes 2 and 3. Toes 4 and 5 appear normal. Radiographs show 
absence of the distal phalanx of digits 1, 2, and 3, hypoplasia of the middle phalanges of 
digits 2 and 3, and fusion of the middle and distal phalanges of digits 4 and 5. The right 
foot also shows short toes 1–3 without nails, and partial cutaneous syndactyly between 
toes 2 and 3. Radiographs show hypoplasia of the distal phalanx of digits 1 and 3, and 
absence in digit 2. There is fusion of the middle and distal phalanges of digits 4 and 5 (Figs. 
1A and 4A). The patient developed intractable epilepsy at age 19. Brain MRI showed 
bilateral symmetric occipital PNH (Fig. 2A). Psychomotor development was normal, and he 
finished high school. There are no facial anomalies. Occipitofrontal circumference is 
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ABSTRACT 
 
Malformations of cerebral cortical development, in particular periventricular nodular 
heterotopia (PNH), and distal transverse limb deficiency have been reported as associated 
congenital anomalies. Patients with PNH and transverse limb deficiency can be classified 
as having amniotic band sequence or Adams-Oliver syndrome (AOS). Controversy exists 
whether these should be considered separate entities. In some AOS patients, autosomal 
recessive inheritance has been shown, but in most patients causes are unknown, and both 
environmental and genetic factors have been implicated. We present three patients with 
PNH and distal transverse limb deficiency to support the hypothesis that these should be 
considered part of one group of disorders, and highlight the variable severity of the clinical 
and neuroradiological phenotype. Chromosome abnormalities were excluded by copy 
number analysis on 250K SNP microarray data. Research done on limb deficiency as on 
PNH caused by mutations in known genes, suggests the involvement of vascular 
developmental pathways. The combination of limb deficiency and PNH may have a 
common causative mechanism. Recognition and grouping of patients with this 
combination of abnormalities will help elucidating the cause. 
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PERIVENTRICULAR NODULAR HETEROTOPIA AND DISTAL LIMB DEFICIENCY 
A recurrent association 
  
INTRODUCTION 
Malformations of cerebral cortical development (MCD) such as periventricular nodular 
heterotopia (PNH), or polymicrogyria (PMG) can occur as an isolated malformation or in 
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with limb anomalies. A combination of limb deficiency and PNH has also been described in 
the amniotic band sequence (OMIM 217100) and Adams–Oliver syndrome (AOS, OMIM 
100300). Both diagnoses have even been suggested in the same patient, highlighting the 
overlapping findings.2,3 Amniotic band sequence refers to congenital disruption with distal 
limb deficiencies and constriction rings, associated with other congenital anomalies.4 It 
remains controversial whether these are caused by external constriction by amniotic 
bands or by genetic factors that cause both the congenital anomalies and the formation of 
amniotic bands. AOS is a variable syndrome of scalp defects and distal limb deficiencies. 
The severe variant with central nervous system involvement is thought to be autosomal 
recessive.3,5,6 Other patients with PNH and limb deficiencies are not classified as AOS or 
amniotic bandsequence.7 In this report we focus on malformations of cortical 
development, particularly PNH, associated with distal transverse limb deficiency and 
suggest these may have a shared pathogenesis. To support this, we present three patients 
with PNH and distal limb deficiency. 
 
PATIENTS 
Patient 1 
This boy was born to non-consanguineous parents at 32 weeks of gestation after an 
uneventful pregnancy. At birth defects of the limbs were noted and he was diagnosed with 
amniotic band sequence. The left hand is normal, but with a ring constriction at the wrist. 
Radiographs are normal. The right hand has a normal thumb. There is cutaneous 
syndactyly, partial between 2 and 3, 4 and 5, and complete between 3 and 4, and a lack of 
finger creases. There are nails present on digit 2, the fused digits 3–4 and digit 5. 
Radiographs show a normal thumb and normal metacarpals. Digits 2–5 lack phalanges. 
Digits 2 and 4 have fused phalanges, digits 3–5 hypoplastic proximal phalanges. The left 
foot shows short toes 1–3 without nails, with partial cutaneous syndactyly of toes 1 and 2, 
and complete syndactyly of toes 2 and 3. Toes 4 and 5 appear normal. Radiographs show 
absence of the distal phalanx of digits 1, 2, and 3, hypoplasia of the middle phalanges of 
digits 2 and 3, and fusion of the middle and distal phalanges of digits 4 and 5. The right 
foot also shows short toes 1–3 without nails, and partial cutaneous syndactyly between 
toes 2 and 3. Radiographs show hypoplasia of the distal phalanx of digits 1 and 3, and 
absence in digit 2. There is fusion of the middle and distal phalanges of digits 4 and 5 (Figs. 
1A and 4A). The patient developed intractable epilepsy at age 19. Brain MRI showed 
bilateral symmetric occipital PNH (Fig. 2A). Psychomotor development was normal, and he 
finished high school. There are no facial anomalies. Occipitofrontal circumference is 
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normal. He has amblyopia of the left eye with divergent strabismus. Neurological findings 
are normal.  
 
Patient 2 
This girl was born at term by caesarean section, which was prompted by fetal distress. She 
was dysmature weighing 1,900 g, which was attributed to maternal cannabis, oxazepam, 
and tramadol use and cigarette smoking. These substances are not reported to cause MCD 
or limb defects. She has distal deficiencies of three limbs (Fig. 4B). On the left hand digits 2, 
3, and 4 are absent. The left thumb is normal, and the fifth finger is short. Radiographs 
show a normal thumb, lack of the middle or distal phalanx of the fifth finger, short 
metacarpals 2, 3, and 4 and absence of all phalanges of digits 2, 3, and 4 (Fig. 1B). On the 
right hand there is a normal thumb and short fifth finger. Digit 2 is hypoplastic with a 
normal nail. Digits 3 and 4 are rudimentary with ring constrictions, and have no nail. 
Radiographs show normal metacarpals and thumb. The fifth finger shows no (ossification 
of the) middle phalanx, and is otherwise normal. Digit 2 shows a delta-shaped proximal 
phalanx, rudimentary ossification of the middle phalanx, and a hypoplastic distal phalanx. 
Digit 3 shows rudimentary ossification of the proximal phalanx and absence of other 
bones. Digit 4 shows a hypoplastic proximal phalanx. The left foot is short with a bud for 
digits 1 and 5 and dimples at the location of the other digits. Radiographs show absence of 
metatarsal bones and toes. On the right, there is a clubfoot with cutaneous syndactyly 
between 2 and 3, otherwise normal toes and nails (Fig. 4B). Radiographs are normal (Fig. 
1B). Minor facial anomalies include bilateral epicanthic folds and telecanthus, upward 
slant of the palpebral fissures, small bitemporal diameter, and prominent upper lip (Fig. 
3A). Brain MRI shows a large PNH at the left anterior ventricle (Fig. 2B). She had not 
developed epilepsy up to the present age of 2 years. Repeated EEGs were normal. 
Psychomotor development is mildly delayed, and she recently acquired walking. OFC 
grows at -0.5 SD. On neurological exam she was found to have bilateral abducens nerve 
palsy and symmetric facial palsy, compatible with Möbius syndrome (OMIM 157900). 
Muscle tone and strength are normal. Tendon reflexes are symmetrically normal and 
plantar responses are flexor.  
 
Patient 3 
This boy was born at term by caesarean, prompted by fetal distress, to non-
consanguineous parents. He had hydrocephalus with OFC at +3.5 SD and received a 
ventriculo-peritoneal shunt, 1 day after birth. His OFC growth curve dropped to -1 SD over 
the course of 5 years. At 7 months he developed infantile spasms. MRI showed bilateral 
PNH with abnormal overlying cortex, consistent with PMG and partial agenesis of the 
corpus callosum (Fig. 2C). He has limb deficiencies of the left foot with a short first and 
fourth toes, short toes 2 and 3 with constrictions, all without nails, and normal fifth (Fig. 
1C). Radiographs show hypoplasia of the distal phalanx of digit 1, hypoplasia of the 
proximal phalanx of digits 2–4 and absent middle and distal phalanges of digits 2–5. The 
right foot shows cutaneous syndactyly between digits 2 and 3, and normal radiographs 
(Fig. 4C). The hands are normal. Other findings included a supernumerary nipple, bilateral 
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ptosis, short palpebral fissures, and bilateral epicanthal folds (Fig. 3B). He is included in our 
cohort study of children with MCD.1 He is now 8 years old and has severe psychomotor 
retardation with intractable epilepsy, spastic tetraplegia, and scoliosis. 
 
 
  
Figure 1: Radiographs of hands and feet. A: Patient 1 at 39 years. Upper panel: normal left hand and 
transverse limb deficiency of the right hand. Lower panel: feet with deficiencies on both sides. B: Patient 
2 at 3.5 months. Upper panel: deficiencies of both hands. Lower panel: absence of metatarsal bones and 
toes of the left foot, and a normal right foot. C: Patient 3 at 9 years. Upper panel: normal hands. Lower 
panel: deficiencies of the left foot and a normal right foot. 
 
 
  
Figure 2: Brain MRI of all patients. A: Patient 1 at age 39 years, T1 weighted image. Note bilateral PNH in 
the occipital horns of the lateral ventricles (arrows). B: Patient 2 at age 11 months, T2 weighted image. 
Note a large PNH in the frontal horn of the left lateral ventricle (arrow). Ventricles are mildly enlarged 
for age. C: Patient 3 at age 3 years. T1 weighted image. Note bilateral PNH (arrows), hydrocephalus and 
diffuse polymicrogyria. 
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Figure 3: Facial appearance. A: Patient 2 at age 10 months. Note bilateral epicanthic folds and 
telecanthus, mild upward slant of palpebral fissures, narrow bitemporal diameter, and prominent upper 
lip. B: Patient 3 at age 9 years. Note bilateral ptosis, short palpebral fissures, bilateral epicanthal folds, 
and prominent upper central incisors. 
 
 
 
Figure 4: Limbs. A: Patient 1 at age 39 years. Upper panel: normal left hand and cutaneous syndactyly on 
the right hand. Lower panel: feet show absence of nails on digits 1–3, and cutaneous syndactyly. B: 
Patient 2 at age 3 months. Upper panel: absence of digits 2, 3, and 4, and short fifth finger on the left 
hand. On the right hand digit 2 is hypoplastic, digits 3 and 4 are rudimentary with ring constrictions, and 
the fifth finger is short. Lower panel: short left foot with a bud for digits 1 and 5 and absence of the 
other digits. On the right, a clubfoot with cutaneous syndactyly between digits 2 and 3. C: Patient 3 at 
age 6 months. Upper panel: hands are normal and were not photographed. Lower panel: left foot with 
short toes 1–4, all without nails. The right foot shows cutaneous syndactyly between digits 2 and 3. 
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Genetic analysis 
Standard G banding karyotyping showed apparently normal chromosomes in all patients. 
FLNA sequence analysis was done in Patients 1 and 2 with normal results. This was not 
done in Patient 3 as the MRI phenotype did not fit the FLNA-pattern. DNA-analysis of all 
patients on Affymetrix 250K NspI SNP arrays, by the CNAG copy number method, did not 
show any pathogenic chromosome rearrangement. Copy neutral LOH analysis showed 
several homozygous areas on different chromosomes only in Patient 3, suggesting parental 
consanguinity. 
 
DISCUSSION 
The combination of periventricular nodular heterotopia (PNH) or other cortical 
malformations and distal transverse limb deficiency is a rare but consistent finding (Table 
I). PNH and distal limb deficiencies have been reported in patients classified as severe AOS, 
amniotic band sequence, or with other congenital anomalies. Several case reports describe 
patients with PNH, limb deficiency, and microphthalmia, cleft palate or midface 
hypoplasia.2,8 The phenotype of our patients overlaps with the severe variant of AOS, 
although our patients do not have scalp or skin defects.3,5,6 The extent of the digital defects 
in our patients is highly variable, as also seen in AOS patients. A combination of PNH with 
scalp defect without limb deficiency has also been described.9 In a recent overview of PNH-
phenotypes, four patients (one male) with limb deficiency were included.7 Limb deficiency 
has been described with other cortical malformations, but the combination with PNH 
seems more commonly found (Table I).  
Vascular disruption has been implicated in limb deficiencies, supported by the association 
with facial clefts, maternal bleeding, twin pregnancies, and other birth defects.10-12 The 
pathogenesis of AOS is also thought to be related to vascular problems, such as vascular 
disruption, abnormal development of small vessels, or abnormal pericyte recruitment to 
blood vessels.5,13,14 AOS is associated with other presumably vascular determined 
congenital defects, such as Poland sequence (OMIM 173800).15 Möbius syndrome, as in 
Patient 2, can occur with limb defects such as oligodactyly, brachydactyly, syndactyly, 
polydactyly, or Poland sequence and again abnormal vascular development is 
implicated.16,17 AOS is also associated with cardiac developmental anomalies and cutis 
marmorata.18 
PNH is a neuronal migration disorder resulting from an inability of early neurons to 
migrate from the subventricular zone to the cortex. Mutations in the genes coding for 
filamin A (FLNA, OMIM 30017), and for BIG2 (ARFGEF2, OMIM 605371) have been found in 
humans with PNH. The most frequent genetic cause of PNH without limb deficiencies, 
found in approximately 30% of patients, are mutations in the X-linked FLNA gene.7 In the 
absence of normal filamin A function, impaired migration of later neurons is due to 
disrupted cell adhesion and abnormal ventricular ependymal function.19 FLNA mutations 
also cause cardiovascular developmental defects and connective tissue abnormalities, and 
autopsy studies additionally show abnormal glomeruloid microvascular proliferations in 
the brain in patients with FLNA related PNH.19,20 PNH is not likely to be directly caused by 
vascular disruption, but the association with cardiac and vascular anomalies in FLNA 
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patients shows that pathways involved in cell adhesion can affect both the neuro-
epithelium and vascular development. Other proteins that regulate axon guidance during 
brain development, such as Semaphorins, Netrins, Slits, and Ephrins, are also involved in 
vascular patterning and endothelial cell migration, processes which are essential for limb 
bud formation.21,22 Pathways that affect neuronal migration can also affect vascular 
development, which may increase the chance of prenatal vascular disruption. 
Vascular factors have also been implicated in other MCD, mostly polymicrogyria (PMG). 
Gestational insults, such as cytomegalovirus infection or ischemia, can cause PMG.1,23 
Embryonic vascular factors have been implicated in perisylvian PMG with or without limb 
anomalies in 22q11 microdeletion syndrome.24 Congenital constriction bands with limb 
deficiencies or AOS are associated with bilateral perisylvian PMG, septo-optic dysplasia 
and periventricular leukomalacia.5,25-27 
In some patients limb deficiencies seem to have resulted from external constriction by 
amniotic bands; however the recurrent association with cerebral malformation suggests a 
common, possibly genetic cause in other patients. Our observation suggests that patients 
with PNH and limb deficiencies manifest abnormalities with a common pathogenesis. 
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Table I: Comparison of published cases of patients with a combination of distal limb deficiency and 
cerebral anomalies 
 
Authors Sex PNH Brain imaging Scalp/ 
skull 
defect 
Other reported findings 
F - CT: Periventricular calcification and 
atrophy 
+ Vitreoretinal anomaly Örstsavik et al., 
1995 (sibs) [28] 
M - Autopsy: partial agenesis corpus 
callosum, PVL 
+ Vitreoretinal anomaly 
Fryns et al., 1996 
[29] 
M - CT: porencephalic cyst L hemisphere + - 
M - CT: unilateral PMG + - Savarirayan et al., 
1999 (sibs) [13] F - ND + Pulmonary valve stenosis 
Chitayat et al., 
1992 [30] 
M - CT angiography : abnormal brain 
vasculature. 
+ Bicuspid aortic valve 
Romani et al., 
1998 [31] 
M - CT : periventricular calcification, wide 
ventricles 
+ - 
Mempel et al. 
1999 [32] 
M - MRI : bilateral  PMG + Cutis marmorata, cardiac 
defect 
M - CT: unilateral  PMG + Cutaneous telangiectasia Amor et al., 2000 
(sibs) [5] F  MRI: bilateral  PMG - Prominent veins, 
lymphoedema 
Unay et al., 2001 
[33] 
F - CT: periventricular calcification + - 
Piazza et al., 2004 
[34] 
M - MRI: periventricular calcification + Cutis marmorata, 
pulmonary hypertension 
M - MRI: periventricular calcification with 
infarction, hypoplastic veins 
+ Cutis marmorata, cardiac 
defect 
Patel et al., 2004 
(unrelated) [14] 
M - CT: periventricular calcification + Cutis marmorata, cardiac 
defect. Twin pregnancy. 
M + MRI: diffuse bilateral PNH* - - 
F + MRI: diffuse bilateral PNH - - 
F + MRI: diffuse bilateral PNH* - - 
Parrini et al., 
2006 (unrelated) 
[7] 
F + MRI: diffuse bilateral PNH* - - 
F + MRI: bilateral PNH and agenesis corpus 
callosum 
- Arthrogryposis, café au lait 
spots 
Musumeci et al., 
2006 (unrelated) 
[35] F + MRI: diffuse bilateral PNH - - 
F - MRI: partial agenesis corpus callosum, 
periventricular calcification * 
- Cutis marmorata 
prominent veins 
McGoey and 
Lacassie, 2008 
(sibs) [6] F - CT: periventricular calcification * - Hemangioma face and 
occiput 
Prothero et al., 
2007 [36] 
M - MRI: periventricular calcification, wide 
ventricles a 
+ Falciform retinal folds 
Brancati et al., 
2008 [3] 
F + MRI: diffuse bilateral PNH - Prominent veins on trunk 
Papadopoulou et 
al., 2008 [27] 
M - MRI: PVL and calcifications + - 
M - MRI: periventricular calcification* - Cardiac defect  Balasubramanian 
and Collins, 2009 
(sibs) [37] 
F - MRI: PVL * + - 
M + MRI: occipital bilateral PNH - - 
F + MRI: unilateral PNH - Möbius syndrome 
Current report 
(unrelated) 
M + MRI: bilateral PNH and PMG - - 
PNH: periventricular nodular heterotopia; PMG: polymicrogyria; PVL: periventricular leukomalacia. 
* MRI imaging not published, only description available  
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M - CT angiography : abnormal brain 
vasculature. 
+ Bicuspid aortic valve 
Romani et al., 
1998 [31] 
M - CT : periventricular calcification, wide 
ventricles 
+ - 
Mempel et al. 
1999 [32] 
M - MRI : bilateral  PMG + Cutis marmorata, cardiac 
defect 
M - CT: unilateral  PMG + Cutaneous telangiectasia Amor et al., 2000 
(sibs) [5] F  MRI: bilateral  PMG - Prominent veins, 
lymphoedema 
Unay et al., 2001 
[33] 
F - CT: periventricular calcification + - 
Piazza et al., 2004 
[34] 
M - MRI: periventricular calcification + Cutis marmorata, 
pulmonary hypertension 
M - MRI: periventricular calcification with 
infarction, hypoplastic veins 
+ Cutis marmorata, cardiac 
defect 
Patel et al., 2004 
(unrelated) [14] 
M - CT: periventricular calcification + Cutis marmorata, cardiac 
defect. Twin pregnancy. 
M + MRI: diffuse bilateral PNH* - - 
F + MRI: diffuse bilateral PNH - - 
F + MRI: diffuse bilateral PNH* - - 
Parrini et al., 
2006 (unrelated) 
[7] 
F + MRI: diffuse bilateral PNH* - - 
F + MRI: bilateral PNH and agenesis corpus 
callosum 
- Arthrogryposis, café au lait 
spots 
Musumeci et al., 
2006 (unrelated) 
[35] F + MRI: diffuse bilateral PNH - - 
F - MRI: partial agenesis corpus callosum, 
periventricular calcification * 
- Cutis marmorata 
prominent veins 
McGoey and 
Lacassie, 2008 
(sibs) [6] F - CT: periventricular calcification * - Hemangioma face and 
occiput 
Prothero et al., 
2007 [36] 
M - MRI: periventricular calcification, wide 
ventricles a 
+ Falciform retinal folds 
Brancati et al., 
2008 [3] 
F + MRI: diffuse bilateral PNH - Prominent veins on trunk 
Papadopoulou et 
al., 2008 [27] 
M - MRI: PVL and calcifications + - 
M - MRI: periventricular calcification* - Cardiac defect  Balasubramanian 
and Collins, 2009 
(sibs) [37] 
F - MRI: PVL * + - 
M + MRI: occipital bilateral PNH - - 
F + MRI: unilateral PNH - Möbius syndrome 
Current report 
(unrelated) 
M + MRI: bilateral PNH and PMG - - 
PNH: periventricular nodular heterotopia; PMG: polymicrogyria; PVL: periventricular leukomalacia. 
* MRI imaging not published, only description available  
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ABSTRACT 
 
The combination of megalencephaly, perisylvian polymicrogyria, polydactyly and 
hydrocephalus (MPPH) is a rare syndrome of unknown cause. We observed two first 
cousins affected by an MPPH-like phenotype with a submicroscopic chromosome 5q35 
deletion as a result of an unbalanced der(5)t(5;20)(q35.2;q13.3) translocation, including the 
NSD1 Sotos syndrome locus. We describe the phenotype and the deletion breakpoints of 
the two MPPH-like patients and compare these with five unrelated MPPH and Sotos 
patients harboring a 5q35 microdeletion. Mapping of the breakpoints in the two cousins 
was performed by MLPA, FISH, high density SNP-arrays and Q-PCR for the 5q35 deletion 
and 20q13 duplication. The 5q35 deletion area of the two cousins almost completely 
overlaps with earlier described patients with an atypical Sotos microdeletion, except for 
the DRD1 gene. The five unrelated MPPH patients neither showed submicroscopic 
chromosomal aberrations nor DRD1 mutations. We reviewed the brain MRI of ten Sotos 
patients and did not detect polymicrogyria in any of them. In our two cousins, the MPPH-
like phenotype is probably caused by the contribution of genes on both chromosome 5q35 
and 20q13. Some patients with MPPH may harbor a submicroscopic chromosomal 
aberration and therefore high-resolution array analysis should be part of the diagnostic 
workup. 
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INTRODUCTION 
Polymicrogyria (PMG) is generally considered to be a post-migratory disorder of cortical 
organization mostly associated with motor and sensory defects and often with epilepsy 
and psychomotor retardation. Prenatal insults like intoxications, infections and 
hypoperfusion can cause PMG.1 The recent discovery of KIAA1279 mutations in Goldberg-
Shprintzen syndrome with diffuse PMG and other familial PMG syndromes indicate that 
genetic factors play an important role.2-6 New chromosomal loci have been associated with 
PMG.7,8 One of the PMG syndromes of unknown etiology is the recently described 
megalencephaly with perisylvian polymicrogyria, polydactyly and hydrocephalus 
(MPPH).9-12  Megalencephaly is thought to be a proliferation defect of the cerebral cortex. 
Although it has been associated with overgrowth syndromes like Sotos and Cutis 
marmorata telangiectasia congenita (M-CM) syndrome, hamartomatoses like Pallister-Hall, 
Bannayan-Zonana syndrome and metabolic disorders, no gene mutations are known 
causing exclusively megalencephaly in humans.13,14 Overlap between MPPH and M-CM has 
recently been suggested.15  
We describe a family with two first cousins presenting with megalencephaly and 
polymicrogyria resembling MPPH syndrome. They both carry a derivative chromosome 5q 
as a result of the unbalanced segregations of a translocation t(5;20)(q35.2;q13.3) resulting 
in a chromosome 5q35.2-qter deletion encompassing the NSD1 locus for Sotos syndrome, 
and a partial trisomy of chromosome 20q13.3-qter. We have fine-mapped the deletion 
breakpoints and compare these with the phenotype and breakpoints of Sotos 
microdeletion patients. We also genotyped five other MPPH patients using high resolution 
SNP array analysis and sequenced the DRD1 gene as a possible candidate gene for MPPH.  
 
PATIENT DESCRIPTION  
Patient 1 and 2 are first cousins, both from healthy Dutch parents (Fig. 1A). Their mothers 
are sisters. Patient 1 (III-1 in Fig 1A) is a girl examined at the age of 2 years for a severe 
psychomotor retardation, axial hypotonia, spasticity and epilepsy. The pregnancy was 
complicated by polyhydramnion, intrauterine growth retardation and pre-eclampsia. The 
delivery followed in the 37th week with a birth weight of 2180 grams (-2 SD) and OFC of 
33.0 cm (0 SD). The neonatal period was complicated by E.Coli sepsis, cholestasis and liver 
dysfunction. She also presented with a small ASD type II and hypothalamic 
hypothyroidism with low TSH values. In time she developed kyphoscoliosis, pectus 
carinatum and signs of rickets, which did not improve with vitamin D supplementation. 
She experienced several urinary infections caused by grade IV vesicoureteral reflux. 
Psychomotor development was delayed, but at the age of 1.5 years a status epilepticus 
caused regression. Examination at the age of 2 years showed macrocephaly (OFC at +3 SD, 
height at 0 SD), high broad forehead, large fontanel, hypertelorism with epicanthic folds, 
short upturned nose with hypoplastic nostrils, down turned corners of the mouth with 
thick vermilion of the lips, high arched palate, small pointed chin with a vertical groove, 
large low-set ears, barrel shaped chest with kyphoscoliosis, postaxial polydactyly of the 5th 
right toe. She had severe head lag, was unable to sit unsupported, showed a spastic 
tetraparesis, made eye contact and had no speech development. Brain MRI revealed 
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ABSTRACT 
 
The combination of megalencephaly, perisylvian polymicrogyria, polydactyly and 
hydrocephalus (MPPH) is a rare syndrome of unknown cause. We observed two first 
cousins affected by an MPPH-like phenotype with a submicroscopic chromosome 5q35 
deletion as a result of an unbalanced der(5)t(5;20)(q35.2;q13.3) translocation, including the 
NSD1 Sotos syndrome locus. We describe the phenotype and the deletion breakpoints of 
the two MPPH-like patients and compare these with five unrelated MPPH and Sotos 
patients harboring a 5q35 microdeletion. Mapping of the breakpoints in the two cousins 
was performed by MLPA, FISH, high density SNP-arrays and Q-PCR for the 5q35 deletion 
and 20q13 duplication. The 5q35 deletion area of the two cousins almost completely 
overlaps with earlier described patients with an atypical Sotos microdeletion, except for 
the DRD1 gene. The five unrelated MPPH patients neither showed submicroscopic 
chromosomal aberrations nor DRD1 mutations. We reviewed the brain MRI of ten Sotos 
patients and did not detect polymicrogyria in any of them. In our two cousins, the MPPH-
like phenotype is probably caused by the contribution of genes on both chromosome 5q35 
and 20q13. Some patients with MPPH may harbor a submicroscopic chromosomal 
aberration and therefore high-resolution array analysis should be part of the diagnostic 
workup. 
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INTRODUCTION 
Polymicrogyria (PMG) is generally considered to be a post-migratory disorder of cortical 
organization mostly associated with motor and sensory defects and often with epilepsy 
and psychomotor retardation. Prenatal insults like intoxications, infections and 
hypoperfusion can cause PMG.1 The recent discovery of KIAA1279 mutations in Goldberg-
Shprintzen syndrome with diffuse PMG and other familial PMG syndromes indicate that 
genetic factors play an important role.2-6 New chromosomal loci have been associated with 
PMG.7,8 One of the PMG syndromes of unknown etiology is the recently described 
megalencephaly with perisylvian polymicrogyria, polydactyly and hydrocephalus 
(MPPH).9-12  Megalencephaly is thought to be a proliferation defect of the cerebral cortex. 
Although it has been associated with overgrowth syndromes like Sotos and Cutis 
marmorata telangiectasia congenita (M-CM) syndrome, hamartomatoses like Pallister-Hall, 
Bannayan-Zonana syndrome and metabolic disorders, no gene mutations are known 
causing exclusively megalencephaly in humans.13,14 Overlap between MPPH and M-CM has 
recently been suggested.15  
We describe a family with two first cousins presenting with megalencephaly and 
polymicrogyria resembling MPPH syndrome. They both carry a derivative chromosome 5q 
as a result of the unbalanced segregations of a translocation t(5;20)(q35.2;q13.3) resulting 
in a chromosome 5q35.2-qter deletion encompassing the NSD1 locus for Sotos syndrome, 
and a partial trisomy of chromosome 20q13.3-qter. We have fine-mapped the deletion 
breakpoints and compare these with the phenotype and breakpoints of Sotos 
microdeletion patients. We also genotyped five other MPPH patients using high resolution 
SNP array analysis and sequenced the DRD1 gene as a possible candidate gene for MPPH.  
 
PATIENT DESCRIPTION  
Patient 1 and 2 are first cousins, both from healthy Dutch parents (Fig. 1A). Their mothers 
are sisters. Patient 1 (III-1 in Fig 1A) is a girl examined at the age of 2 years for a severe 
psychomotor retardation, axial hypotonia, spasticity and epilepsy. The pregnancy was 
complicated by polyhydramnion, intrauterine growth retardation and pre-eclampsia. The 
delivery followed in the 37th week with a birth weight of 2180 grams (-2 SD) and OFC of 
33.0 cm (0 SD). The neonatal period was complicated by E.Coli sepsis, cholestasis and liver 
dysfunction. She also presented with a small ASD type II and hypothalamic 
hypothyroidism with low TSH values. In time she developed kyphoscoliosis, pectus 
carinatum and signs of rickets, which did not improve with vitamin D supplementation. 
She experienced several urinary infections caused by grade IV vesicoureteral reflux. 
Psychomotor development was delayed, but at the age of 1.5 years a status epilepticus 
caused regression. Examination at the age of 2 years showed macrocephaly (OFC at +3 SD, 
height at 0 SD), high broad forehead, large fontanel, hypertelorism with epicanthic folds, 
short upturned nose with hypoplastic nostrils, down turned corners of the mouth with 
thick vermilion of the lips, high arched palate, small pointed chin with a vertical groove, 
large low-set ears, barrel shaped chest with kyphoscoliosis, postaxial polydactyly of the 5th 
right toe. She had severe head lag, was unable to sit unsupported, showed a spastic 
tetraparesis, made eye contact and had no speech development. Brain MRI revealed 
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megalencephaly, asymmetric mild dilatation of the lateral ventricles (right > left) and right 
perisylvian polymicrogyria (Figure 2A). Family history showed two miscarriages, one 
concerning an anencephalic embryo.  
Patient 2 (III-2 in Fig. 1A and B) was born to the sister of Patient 1’s mother after a 
pregnancy complicated by polyhydramnion and fetal hydrops with hydrothorax. The 
delivery in the 35th week was complicated by perinatal asphyxia, shearing of umbilical 
cord, haemorrhage and fetal shock. She was macrosomic and macrocephalic at birth 
(weight 3160 grams, +2.5 SD; OFC 38 cm, +3.5 SD). The neonatal period was complicated by 
multiorgan failure, persistent hydrothorax, cholestasis, rickets, hypothalamic hypo-
thyroidism with low TSH and FT4, vesicoureteral reflux causing urosepsis and a non-
symptomatic cardiac ASD type II.  She developed severe intractable epilepsy and 
tetraparesis and progressive hydrocephalus requiring a ventriculo-peritoneal shunt at the 
age of 1 year. At that age, physical exam showed length at 0 SD, no psychomotor 
development, prominent forehead, deep-set eyes, short nose with hypoplastic nares, down 
turned mouth corners, pointed chin.  Abdominal ultrasound showed hepatomegaly with 
foci suspected for hepatoma. She died of progressive respiratory and heart failure during 
pneumonia at the age of 1.5 years. Brain CT at the age of 1 year showed macrocephaly with 
generalized hydrocephalus, cavum septum pellucidum and abnormal gyral pattern in the 
perisylvian regions most consistent with PMG. (Figure 2B).  Family history revealed one 
miscarriage.  
Patient 3 is a Dutch full term born girl with a birth weight of 2170 gram (- 2.5 SD), who was 
diagnosed with a large ASD, a perimembranous VSD and patent ductus arteriosus. OFC at 
the age of 1 week was 32.5 cm (-2.5 SD). Generalized hypotonia and developmental delay 
persisted after heart surgery, which justified neurological investigation. Brain MRI at the 
age of 5 months, 1 and 3 year showed prominent frontal lobes, deep sulci, delayed 
myelination of periventricular white matter, apparently normal cortical development (Fig. 
2C). Her development is severely delayed. Hypercalcemia with nephrocalcinosis and severe 
hypotonia persist at the age of 2 years, with height and OFC at 0 SD. Facial features and 
congenital anomalies suggested the diagnosis of Sotos syndrome. 
Patients 4, 5 and 6 have been clinically described by Mirzaa et al. (corresponding to LP95-
025, LR02-064 and LR04-181) as affected by MPPH. 9 
Patient 7 has been diagnosed by L.G. and W.B.D. as having features of MPPH. Clinical details 
are reported separately.11 
Patient 8 is a full term girl born with macrocephaly (OFC 41 cm) who showed squint and no 
visual awareness at the age of 3 months.  Head circumference grows along the +4 SD. A 
brain MRI at the age of 3 months showed megalencephaly with mild ventricle dilatation, 
delayed myelination, periventricular white matter loss, cavum septum pellucidum, 
frontoparietal and perisylvian polymicrogyria (Fig 2D). She did not present with 
polydactyly. The clinical and MRI findings are compatible with MPPH. 
 
Clinical and radiology data of Sotos and MPPH patients are summarized in table 1. 
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Figure 1:  
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1
 A: Pedigree of family with patient 1 (III-1) and 2 (III-2). (A) Pedigree, with two affected first cousins, 
patient 1 and 2 (filled symbols), carrying an unbalanced 46,XXder(5)t(5;20)(q35.3;q13.3) translocation. 
Black dots indicate carriers of the balanced t(5;20)(q35.2;q13.3) translocation.  
 
B 
  
B: Patient 2 at the age of 3 months [Color figure can be viewed in the online issue of the Am J Med 
Genet, available at www.interscience.wiley.com]. 
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megalencephaly, asymmetric mild dilatation of the lateral ventricles (right > left) and right 
perisylvian polymicrogyria (Figure 2A). Family history showed two miscarriages, one 
concerning an anencephalic embryo.  
Patient 2 (III-2 in Fig. 1A and B) was born to the sister of Patient 1’s mother after a 
pregnancy complicated by polyhydramnion and fetal hydrops with hydrothorax. The 
delivery in the 35th week was complicated by perinatal asphyxia, shearing of umbilical 
cord, haemorrhage and fetal shock. She was macrosomic and macrocephalic at birth 
(weight 3160 grams, +2.5 SD; OFC 38 cm, +3.5 SD). The neonatal period was complicated by 
multiorgan failure, persistent hydrothorax, cholestasis, rickets, hypothalamic hypo-
thyroidism with low TSH and FT4, vesicoureteral reflux causing urosepsis and a non-
symptomatic cardiac ASD type II.  She developed severe intractable epilepsy and 
tetraparesis and progressive hydrocephalus requiring a ventriculo-peritoneal shunt at the 
age of 1 year. At that age, physical exam showed length at 0 SD, no psychomotor 
development, prominent forehead, deep-set eyes, short nose with hypoplastic nares, down 
turned mouth corners, pointed chin.  Abdominal ultrasound showed hepatomegaly with 
foci suspected for hepatoma. She died of progressive respiratory and heart failure during 
pneumonia at the age of 1.5 years. Brain CT at the age of 1 year showed macrocephaly with 
generalized hydrocephalus, cavum septum pellucidum and abnormal gyral pattern in the 
perisylvian regions most consistent with PMG. (Figure 2B).  Family history revealed one 
miscarriage.  
Patient 3 is a Dutch full term born girl with a birth weight of 2170 gram (- 2.5 SD), who was 
diagnosed with a large ASD, a perimembranous VSD and patent ductus arteriosus. OFC at 
the age of 1 week was 32.5 cm (-2.5 SD). Generalized hypotonia and developmental delay 
persisted after heart surgery, which justified neurological investigation. Brain MRI at the 
age of 5 months, 1 and 3 year showed prominent frontal lobes, deep sulci, delayed 
myelination of periventricular white matter, apparently normal cortical development (Fig. 
2C). Her development is severely delayed. Hypercalcemia with nephrocalcinosis and severe 
hypotonia persist at the age of 2 years, with height and OFC at 0 SD. Facial features and 
congenital anomalies suggested the diagnosis of Sotos syndrome. 
Patients 4, 5 and 6 have been clinically described by Mirzaa et al. (corresponding to LP95-
025, LR02-064 and LR04-181) as affected by MPPH. 9 
Patient 7 has been diagnosed by L.G. and W.B.D. as having features of MPPH. Clinical details 
are reported separately.11 
Patient 8 is a full term girl born with macrocephaly (OFC 41 cm) who showed squint and no 
visual awareness at the age of 3 months.  Head circumference grows along the +4 SD. A 
brain MRI at the age of 3 months showed megalencephaly with mild ventricle dilatation, 
delayed myelination, periventricular white matter loss, cavum septum pellucidum, 
frontoparietal and perisylvian polymicrogyria (Fig 2D). She did not present with 
polydactyly. The clinical and MRI findings are compatible with MPPH. 
 
Clinical and radiology data of Sotos and MPPH patients are summarized in table 1. 
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 A: Pedigree of family with patient 1 (III-1) and 2 (III-2). (A) Pedigree, with two affected first cousins, 
patient 1 and 2 (filled symbols), carrying an unbalanced 46,XXder(5)t(5;20)(q35.3;q13.3) translocation. 
Black dots indicate carriers of the balanced t(5;20)(q35.2;q13.3) translocation.  
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B: Patient 2 at the age of 3 months [Color figure can be viewed in the online issue of the Am J Med 
Genet, available at www.interscience.wiley.com]. 
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Figure 2: Brain imaging. (A) T1 weighted axial brain MRI of patient 1 at the age of 2 years showing 
asymmetry of lateral ventricles with right-sided porencephalic cystic dilatation and perisylvian 
polymicrogyria (arrows). (B) Brain CT scan of patient 2 at the age of 1.5 years showing hydrocephalus 
and bilateral wide sylvian fissures and cortical anomaly compatible with perisylvian polymicrogyria. (C) 
T1 weighted axial brain MRI of patient 3 at the age of 3 years, showing prominent frontal lobes and no 
polymicrogyria. (D) T2 weighted axial brain MRI of patient 8 at the age of 3 months, showing enlarged 
lateral ventricles and bilateral cortical polymicrogyria most prominent in perisylvian areas. 
 
METHODS 
Karyotyping and MLPA 
Standard G banding karyotyping was performed in all patients. A subtelomeric MLPA to detect 
chromosomal imbalances using DNA from patient 1 and 2 was performed using the P036 and P070 kits 
(MRC-Holland, Amsterdam, The Netherlands). 
 
FISH analysis 
Fish analysis was performed in patients III-1, III-2, and their relatives and pt 3. The BAC clones used were 
all selected from the University of California Santa Cruz UCSC browser. The clones were purchased from 
BACPAC Resources. DNA was semi-automatically isolated with a AutoGenPrep 3000 robot (Autogen, 
Holliston, MA), after a whole genome amplification (WGA) (Repli-g kit Qiagen Benelux BV, The 
Netherlands), the DNA was digested and labelled with Bio-16-dUTP or dig -11-dUTP by a Random Prime 
labelling system (Invitrogen, Carlsbad, CA). Before use the probes were validated on metaphase cells 
from a healthy person to confirm their cytogenetic location. The FISH experiments were performed 
according to standard protocols with minor modifications. FISH slides were analysed with an Axioplan 2 
Imaging microscope (Zeiss, Sliedrecht, The Netherlands), images were captured using the fluorescent 
software Isis (MetaSystems, Altlussheim, Germany). Names and location of the BAC clones from 5pter: 
RP1-24H17; 5p13.2: RP11-253B9; 5qter: RP11- 1240G13; NSD specific 5q35.3 probes: RP1-118M12 and 
RP11-47L17; 20pter: RP5-1061L1; 20qter: RP1-81F12. 
 
SNP-array analysis 
Whole genome analysis was performed by microarray analysis using Affymetrix GeneChip 50 and 250K 
arrays. The assays were carried out according to the standard protocol. Briefly, 250 ng of total genomic 
DNA was digested with either HindIII (50K) or NspI (250K). Appropriate adaptors were ligated to the four 
base-pair overhang of the DNA fragments. A single primer was used for amplification and PCR products 
were purified. After fragmentation with DNAse I, products were labeled with biotin and hybridized to 
the array. The arrays were washed and stained with streptavidin-phycoerythrin in the Affymetrix 
fluidics station 450 and scanned in the GeneChip Scanner 3000 G7. The images of the scans were 
collected and intensities measured in the Affymetrix GeneChip operating Software (GCOS). Genotype 
data analysis was performed in Affymetrix GeneChip Genotyping analysis software (GTYPE) using the 
Dynamic Model algorithm (DM) for 50K analysis and the BRLMM algorithm for 250K analysis. 
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Copy Number analysis 
Copy number analysis was performed on the allele intensities of each SNP by using the software 
package: Copy Number Analyzer for Affymetrix GeneChip (CNAG version 3.0, Nannya et al, Cancer Res. 
2005 Jul 15;65(14):6071-9). For real-time PCR, primers and sequence analysis see supporting 
information Supplementary Methods which may be found in the online issue of the Am J Med Genet, 
available at www.interscience.wiley.com. 
 
 
Table 1: Clinical and MRI findings of MPPH and Sotos syndrome patients. 
Patient 
with Sotos 
or MPPH 
Laboratory 
diagnosis 
Brain MRI  (age) Clinical presentation Reference 
Patient 1 
MPPH 
del Megalencephaly, wide ventricles, 
unilateral perisylvian 
polymicrogyria 
Macrocephaly, PMR, epilepsy, 
spastic tetraparesis, postaxial 
polydactyly right foot, VUR, 
hypothyroidism, rickets, ASD II 
This report 
Patient 2 
MPPH 
del  Megalencephaly, hydrocephalus, 
abnormal perisylvian gyral pattern 
on CT, cavum septum pellucidum 
Macrocephaly, macrosomia, 
profound PMR, epilepsy, spastic 
tetraparesis, no polydactyly, 
hypothyroidism, hepatoma, 
cholestasis, VUR, ASD II 
This report 
Patient 4 
MPPH 
- Asymmetric megalencephaly, 
bilateral perisylvian PMG, short 
CC, hydrocephalus 
Macrocephaly, profound MR, 
seizures, spastic quadriplegia; no 
polydactyly 
LP95-025 
in ref. 9 
Patient 5 
MPPH 
 
- Megalencephaly, bilateral 
perisylvian PMG, hydrocephalus, 
enlarged LV 
Macrocephaly, profound 
MR; postaxial polydactyly 4 limbs 
LR02-064 
in ref. 9 
Patient 6 
MPPH 
 
- Symmetric megalencephaly, 
perisylvian PMG, hydrocephalus 
Macrocephaly, profound 
MR, seizures, hypotonia, 
polydactyly 4 limbs 
LR01-181 
in ref. 9 
Patient 7 
MPPH 
 
- Symmetric megalencephaly, 
perisylvian PMG, hydrocephalus 
Macrocephaly, large 
fontanel, hypertelorism, 
depressed nasal bridge; postaxial 
polydactyly 3 limbs 
Ref. 11 
Patient 8 
MPPH 
 
- megalencephaly, bilateral 
frontoparietal PMG, delayed 
myelination 
Macrocephaly at birth, squint, no 
visual awareness 
at 3 months 
This report 
Sotos 1 
(patient 3 
in text) 
del Dolichocephalic skull, prominent 
frontal lobes (8 m) 
Severe PMR, hypotonia This report 
Sotos 2 mut Prominent perivascular spaces, 
cerebellar arachnoidal cyst (11y) 
Motor delay This report 
Sotos 3 mut Cavum septum pellucidum, 
ventriculomegaly (5 y) 
PMR, epilepsy from 2 yr This report 
Sotos 4 mut Cavum septum pellucidum, 
prominent perivascular spaces (3 
y) 
Mild PMR This report 
Sotos 5 mut Ventriculomegaly, cerebellar 
arachnoidal cyst (3 y) 
Behavioral problem, mild LD This report 
Sotos 6 mut Ventriculomegaly (5 m) PMR and hypotonia at age 5 m This report 
Sotos 7 mut Ventriculomegaly, thin corpus 
callosum, diffuse atrophy, 
prominent frontal lobes (1.5 y) 
PMR, intrauterine asphyxia, 
neonatal hypoglycaemia 
This report 
Sotos 8 mut Ventriculomegaly, thick corpus 
callosum (7 months) 
VSD, West syndrome, 
moderate PMR 
This report 
Sotos 9 del Ventriculomegaly, diffuse atrophy 
(1 y) 
Moderate PMR Patient 8 in 
ref.23 
Sotos 10 mut Ventriculomegaly, diffuse atrophy, 
gliosis of WM (8 y) 
Mild PMR, mild hemiplegia This report 
PMR= psychomotor retardation, LD= learning disability, WM= white matter, del = NSD1 microdeletion by FISH, mut= 
intragenic mutation NSD1, y=year 
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Figure 2: Brain imaging. (A) T1 weighted axial brain MRI of patient 1 at the age of 2 years showing 
asymmetry of lateral ventricles with right-sided porencephalic cystic dilatation and perisylvian 
polymicrogyria (arrows). (B) Brain CT scan of patient 2 at the age of 1.5 years showing hydrocephalus 
and bilateral wide sylvian fissures and cortical anomaly compatible with perisylvian polymicrogyria. (C) 
T1 weighted axial brain MRI of patient 3 at the age of 3 years, showing prominent frontal lobes and no 
polymicrogyria. (D) T2 weighted axial brain MRI of patient 8 at the age of 3 months, showing enlarged 
lateral ventricles and bilateral cortical polymicrogyria most prominent in perisylvian areas. 
 
METHODS 
Karyotyping and MLPA 
Standard G banding karyotyping was performed in all patients. A subtelomeric MLPA to detect 
chromosomal imbalances using DNA from patient 1 and 2 was performed using the P036 and P070 kits 
(MRC-Holland, Amsterdam, The Netherlands). 
 
FISH analysis 
Fish analysis was performed in patients III-1, III-2, and their relatives and pt 3. The BAC clones used were 
all selected from the University of California Santa Cruz UCSC browser. The clones were purchased from 
BACPAC Resources. DNA was semi-automatically isolated with a AutoGenPrep 3000 robot (Autogen, 
Holliston, MA), after a whole genome amplification (WGA) (Repli-g kit Qiagen Benelux BV, The 
Netherlands), the DNA was digested and labelled with Bio-16-dUTP or dig -11-dUTP by a Random Prime 
labelling system (Invitrogen, Carlsbad, CA). Before use the probes were validated on metaphase cells 
from a healthy person to confirm their cytogenetic location. The FISH experiments were performed 
according to standard protocols with minor modifications. FISH slides were analysed with an Axioplan 2 
Imaging microscope (Zeiss, Sliedrecht, The Netherlands), images were captured using the fluorescent 
software Isis (MetaSystems, Altlussheim, Germany). Names and location of the BAC clones from 5pter: 
RP1-24H17; 5p13.2: RP11-253B9; 5qter: RP11- 1240G13; NSD specific 5q35.3 probes: RP1-118M12 and 
RP11-47L17; 20pter: RP5-1061L1; 20qter: RP1-81F12. 
 
SNP-array analysis 
Whole genome analysis was performed by microarray analysis using Affymetrix GeneChip 50 and 250K 
arrays. The assays were carried out according to the standard protocol. Briefly, 250 ng of total genomic 
DNA was digested with either HindIII (50K) or NspI (250K). Appropriate adaptors were ligated to the four 
base-pair overhang of the DNA fragments. A single primer was used for amplification and PCR products 
were purified. After fragmentation with DNAse I, products were labeled with biotin and hybridized to 
the array. The arrays were washed and stained with streptavidin-phycoerythrin in the Affymetrix 
fluidics station 450 and scanned in the GeneChip Scanner 3000 G7. The images of the scans were 
collected and intensities measured in the Affymetrix GeneChip operating Software (GCOS). Genotype 
data analysis was performed in Affymetrix GeneChip Genotyping analysis software (GTYPE) using the 
Dynamic Model algorithm (DM) for 50K analysis and the BRLMM algorithm for 250K analysis. 
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Copy Number analysis 
Copy number analysis was performed on the allele intensities of each SNP by using the software 
package: Copy Number Analyzer for Affymetrix GeneChip (CNAG version 3.0, Nannya et al, Cancer Res. 
2005 Jul 15;65(14):6071-9). For real-time PCR, primers and sequence analysis see supporting 
information Supplementary Methods which may be found in the online issue of the Am J Med Genet, 
available at www.interscience.wiley.com. 
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with Sotos 
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Laboratory 
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Patient 1 
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del Megalencephaly, wide ventricles, 
unilateral perisylvian 
polymicrogyria 
Macrocephaly, PMR, epilepsy, 
spastic tetraparesis, postaxial 
polydactyly right foot, VUR, 
hypothyroidism, rickets, ASD II 
This report 
Patient 2 
MPPH 
del  Megalencephaly, hydrocephalus, 
abnormal perisylvian gyral pattern 
on CT, cavum septum pellucidum 
Macrocephaly, macrosomia, 
profound PMR, epilepsy, spastic 
tetraparesis, no polydactyly, 
hypothyroidism, hepatoma, 
cholestasis, VUR, ASD II 
This report 
Patient 4 
MPPH 
- Asymmetric megalencephaly, 
bilateral perisylvian PMG, short 
CC, hydrocephalus 
Macrocephaly, profound MR, 
seizures, spastic quadriplegia; no 
polydactyly 
LP95-025 
in ref. 9 
Patient 5 
MPPH 
 
- Megalencephaly, bilateral 
perisylvian PMG, hydrocephalus, 
enlarged LV 
Macrocephaly, profound 
MR; postaxial polydactyly 4 limbs 
LR02-064 
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Patient 6 
MPPH 
 
- Symmetric megalencephaly, 
perisylvian PMG, hydrocephalus 
Macrocephaly, profound 
MR, seizures, hypotonia, 
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LR01-181 
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Macrocephaly, large 
fontanel, hypertelorism, 
depressed nasal bridge; postaxial 
polydactyly 3 limbs 
Ref. 11 
Patient 8 
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- megalencephaly, bilateral 
frontoparietal PMG, delayed 
myelination 
Macrocephaly at birth, squint, no 
visual awareness 
at 3 months 
This report 
Sotos 1 
(patient 3 
in text) 
del Dolichocephalic skull, prominent 
frontal lobes (8 m) 
Severe PMR, hypotonia This report 
Sotos 2 mut Prominent perivascular spaces, 
cerebellar arachnoidal cyst (11y) 
Motor delay This report 
Sotos 3 mut Cavum septum pellucidum, 
ventriculomegaly (5 y) 
PMR, epilepsy from 2 yr This report 
Sotos 4 mut Cavum septum pellucidum, 
prominent perivascular spaces (3 
y) 
Mild PMR This report 
Sotos 5 mut Ventriculomegaly, cerebellar 
arachnoidal cyst (3 y) 
Behavioral problem, mild LD This report 
Sotos 6 mut Ventriculomegaly (5 m) PMR and hypotonia at age 5 m This report 
Sotos 7 mut Ventriculomegaly, thin corpus 
callosum, diffuse atrophy, 
prominent frontal lobes (1.5 y) 
PMR, intrauterine asphyxia, 
neonatal hypoglycaemia 
This report 
Sotos 8 mut Ventriculomegaly, thick corpus 
callosum (7 months) 
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RESULTS 
Cytogenetic, MLPA and FISH analysis 
Standard G banding chromosome investigation (550 bands) was normal in all patients. 
MLPA analysis with subtelomere probe kits in patients III-1 and III-2 and their mothers II-2  
and II-3, respectively, revealed a loss of signal at the subtelomeric region of chromosome 
5q35 and a gain of signal for chromosome 20q13 only for the patients III-1 and III-2. FISH 
analysis was performed with chromosome 5qter and 5pter BAC probes, probes specific for 
the NSD1 locus on chromosome 5q35.3 and chromosome 20 probes. Results confirmed an 
unbalanced translocation in both patients III-1 and III-2 resulting in the karyotype 
46,XX,der(5)t(5;20)(q35.2;q13.3). Further FISH analysis with probes on chromosomes 5q and 
20 q revealed a balanced t(5;20)(q35.2;q13.3) translocation in both mothers II-1 and II-3 of 
patient III-1 and III-2, respectively, and the grandfather I-1. Targeted FISH analysis of the 
sporadic patient 3, performed in the suspicion of Sotos syndrome, showed a microdeletion 
with the NSD1-specific probe RP11-47L17.  
 
SNP array analysis 
To define the deletion breakpoints in patient 1 and to investigate the genome of patients 3-
8 for chromosomal abnormalities, DNA of these patients was hybridized on either 100K or 
250K SNP arrays (Affymetrix). Patient 1 showed a 5.7 Mb terminal deletion on chromosome 
5q35.2-qter. The proximal deletion breakpoint on chromosome 5q35.2 is rs11953281, as 
indicated by copy number analysis (CNAG).16 The breakpoint, confirmed by Q-PCR analysis 
is between the genes LOC645398 (present) and DRD1 (absent). In addition, an amplification 
of 8 Mb was seen for chromosome 20q13.3-qter. Copy number analysis indicated rs4811719 
as the proximal SNP bordering the amplification, present in 2 copies, and rs6014787 as the 
first SNP present in 3 copies. The breakpoint was confirmed by Q-PCR between 
LOC100131175 (2 copies) and the TFAP2C gene.  
 
Comparison with other 5q35.3 microdeletion patients 
Many of the symptoms of patients 1 and 2 resembled Sotos syndrome, however 
overgrowth was not evident in patient 1 and the phenotype was much more severe. 
Therefore we also studied in detail the genotype of patient 3 with a similarly severe 
phenotype and lack of overgrowth. Japanese Sotos microdeletion patients have been 
described with broader and more severe phenotypic abnormalities than Caucasian 
microdeletions.17,18,19 SNP array analysis for patient 3 showed an interstitial 5q35.3 deletion 
spanning about 2 Mb, between rs9313730 and rs11745917, involving about 60 genes. This 
deletion is within the common microdeletion range of Caucasian Sotos patients.20,21 The 
most proximally deleted gene in patient 3 is THOC3 and the most distally (telomeric) 
located is LOC653314. We have aligned the deletions in our patients 1-3 with the 
chromosome 5q deletions spanning the NSD1 locus fine mapped by FISH, as reported by 
Tatton-Brown et al. and deletions mapped by QMPSF by Saugier-Veber et al.20,21 All the 
described patients were diagnosed with Sotos syndrome, including patient COG025 Tatton-
Brown et al., whose deletion extends until 5qter.20 Two other patients, COG231 and 
COG342, have the largest reported deletions extending on the proximal site and overlap 
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with our patients 1 and 2 (Fig. 4B).20 However, the most proximal probe (SOT21) used for 
the COG231 and COG342 patients gives uninformative results, possibly excluding FLJ16171 
and DRD1 from the deleted area. Patients 14 and 15 from Saugier-Veber et al. also have 
unusually large deletions.21 Here the breakpoint is somewhere between the FLJ16171 and 
SFXN1 genes, also giving inconclusive results for DRD1. Clinical details in both studies from 
Tatton-Brown et al. and Saugier-Veber et al. did not include MRI findings of the patients 
but the general conclusion was that, except for a more common deep learning disability 
and lack of overgrowth, the microdeletion patients presented with the same features of the 
patients with NSD1 mutation.20,21 In the five unrelated MPPH patients 4-8, SNP array 
analysis did not reveal pathogenic rearrangements. DNA of patients 4,5,6 and 8 was 
analysed by 100K SNP array, of patient 7 by 250K SNP array. Assuming that the MPPH 
phenotype of our patients 1 and 2 could be (in part) related to a larger 5q35 deletion than 
previously described in Sotos patients we tested DRD1 as a possible candidate and 
sequenced it in MPPH patients 4-8. No mutations were found. 
 
Review of brain imaging in Sotos syndrome 
Sotos syndrome has not been previously associated with polymicrogyria. After the 
observation of polymicrogyria in patients 1 and 2 we reviewed brain MRIs of 10 Sotos 
patients with intragenic NSD1 mutations and/or microdeletions detected by FISH, 
diagnosed in our and other academic centers, including patients with a more severe 
phenotype like our patient 3 and the patient 8 described by Sogaard et al.23 Almost 
constant MRI findings were megalencephaly with prominent frontal lobes, wide lateral 
ventricles, cavum septum pellucidum and wide Virchow-Robin perivascular spaces. In 
none typical polymicrogyria was observed (Table 1). We therefore conclude that PMG does 
not belong to the phenotype of Sotos syndrome. 
 
DISCUSSION 
We describe two first cousins, with a submicroscopic deletion of a 5.7 Mb region on 
chromosome 5q35.2-qter, including the NSD1 locus and an 8 Mb 20q13.3-qter 
amplification, as the result of a derivative chromosome 5 of a familial balanced 
translocation t(5;20)(q35.2;q13.3). Development and head circumference of the relatives 
bearing the balanced translocation are normal. The features of our patients overlap with 
the recently described MPPH syndrome, including the polydactyly in patient 1 and 
perisylvian polymicrogyria on brain MRI of both patients.9 No patients with chromosomal 
rearrangements at 5q and 20q have been described with these features.  
Macrocephaly with megalencephaly and mild enlargement of the cerebral ventricles is 
typical of Sotos syndrome. Patients with large telomeric deletions of chromosome 5q35 
including NSD1 seem, with some exception, to be severely affected, but no brain MRI has 
been reported.24-27 We reviewed the brain MRI of our patient 3, the patient 8 of Sogaard et 
al. and eight other molecularly confirmed Sotos patients and consistently observed 
megalencephaly, mostly of frontal lobes, with apparently normal cortex, enlarged 
ventricles but no signs of high pressure hydrocephalus (Table 1).23 Therefore we conclude 
that PMG and high-pressure hydrocephalus are not part of the Sotos phenotype and the 
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MPPH-like features of patients 1 and 2 are probably not caused by NSD1 
haploinsufficiency. Rare deletions distal to and excluding the NSD1 locus have been 
associated with a relatively mild clinical phenotype, but systematic analysis of the 
neuroimaging of the patients has not been reported.24,28 
The deletion breakpoint of the patients 1 and 2 on chromosome 5 was mapped between 
the gene of unknown function FLJ16171 (present) and DRD1 (deleted) and it is to our 
knowledge the largest microdeletion in the 5q35.2qter area. In- or exclusion of DRD1 in 
areas of other Sotos microdeletion patients was not clear from literature data; therefore we 
tested DRD1 as a candidate for MPPH, but found no mutation in 5 unrelated MPPH 
patients. Nagai et al. reported severe phenotypic abnormalities in Japanese patients with 
microdeletions at the NSD1 locus, including cardiac, urinary and endocrine problems 
compared to patients with intragenic NSD1 mutations.17 This genotype-phenotype 
correlation, although less evident, was also confirmed in Caucasian Sotos patients.22 Low 
copy repeats (LCRs) have been considered responsible for non-allelic homologous 
recombination (NHAR) as a mechanism causing the microdeletion, supporting the 
definition of Sotos syndrome as a genomic disorder.29 In the 5q35 area however, different 
mechanisms seem to be responsible for NAHR. LCRs (SoSPREP and SoSDREP) at 5q35.3 
define the recurrent 1.9 Mb deletion in Sotos patients.30 However, atypical shorter non-
recurrent deletions have been described, and in some of these Alu-mediated NAHR is 
suggested.18,19,20 In addition in the 5q35.1 area the contribution of highly homologous LINE 
elements seems to be responsible for induction of NAHR.31     
In unbalanced translocations, the general assumption is that developmental defects are 
mostly the result of genetic haploinsufficiency. In a large series of over 5000 patients with 
developmental defects much fewer pathogenic microduplications than microdeletions 
have been detected.32 In our patients 1 and 2, however, the 20q13.3-qter amplification 
could also contribute to the phenotypic abnormalities. 
The amplification breakpoint on chromosome 20q13.3 of patient 1 and 2 was mapped 
between LOC388799 (2 copies) and the known gene TFAP2C (3 copies).  Previously reported 
chromosome 20q amplifications are much larger than in our patients, being 20q11.2-qter 
and 20q13.1-qter.32,33,34  Most of these are not pure trisomies, but are combined with 
complex rearrangements.35 Most common features in these patients are brachycephaly, 
bulging forehead, deep-set eyes, short nose, large ears, dimpled chin, heart defects, 
hydrocephalus, cortical atrophy, cerebellar atrophy and phenotypes vary from mildly to 
severely affected.33,34,36,37 Some of these features are easily recognizable in our patients 1 
and 2. A submicroscopic 20q13.1-qter duplication, extending 1Mb proximally of our 
patients’ duplication, was recently reported in a patient with mental retardation, without 
clinical detail.38  
The chromosome 20q13 area contains some genes subjected to genomic imprinting.39 The 
best known is GNAS1, involved in the pathogenesis of Albright osteodystrophy.40 It is not 
clear whether the extra maternal chromosome 20q13 material in our patients contributes 
to some of their phenotypic manifestations through imbalances in the imprinted GNAS 
cluster.41 Paternally inherited deletions at the 20q13.3 locus including GNAS have been 
associated with major phenotypic abnormalities, suggesting that, besides the GNAS cluster, 
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also other genes like i.e. TF2PC might influence imbalances between maternal and paternal 
alleles.42 
MPPH syndrome has been described so far in sporadic patients, therefore it is considered to 
result from de novo dominant mutations. We show MPPH-like features in two patients 
with a 5q35.3 deletion and 20q13.3 trisomy, but we excluded submicroscopic 
rearrangements in 5 typical MPPH patients. Our findings support the hypothesis that 
MPPH is a heterogeneous disorder, with more mechanisms involved in its pathogenesis, 
some of which are apparently linked to the rearrangements of genes at terminal regions of 
chromosome 5q and 20q.15 We therefore advise high-resolution microarray analysis in the 
workup of patients with MPPH. 
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GENERAL DISCUSSION 
 
Malformations of cortical development (MCD) are a group of disorders characterized by a 
congenital abnormal structure of the cerebral cortex. These MCD include different 
structural abnormalities, and they have a diverse array of causes, both genetic and 
environmental. Although different subgroups of MCD are rare or very rare, MCDs as a 
group are responsible for significant morbidity in psychomotor developmental delay and 
epilepsy. For example, up to 20% of children with intractable epilepsy are found to have an 
MCD. Improved neuroimaging and genetic laboratory techniques have revealed new 
information on patterns and causes of MCD. Unfortunately, the underlying cause often still 
remains elusive and specific treatments are not available. 
 
The primary aim of this thesis was to study patients with malformations of cortical 
development to determine if a multidisciplinary approach including clinical and imaging 
classification of the malformation combined with available diagnostic laboratory 
techniques, would lead to an increase of etiological diagnoses, improvements in 
description of the phenotypes, and recognition of ‘new’ syndromes. We expect that a 
multidisciplinary approach will improve the diagnostic process in these patients, and can 
also improve care and treatment. Here I will also make recommendations regarding the 
best care for these patients based on our findings regarding neuroimaging, clinical 
observation and genetic testing. 
 
Neuroimaging 
The diagnosis of MCD begins with imaging of the brain with MRI. A clinically useful 
classification should therefore be based on neuroimaging characteristics and lead to 
recommendations for additional diagnostic testing. Information on sex, dysmorphological 
information (e.g. microcephaly) or other clinical features that can be directly observed from 
the patient should also be incorporated in this system. The currently most used 
classification system for MCD is the Barkovich classification updated in 2005.1 This 
classification is based on the proposed underlying disturbance of normal developmental 
processes, and uses a mix of morphological (e.g. lissencephaly) and etiological categories 
(e.g. specific gene mutations). This makes it difficult to classify and compare patients 
before all genetic tests are done, and we found that not all patients fit into defined 
categories (chapter 2).2 Also, it results in changes in the classification system as new 
underlying mechanisms are found, but also when new phenotypes are found to be 
associated with known causes. For example the 22q11 microdeletion is classified as a 
subgroup of bilateral perisylvian PMG, while we have since found that it can also be found 
in unilateral PMG.3,4 Although the Barkovich classification is the best available, in a next 
revision morphological classification and genetic classification could be more clearly 
separated. 
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During our studies we learned that a detailed MRI classification should lead the choice for 
additional metabolic or genetic tests (chapter 2).2,3 Many genetic and metabolic tests are 
labour-intensive and time-consuming, but also very expensive. As basing tests on faulty 
information obviously does not lead to the desired result, MRI reports should be as up-to-
date as possible. In reevaluation of older MRIs by our multidisciplinary team 
(neuroradiologist, pediatric neurologist and clinical geneticist) we found the original 
radiological diagnosis regularly to be incorrect (chapter 2).2 Even MRIs reported in the 
literature should be evaluated critically. 3 
 
Using MRI scanners with a higher resolution (Tesla values) and more advanced software 
settings (e.g. scans based on the diffusivity of water molecules) differences in MCD can be 
visualized more accurately. For example, it can be difficult to distinguish polymicrogyria 
and cobblestone malformation on MRI and more detailed imaging may improve 
understanding of these malformations.5 Possibly, in the future molecular neuroimaging 
with targeted contrast agents can further improve the accuracy of neuro-imaging, be it 
with MRI, PET scan or otherwise.6,7,8 
Besides creating more detailed MRI images, recognition of MCD may also be improved by 
computerized pattern recognition. Such computerized recognition is for example already 
widely used in ECG reading, but its application in brain imaging will be more challenging 
due to the facts that MRIs cannot easily be made in exactly the same position at different 
instances, that the appearance of the brain changes with age, and that different types of 
artifacts are often present. Obviously, to obtain good quality images the patient needs to 
lie still in the scanner. This is difficult in the case of children or patients with cognitive 
impairment or psychiatric disorders, making it necessary to use general anesthesia.  
Different protocols can be chosen to make MRI images, each aimed at visualizing specific 
pathologies or specific parts of the brain. If a MCD is not expected beforehand, the image 
may not be ideal to classify the malformation or small abnormalities may be missed. In our 
cohort, classification was sometimes difficult due to suboptimal imaging and repeat MRIs 
are not always feasible considering the burden of the general anesthesia, costs and waiting 
lists (chapter 3.1). Also, the MRI aspect of the brain changes considerably during the first 
two years of life due to myelination making it difficult to compare scans of different 
patients or of the same patient made at different ages. We recommend repeating an MRI 
after the age of 18-24 months, if the diagnosis of a possible MCD is uncertain in an infant. 
 
Clinical observations 
To make a diagnosis of MCD, neuroimaging information needs to be combined with 
observations on neurological deficits, psychomotor development, epilepsy, dysmorphic 
clinical features, other congenital anomalies and growth pattern. Pattern recognition can 
lead to a syndrome diagnosis relatively quickly.9 Description of clinical features is also 
important when the underlying cause of a specific subgroup of MCD has been discovered, 
to determine the extent and variation of the phenotype. Firstly, in the case of a genetic 
cause, this enables to determine genotype-phenotype relationships and what the in- and 
exclusion criteria for a genetic test should be. Secondly, this knowledge improves the 
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GENERAL DISCUSSION 
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To make a diagnosis of MCD, neuroimaging information needs to be combined with 
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lead to a syndrome diagnosis relatively quickly.9 Description of clinical features is also 
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information we give patients and parents on prognosis and it can also improve genetic 
counseling as to what recurrence risk parents may expect for their next child. Many 
examples of the use of clinical observations can be found in this thesis. We reported that 
epilepsy or congenital microcephaly are not always present in ARFGEF2 mutations, but 
that a combination of a movement disorder based on basal ganglia abnormalities 
combined with periventricular nodular heterotopia should also prompt DNA testing of this 
gene (chapter 4.1).10 We showed that there is a wide variability in the phenotype of 
patients with FLNA-gene related periventricular nodular heterotopia and that epilepsy is 
not obligatory (chapter 3.2 and 3.3).11 We reported that the brain phenotype of the rare 
malonyl-CoA decarboxylase deficiency can include pachygyria and periventricular nodular 
heterotopia (chapter 5).12 We showed that the combination of microcephaly with 
simplified gyral pattern and early onset diabetes can be seen in mutations of EIF2AK3, but 
also that this phenotypic syndrome is genetically heterogeneous and that more genes 
must be involved to explain a similar phenotype seen in other patients (chapter 4.2).13 
Further research in these patients is ongoing. 
If the underlying cause cannot be determined, groups of patients with similar features that 
probably share a common cause can be identified, and new syndromes can be delineated. 
Identifying new syndromes is the first step to enable further genetic research into its 
cause. We described, for example, a group of unrelated patients that shared a similar MCD 
combined with similar defect of their hands and feet (chapter 6.1).14 
 
Genetic tests 
In our studies we showed that we are able to make an etiological diagnosis in almost half 
of the patients, using current standard techniques, however in a minority this includes a 
molecularly established diagnosis, e.g. by a metabolic or genetic test.2 A molecularly 
confirmed diagnosis enables physicians to give parents the best possible answer on 
questions regarding the cause of the problems of their child, his or her prognosis, and what 
the recurrence risk is in the family. We also noted that genetic causes seem to be more 
common than non-genetic causes and care should be taken not to attribute the MCD too 
easily to problems during the pregnancy. This may result in an incorrect estimate of the 
recurrence risk. For example in our cohort, the periventricular nodular heterotopia of a 
particular child were thought to be caused by maternal cocaine abuse during pregnancy, 
but further testing based on the specific MRI pattern revealed a pathogenic FLNA mutation 
(chapter 2).2 On a higher level, molecularly confirmed diagnoses will help physicians and 
scientists to understand the underlying problems and search for the best possible 
treatments.  
With the advance of genetic laboratory techniques, more genetic abnormalities will be 
detected. An important recent new option is whole genome analysis using the microarray 
technique that allows detection of small chromosomal deletions or duplications (copy 
number variations). This will improve the yield of diagnoses, also in our cohort 
(unpublished data). It also comes with new challenges, as it is not always apparent what 
the meaning of the found abnormalities is or what the relationship is to the signs and 
symptoms of the patient. 15 
General discussion 
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In the near future new technologies will become available that enable testing of several 
genes in one patient in a relatively short time by targeted arrays and resequencing chips. 
This also includes techniques allowing sequencing of the whole genome in each patient. It 
will make genetic tests less time consuming and more cost-effective. MCD classification 
will not become obsolete however, not only with respect to choosing the appropriate gene 
chip, but mostly to interpreting the enormous bulk of genomic data from an individual 
patient. The interpretation of this data will require the integration of knowledge in 
different fields, ideally expanded into a systems biology approach.  
 
For the time being, if a MCD patient has a phenotype not directly suggesting the 
involvement of a known gene, but a genetic cause is likely due to the family history or due 
to the presence of multiple congenital anomalies and/or dysmorphic features, the genetic 
cause can be difficult to find. Only very rarely a MCD is found in several patients over 
different generations in a family tree, making the traditional approach of linkage not 
feasible. Using homozygosity mapping from genomic microarray data (usually SNP-based 
arrays), can allow locus identification in smaller consanguineous families.16 Information 
on submicroscopic copy number variations found by array techniques in different patients 
with similar phenotypes may be combined to find new loci. In a family with two first 
cousins with perisylvian polymicrogyria we found an unbalanced der(5)t(5;20) 
(q35.2;q13.3) translocation by array technique (chapter 6.2).17 As both these girls show a 
phenotype similar to the MPPH-syndrome (megalencephaly, perisylvian polymicrogyria, 
polydactyly and hydrocephalus) our findings suggest that the underlying genetic cause for 
this syndrome may be found in the affected chromosome regions of our patients(chapter 
6.2).17 We were unable to confirm this, and such findings may remain unique for one 
family. Alternatively, this might indicate that the MPPH-syndrome is not an homogeneous 
disorder but rather an expression of different disease mechanisms.18 
When a possible chromosomal locus is identified by any of the above described techniques, 
candidate genes can be more easily identified by using knowledge of the underlying 
defective mechanism or pathway in different MCD, combined with knowledge of the 
pathways involved and information on possibly involved genes available from animal 
studies.  
 
Some important pathways in MCD are: 
 Cell proliferation; in patients with microcephaly with simplified gyral pattern 
mutations have been detected in genes involved in mitosis and mitotic spindle 
integrity (see appendix). These patients have a relatively mild neurological phenotype 
with mental retardation. Patients with similar neuroimaging but severe mental 
retardation, epilepsy, and early death have been found to have mutation in genes 
involved in apoptosis or DNA repair (see appendix and chapter 4.2). 
 Microtubules, the cytoskeleton and the microtubule organizing center; the most common 
genes found in lissencephaly, subcortical band heterotopia and nodular heterotopia: 
LIS1, DCX, FLNA and TUBA1A, encode proteins involved in the function of microtubules 
and the cytoskeleton. 
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questions regarding the cause of the problems of their child, his or her prognosis, and what 
the recurrence risk is in the family. We also noted that genetic causes seem to be more 
common than non-genetic causes and care should be taken not to attribute the MCD too 
easily to problems during the pregnancy. This may result in an incorrect estimate of the 
recurrence risk. For example in our cohort, the periventricular nodular heterotopia of a 
particular child were thought to be caused by maternal cocaine abuse during pregnancy, 
but further testing based on the specific MRI pattern revealed a pathogenic FLNA mutation 
(chapter 2).2 On a higher level, molecularly confirmed diagnoses will help physicians and 
scientists to understand the underlying problems and search for the best possible 
treatments.  
With the advance of genetic laboratory techniques, more genetic abnormalities will be 
detected. An important recent new option is whole genome analysis using the microarray 
technique that allows detection of small chromosomal deletions or duplications (copy 
number variations). This will improve the yield of diagnoses, also in our cohort 
(unpublished data). It also comes with new challenges, as it is not always apparent what 
the meaning of the found abnormalities is or what the relationship is to the signs and 
symptoms of the patient. 15 
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patient. The interpretation of this data will require the integration of knowledge in 
different fields, ideally expanded into a systems biology approach.  
 
For the time being, if a MCD patient has a phenotype not directly suggesting the 
involvement of a known gene, but a genetic cause is likely due to the family history or due 
to the presence of multiple congenital anomalies and/or dysmorphic features, the genetic 
cause can be difficult to find. Only very rarely a MCD is found in several patients over 
different generations in a family tree, making the traditional approach of linkage not 
feasible. Using homozygosity mapping from genomic microarray data (usually SNP-based 
arrays), can allow locus identification in smaller consanguineous families.16 Information 
on submicroscopic copy number variations found by array techniques in different patients 
with similar phenotypes may be combined to find new loci. In a family with two first 
cousins with perisylvian polymicrogyria we found an unbalanced der(5)t(5;20) 
(q35.2;q13.3) translocation by array technique (chapter 6.2).17 As both these girls show a 
phenotype similar to the MPPH-syndrome (megalencephaly, perisylvian polymicrogyria, 
polydactyly and hydrocephalus) our findings suggest that the underlying genetic cause for 
this syndrome may be found in the affected chromosome regions of our patients(chapter 
6.2).17 We were unable to confirm this, and such findings may remain unique for one 
family. Alternatively, this might indicate that the MPPH-syndrome is not an homogeneous 
disorder but rather an expression of different disease mechanisms.18 
When a possible chromosomal locus is identified by any of the above described techniques, 
candidate genes can be more easily identified by using knowledge of the underlying 
defective mechanism or pathway in different MCD, combined with knowledge of the 
pathways involved and information on possibly involved genes available from animal 
studies.  
 
Some important pathways in MCD are: 
 Cell proliferation; in patients with microcephaly with simplified gyral pattern 
mutations have been detected in genes involved in mitosis and mitotic spindle 
integrity (see appendix). These patients have a relatively mild neurological phenotype 
with mental retardation. Patients with similar neuroimaging but severe mental 
retardation, epilepsy, and early death have been found to have mutation in genes 
involved in apoptosis or DNA repair (see appendix and chapter 4.2). 
 Microtubules, the cytoskeleton and the microtubule organizing center; the most common 
genes found in lissencephaly, subcortical band heterotopia and nodular heterotopia: 
LIS1, DCX, FLNA and TUBA1A, encode proteins involved in the function of microtubules 
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 Signaling molecules that direct migrating neurons; Reelin acts as a signal to stop 
migrating neurons through binding to receptors on their surface. Mutations can result 
in lissencephaly with cerebellar and brainstem hypoplasia. A receptor for Reelin is 
encoded by VLDRL, and mutations in this gene result in a similar phenotype. 
 Glycosylation of alpha-dystroglycan; the genes, Fukutin, FKRP, POMT1, POMT2, and 
POMGnT1, harbor mutations in most patients with cobblestone lissencephaly  and 
encode proteins involved in glycosylation of transmembrane and extracellular matrix 
molecules (see appendix). Problems in the integrity of the basement membranes allow 
migrating neurons to pass beyond the pial membrane and settle within the meningeal 
space. 
 Transcription factors; TBR2 and ARX encode transcription factors and mutations can be 
found in some patients with polymicrogyria and lissencephaly respectively. ARX 
specifically regulate migration of inhibitory GABAergic neurons, but the target genes 
and mechanisms are still largely elusive. 
 Endosomal vesicle transport; ARFGEF2 and RAB3GAP1 are associated with nodular 
heterotopia and polymicrogyria. They both encode proteins involved with the trans-
Golgi network and vesicle trafficking to the plasma membrane.  
 
Coordination of care and treatment of MCD patients 
To be able to find the underlying cause of the MCD in a greater number of patients and to 
improve information on prognosis and care, it is necessary to carefully examine the 
patient from different angles. The patient group is heterogeneous and variable. For 
recognition and classification of the malformations, a multidisciplinary team offers the 
best setting with collaboration between an experienced neuroradiologist, pediatric 
neurologist, and clinical geneticist. As MCD subtypes are rare, follow-up of patients would 
ideally be coordinated in a few specialized centers or shared by a group of physicians 
specifically interested in this patient category. Personal and shared experience improves 
the quality of the observations. Recognition of rare phenotypes or syndromes depends on 
seeing a large number of patients, and both national and international collaboration is 
important to collect sufficient information to delineate new syndromes, find new genes 
and reliably describe genotype-phenotype relationships. 
 
Although MCDs are a developmental malformation of the cerebral cortex, and therefore 
already present at birth, the signs and symptoms of the condition evolve during life. 
Information on the course of the disorder will help to make rational choices in treatment 
options regarding rehabilitation, epilepsy, cognitive development and behavioral 
problems. Prognosis with regard to psychomotor development is variable, and likely 
dependent on the MCD-subtype and extent of cortical development.2 For example, by long 
term follow-up of children with type 1 lissencephaly we have improved the accuracy of the 
information we are able to give parents about the condition of their child and have shown 
that survival is correlated to the severity of the lissencephaly (chapter 3.1). Epilepsy is a 
common complication of MCD, and in some subgroups, e.g. cortical dysplasia, epilepsy 
General discussion 
163 
surgery can be a good treatment option. This makes an early and accurate diagnosis more 
valuable.  
 
New treatments might be targeted against complications of the MCD (e.g. epilepsy) or 
against the underlying defect (pathway dysfunction in the cell). Of course, anatomical 
abnormalities of the cerebral cortex in MCD cannot be corrected, so therapy aimed at the 
underlying defect would only be potentially beneficial if the target pathway also has a 
function in postnatal brain function. More in general on treatment, new options can arise 
from observation of patients or through understanding of the underlying mechanism of 
disease. Observation of a large number of patients, experience with different treatment 
options and trial-and-error, enable a clinician to recognize what might be promising 
treatments. These should then be tested in a clinical trial to confirm the usefulness of such 
a treatment. We know from observation, for example, that in the treatment of seizures 
caused by Tuberous Sclerosis Complex some anti-epileptic drugs are more likely to be 
successful than others (vigabatrin in this case) and this was confirmed in clinical studies.19 
Something similar may well be the case for other cerebral malformations. Another 
example is treatment of patients with cerebral palsy with a specific form of rehabilitation 
therapy that includes constraint of the ‘good arm’, which shows promising effect in clinical 
trials and can even induce a change in cortical function on fMRI.20,21 
Understanding of the underlying mechanism of disease is emerging from the laboratory, 
but in medicine, and pediatric neurology in particular, treatment advances are lagging 
behind the discovery of genes and pathways responsible for the hereditary diseases and 
congenital anomalies. Over the last years, insight in the underlying mechanism of 
particular diseases has resulted in improved treatment in some patients with inborn errors 
of metabolism (notably enzyme replacement therapy in, e.g., Pompe’s disease). Other 
treatments based on influencing the underlying mechanism of disease are expected to 
come in the near future (e.g. influencing gene expression by exon skipping therapy in 
muscular dystrophies). An example in MCD is again found in Tuberous Sclerosis Complex, 
where treatment with drugs targeted against the underlying pathway dysfunction shows 
promising results.22,23 Hopefully, this type of insight may also lead to therapies preventing 
the occurrence of intractable epilepsy (anti-epileptogenic therapy), and to treatments that 
may improve cognitive defects in specific syndromes. The basis of these advances lies in 
translational research, and bridging the gap between the basic sciences and the bedside 
will further benefit patients and their parents in the future. 
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information we are able to give parents about the condition of their child and have shown 
that survival is correlated to the severity of the lissencephaly (chapter 3.1). Epilepsy is a 
common complication of MCD, and in some subgroups, e.g. cortical dysplasia, epilepsy 
General discussion 
163 
surgery can be a good treatment option. This makes an early and accurate diagnosis more 
valuable.  
 
New treatments might be targeted against complications of the MCD (e.g. epilepsy) or 
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abnormalities of the cerebral cortex in MCD cannot be corrected, so therapy aimed at the 
underlying defect would only be potentially beneficial if the target pathway also has a 
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caused by Tuberous Sclerosis Complex some anti-epileptic drugs are more likely to be 
successful than others (vigabatrin in this case) and this was confirmed in clinical studies.19 
Something similar may well be the case for other cerebral malformations. Another 
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therapy that includes constraint of the ‘good arm’, which shows promising effect in clinical 
trials and can even induce a change in cortical function on fMRI.20,21 
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promising results.22,23 Hopefully, this type of insight may also lead to therapies preventing 
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SUMMARY 
 
In chapter 1, the introduction, the current state of knowledge regarding clinical features, 
neuroimaging characteristics, pathology and causes of malformations of cortical 
development (MCD) is summarized. 
 
Chapter 2 describes the consecutive cohort of 113 patients with MCD we investigated from 
1992 to 2006. By combining clinical, radiological, and genetic classification; syndrome 
identification, and family studies with diagnostic molecular testing an etiological 
diagnosis could be made in 40% of the cases of MCD. This contributes to genetic counseling, 
to the possibility of prenatal diagnosis and improved patient treatment and disease 
management. We established an etiological diagnosis in 45 of 113 cases (40%). For 21 
patients (19%), this included molecular and/or genetic confirmation (Miller-Dieker 
syndrome; LIS1, DCX, FLNA, EIF2AK3 or KIAA1279 mutations; or an inborn error of 
metabolism). In 17 patients (15%), a syndrome with an unknown genetic defect was 
diagnosed. In 7 patients (6%), we found evidence of a gestational insult. Of the remaining 
68 patients, 34 probably have a yet-unknown genetic disorder based on the presence of 
multiple congenital anomalies (15 patients), a family history with multiple affected 
persons (12 patients), or consanguineous parents (7 patients). 
 
The next chapters are based on specific observations of patients we investigated from the 
cohort and additional patients that were seen from 2006 to 2009. 
 
Chapter 3 is focused on the natural history of patients with MCD with a known genetic 
cause. In chapter 3.1 we describe the long term follow-up of a cohort of 24 patients with 
lissencephaly type 1 that were born the Netherland from 1972-1990. We reclassified the 
lissencephaly according to current views, and contacted these patients and their parents. 
We found that 19 of 24 patients were alive, which was longer than any of the parents had 
originally been told. Survival showed a significant relationship with the severity of the 
lissencephaly on neuroimaging. All patients showed severe mental retardation, intractable 
epilepsy and complete dependence on care. Molecular analysis of the LIS1-gene was not 
possible at the time of the original study and was now requested by 8 parents. This 
revealed a pathogenic mutation or large deletion of LIS1 in 7 patients. 
In chapters 3.2 and 3.3 we focus on patients with FLNA related periventricular nodular 
heterotopia. First we describe a 71-year-old woman, who was known to have heart valve 
disease and bilateral periventricular nodular heterotopia when she died of a subarachnoid 
haemorrhage. Autopsy showed typical cerebral bilateral periventricular heterotopia and 
vascular abnormalities. Postmortally, the diagnosis of a FLNA mutation was confirmed. It is 
surprising that our patient never had seizures. It was already known that the phenotype 
associated with FLNA mutations include cardiac malformations, particularly aortic or 
mitral valve disease. We showed that other vascular abnormalities, including aneurysms, 
can be seen in these patients. We also confirmed the presences of glomeruloid 
microvascular anomalies in the brain, which had been described once before in a FLNA 
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patient. Recognition during life may have prevented cardiovascular problems and provided 
possibilities for genetic counseling. In the second part we further investigated the cardiac 
phenotype in our FLNA patients and found that these patients often present to a 
cardiologist first. A positive family history, skin of joint hyperlaxity or neurological 
problems may prompt earlier recognition. 
 
Chapter 4 is concerned with new phenotypes associated with known genes. In chapter 4.1 
we report a girl with bilateral periventricular nodular heterotopia (BPNH) based on 
compound heterozygosity for two ARFGEF2 mutations, the first reported patient since the 
discovery of the gene. This patient had a marked severe choreadystonic movement 
disorder, which was a new finding changing the limited knowledge about the phenotype. 
The brain MRI shows bilateral hyperintensity of the putamen, BPNH, and generalized 
atrophy. Loss of ARFGEF2 function affects vesicle trafficking, proliferation/apoptosis, and 
neurotransmitter receptor function. This could explain BPNH and microcephaly. 
We hypothesized that the movement disorder and the preferential damage to the basal 
ganglia, specifically to the putamen, was caused by an increased sensitivity to 
degeneration, a dynamic dysfunction due to neurotransmitter receptor mislocalization or a 
combination of both. In chapter 4.2 we describe two families with a child with 
microcephaly with a simplified gyral pattern of the brain (SGP) and early onset insulin 
dependent diabetes mellitus (IDDM). The first patient was diagnosed with Wolcott–
Rallison syndrome, and a homozygous mutation in the EIF2AK3 gene was found. The 
patient from the second family had no mutation in this gene. SGP is considered to arise 
from decreased neuronal proliferation or increased apoptosis at an early stage of 
embryonic development, but insight into the pathways involved is minimal. EIF2AK3 is 
one of the kinases involved in inhibition of protein translation under cell stress conditions. 
It has been proposed that loss of function mutations reduce the ability of the cell to 
respond to endoplasmic reticulum stress, resulting in apoptosis of pancreatic Langerhans 
cells. Our findings suggest that in some cases, early onset IDDM and SGP can arise from 
common mechanisms leading to increased apoptosis. 
 
In chapter 5 we report a girl with malonyl-CoA decarboxylase deficiency, a rare inborn 
error of metabolism, with diffuse pachygyria and periventricular heterotopia. 
 
Chapter 6 is focused on syndromes that can be clinically delineated in the cohort of MCD 
patients. In chapter 6.1 we describe the association between periventricular nodular 
heterotopia and transverse limb deficiency in three patients with a variable severity of the 
clinical and neuroradiological phenotype. These patients can be classified as having 
amniotic band sequence or Adams-Oliver syndrome (AOS), but there was no gene 
associated with this disorder. We hypothesized that this combination should be considered 
one syndrome, and suggested the involvement of vascular developmental pathways based 
on what is known about limb deficiency and PNH caused by mutations in known genes. In 
chapter 6.2 we present two first cousins with a similar phenotype to the megalencephaly, 
perisylvian polymicrogyria, polydactyly and hydrocephalus (MPPH) syndrome. They both 
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had a submicroscopic chromosome 5q35 deletion as a result of an unbalanced 
der(5)t(5;20)(q35.2;q13.3) translocation. Five unrelated MPPH patients showed no 
submicroscopic chromosomal aberrations, indicating that this disorder is heterogeneous, 
but we conclude that a high-resolution array analysis should be part of the diagnostic 
workup for a patient with MPPH syndrome. 
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SAMENVATTING 
 
In hoofdstuk 1, de introductie, wordt een samenvatting gegeven van de huidige kennis 
over de klinische verschijnselen, beeldvormende technieken, pathologie en oorzaken van 
aanlegstoornissen van de hersenschors.  
 
Hoofdstuk 2 beschrijft een cohort van 113 opeenvolgende patiënten met een aanleg-
stoornis van de hersenschors die onderzocht werden tussen 1992 en 2006. Door gegevens 
te combineren over de klinische verschijnselen, de beeldvorming van de hersenen, 
genetische classificatie, syndroom diagnoses en familie onderzoek met diagnostische 
moleculaire testen bleek het mogelijk om in 40% van de patiënten met een aanlegstoornis 
van de hersenschors een etiologische diagnose te stellen. Dit draagt bij aan 
erfelijkheidsvoorlichting, aan de mogelijkheid van prenatale diagnostiek en geeft een 
verbetering van behandeling van en zorg voor deze patiëntengroep. We stelden een 
etiologische diagnose in 45 van 113 casus (40%). Bij 21 patiënten (19%) betekende dit een 
moleculaire of genetisch bevestigde diagnose (Miller-Dieker syndroom, mutaties in LIS1, 
DCX, FLNA, EIF2AK3 of KIAA1279 of een erfelijke stofwisselingsziekte). Bij 17 (15%) was dit 
een syndroom diagnose, waarvan de onderliggende genetische oorzaak onbekend is. Bij 7 
patiënten (6%) vonden we aanwijzingen voor een prenatale gebeurtenis die een 
aanlegstoornis kan veroorzaken. Van de overgebleven 68 patiënten hebben 34 patiënten 
waarschijnlijk een tot nu toe onbekende genetische aandoening, gezien de aanwezigheid 
van multipele aangeboren afwijkingen (15 patiënten), een familie anamnese met 
meerdere aangedane personen of ouders die bloedverwant zijn (7 patiënten). 
 
De volgende hoofdstukken zijn gebaseerd op specifieke observaties van patiënten uit het 
bovengenoemde cohort en patiënten die we zagen van 2006 tot 2009. 
 
Hoofdstuk 3 gaat over het natuurlijk beloop van patiënten met een aanlegstoornis van de 
hersenschors met een bekende genetische oorzaak. In hoofdstuk 3.1 beschrijven we de 
lange termijn follow-up van een cohort van 24 patiënten met type 1 lissencephalie die in 
Nederland geboren werden tussen 1972 en 1990. We herclassificeerden de lissencephalie 
naar huidige inzichten en probeerden de patiënten en hun ouders opnieuw te bereiken. 
Van de 24 patiënten bleken er 19 nog in leven. Dit is een langere levensverwachting dan 
dat de ouders oorspronkelijk was verteld. De overleving toonde een significante correlatie 
met de ernst van de lissencephalie op de CT-scan. Alle patiënten hadden een ernstige 
mentale retardatie, moeilijk behandelbare epilepsie en volledige afhankelijkheid voor de 
functies van het dagelijks leven. In de tijd dat bij deze patiënten de diagnose gesteld werd, 
was moleculaire analyse van het LIS1 gen nog niet mogelijk en 8 ouders wilden dit 
onderzoek nu alsnog laten doen. Dit toonde bij 7 patiënten een pathogene mutatie in het 
LIS1 gen of een deletie van (een deel van) dit gen.  
 
De hoofdstukken 3.2 en 3.3 zijn gericht op patiënten met periventriculaire nodulaire 
heterotopieën ten gevolge van afwijkingen in het FLNA gen. Eerst beschrijven we een 71-
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aanlegstoornissen van de hersenschors.  
 
Hoofdstuk 2 beschrijft een cohort van 113 opeenvolgende patiënten met een aanleg-
stoornis van de hersenschors die onderzocht werden tussen 1992 en 2006. Door gegevens 
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meerdere aangedane personen of ouders die bloedverwant zijn (7 patiënten). 
 
De volgende hoofdstukken zijn gebaseerd op specifieke observaties van patiënten uit het 
bovengenoemde cohort en patiënten die we zagen van 2006 tot 2009. 
 
Hoofdstuk 3 gaat over het natuurlijk beloop van patiënten met een aanlegstoornis van de 
hersenschors met een bekende genetische oorzaak. In hoofdstuk 3.1 beschrijven we de 
lange termijn follow-up van een cohort van 24 patiënten met type 1 lissencephalie die in 
Nederland geboren werden tussen 1972 en 1990. We herclassificeerden de lissencephalie 
naar huidige inzichten en probeerden de patiënten en hun ouders opnieuw te bereiken. 
Van de 24 patiënten bleken er 19 nog in leven. Dit is een langere levensverwachting dan 
dat de ouders oorspronkelijk was verteld. De overleving toonde een significante correlatie 
met de ernst van de lissencephalie op de CT-scan. Alle patiënten hadden een ernstige 
mentale retardatie, moeilijk behandelbare epilepsie en volledige afhankelijkheid voor de 
functies van het dagelijks leven. In de tijd dat bij deze patiënten de diagnose gesteld werd, 
was moleculaire analyse van het LIS1 gen nog niet mogelijk en 8 ouders wilden dit 
onderzoek nu alsnog laten doen. Dit toonde bij 7 patiënten een pathogene mutatie in het 
LIS1 gen of een deletie van (een deel van) dit gen.  
 
De hoofdstukken 3.2 en 3.3 zijn gericht op patiënten met periventriculaire nodulaire 
heterotopieën ten gevolge van afwijkingen in het FLNA gen. Eerst beschrijven we een 71-
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jarige vrouw die bekend was met een hartklepafwijking en bilaterale periventriculaire 
nodulaire heterotopieën toen zij overleed aan een subarachnoidale bloeding. Obductie 
toonde klassieke bilaterale periventriculaire nodulaire heterotopieën en vaatafwijkingen. 
Postmortem werd de diagnose FLNA mutatie bevestigd. Het is verrassend dat deze patiënte 
nooit epileptische aanvallen heeft gehad. Het is bekend dat bij het fenotype van FLNA 
mutaties ook hartafwijkingen horen, vooral aortaklep en mitralisklep afwijkingen. Onze 
casus liet zien dat ook andere vasculaire afwijkingen, zoals aneurysmata, gezien kunnen 
worden. We bevestigden ook de aanwezigheid van glomeruloïde microvasculaire 
afwijkingen in de hersenen die eenmaal eerder beschreven waren in een FLNA patiënt. Als 
deze genetische aandoening gedurende het leven herkend was, was er mogelijk meer 
aandacht voor het risico op cardiovasculaire problemen geweest en was er de mogelijkheid 
van erfelijkheidsvoorlichting geweest. In het derde deel van hoofdstuk 3 bekijken we het 
cardiale fenotype van onze FLNA patiënten nader en beschrijven dat deze patiënten vaak 
eerst een cardioloog bezoeken. Een positieve familie anamnese, huid- of gewrichts-
hyperlaxiteit of neurologische problemen kunnen voor de cardioloog een aanwijzing zijn 
om deze patiënten eerder te herkennen. 
 
In hoofdstuk 4 bespreken we nieuwe fenotypes bij bekende genen. In hoofdstuk 4.1 
beschrijven we een meisje met bilaterale periventriculaire nodulaire heterotopieën (BPNH) 
ten gevolge van een tweetal mutaties in het ARFGEF2 gen (compound heterozygoot). Dit is 
de eerste patiënt gerapporteerd sinds de ontdekking van dit gen. De patiënt heeft een 
opvallend ernstige choreadystone bewegingsstoornis, wat nog niet eerder beschreven was 
als onderdeel van het fenotype. De MRI van de hersenen toont beiderzijds een 
hyperintensiteit van het putamen en gegeneraliseerd verlies van hersenstof, naast de 
BPNH. Een mutatie in het ARFGEF2 gen veroorzaakt in de cel een stoornis in de functie van 
transportblaasjes, in de proliferatie en geprogrammeerde celdood en in de functie van 
receptoren voor neurotransmitters. Dit kan het optreden van BPNH en microcephalie 
verklaren. We denken dat de bewegingsstoornis en de schade aan de basale kernen, vooral 
het putamen, verklaard kan worden door een verhoogde gevoeligheid voor celafbraak, een 
stoornis in de receptoren voor neurotransmitters of een combinatie van beide. In hoofdstuk 
4.2 beschrijven we twee families met beide een kind met microcephalie met een 
vereenvoudigd gyraal patroon (‘simplified gyral pattern’: SGP) en jong ontstane insuline 
afhankelijke suikerziekte. De eerste patiënt bleek een Wolcott-Rallison syndroom te 
hebben op basis van een homozygote mutatie in het EIF2AK3 gen. De patiënt van de 
tweede familie had geen mutatie in dit gen. Men denkt dat SGP veroorzaakt wordt door 
verminderde neuronale proliferatie en toegenomen apoptose in een vroege fase van de 
embryonale ontwikkeling, maar er is weinig bekend over de betrokken processen. EIF2AK3 
is een van de kinasen die betrokken zijn bij het remmen van de eiwitaanmaak in de cel als 
de omstandigheden ongunstig zijn voor het verwerken van het eiwit. Er wordt gedacht dat 
verlies van functie van EIF2AK3 ervoor zorgt dat de cel slechter om kan gaan met 
problemen van het endoplasmatisch reticulum en dat daardoor de Langerhans cellen in de 
alvleesklier te gronde gaan. Onze casus suggereert dat in sommige gevallen, vroege 
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insuline afhankelijke suikerziekte en SGP kan ontstaan door eenzelfde mechanisme dat 
leidt tot geprogrammeerde celdood. 
 
In hoofdstuk 5 rapporteren we een meisje met een malonyl-CoA decarboxylase deficiëntie, 
een zeldzame aangeboren stofwisselingsziekte, die op MRI van de hersenen diffuse 
pachygyrie liet zien en een periventriculaire heterotopie. 
 
Hoofdstuk 6 gaat over syndromale diagnoses in ons cohort. In hoofdstuk 6.1 beschrijven 
we drie patiënten met allen een combinatie van periventriculaire nodulaire heterotopieën 
en ledemaatafwijkingen. Deze afwijkingen zijn in wisselende ernst aanwezig. De 
verschijnselen bij deze patiënten zouden zowel kunnen passen bij een amniotic band 
sequentie of Adams-Oliver syndroom, maar van deze aandoeningen is geen genetische 
oorzaak bekend. We suggereren dat op basis van algemene kennis over genetische 
oorzaken van heterotopieën en ledemaatafwijkingen dat deze combinatie een 
gezamenlijke oorzaak heeft, waarbij deze waarschijnlijk te vinden zal zijn in mechanismen 
van de bloedvatontwikkeling. 
In hoofdstuk 6.2 presenteren we twee meisjes waarvan de moeders zussen zijn, die beiden 
een fenotype hebben dat doet denken aan het MPPH syndroom ('megalencephalie, 
perisylvian polymicrogyrie, polydactylie en hydrocephalus’- syndroom). Zij hebben allebei 
een submicroscopische chromosoom 5q35 deletie door een ongebalanceerde translokatie 
der(5)t(5;20)(q35.2;q13.3). Bij 5 niet verwante MPPH patiënten konden we geen submicro-
scopische chromosomale afwijking vinden, wat betekent dat deze aandoening genetisch 
heterogeen is. We concluderen dat een chromosoom onderzoek met hoog-resolutie array 
bij patiënten met MPPH-syndroom geïndiceerd is.  
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LIST OF ABBREVIATIONS 
 
CT:  computed tomography 
FISH:  fluorescence in situ hybridization 
FLAIR:  fluid attenuated inversion recovery; type of MRI image 
MCD:  malformation of cortical development 
MRI:  magnetic resonance imaging 
MSG: microcephaly with simplified gyral pattern 
PET:  positron emission tomography 
PMG:  polymicrogyria 
PNH:  periventricular nodular heterotopia 
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LIST OF ABBREVIATIONS 
 
CT:  computed tomography 
FISH:  fluorescence in situ hybridization 
FLAIR:  fluid attenuated inversion recovery; type of MRI image 
MCD:  malformation of cortical development 
MRI:  magnetic resonance imaging 
MSG: microcephaly with simplified gyral pattern 
PET:  positron emission tomography 
PMG:  polymicrogyria 
PNH:  periventricular nodular heterotopia 
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DANKWOORD 
 
Allereerst ben ik dank verschuldigd aan mijn co-promotoren Dr. G.M.S. Mancini en Dr. I.F.M. de 
Coo. Grazia en René, de start van dit project is aan jullie te danken. Graag wil ik hier mijn 
waardering uitspreken voor jullie inspanning, deskundigheid en betrokkenheid. Veel dank voor 
de leerzame periode. Verder dank aan mijn promotoren Prof.dr. W.F.M. Arts van de 
Kinderneurologie en Prof.dr. F.G. Grosveld van de Klinische Genetica. Willem Frans, dank voor je 
betrokkenheid, bewaking van de voortgang en bereidheid toegezonden stukken van zinnig 
commentaar te voorzien. Zeker ook voor je ondersteuning van mijn vaste aanstelling in het 
Sophia Kinderziekenhuis. Aan mijn collega kinderneurologen Coriene Catsman-Berrevoets en 
Rinze Neuteboom veel dank voor jullie steun en het probleemloos overnemen van werk om me 
tijd te geven dit boekje af te ronden. 
 
Dr. D.J.J. Halley, Prof.dr. P.A.E. Sillevis Smitt en Prof.dr. D. Lindhout, dank voor het plaatsnemen in 
de leescommissie ondanks alle drukke werkzaamheden. Dicky, jouw nauwkeurige blik heeft de 
kwaliteit van meerdere hoofdstukken in dit proefschrift veel goeds gedaan. Peter, dank voor je 
inspanning om mij aan te stellen als staflid. Ik kijk uit naar de verdere samenwerking. 
 
Tijdens het onderzoek is de deskundige bijdrage van kinder(neuro-)radioloog Dr. M.H. Lequin 
onmisbaar geweest. Beste Maarten, dank voor de fijne samenwerking bij het beoordelen van alle 
beeldvorming in dit proefschrift en voor de wonderbaarlijke wijze waarop je altijd even tijd vrij 
kan maken voor overleg. 
 
Veel dank aan de deelnemende patiënten en hun ouders.  
 
Dank aan alle collega’s die patiënten naar ons verwezen. Ook aan mijn collega neurologen en 
arts-assistenten van het Erasmus MC voor de goede samenwerking. Poli-assistentes van de 
polikliniek Kinderneurologie, bedankt voor alle hulp bij het zoeken naar statussen en foto’s. 
 
Alle mede-onderzoekers uit mijn tijd op de 22e in willekeurige volgorde: Eric, Mark, Maaike, Bart, 
Marcel, Rinske, Laura, Naghmeh, Rinze, Ilse, Nadine, Heleen, Bas, Liselotte, Karin, Harro, Lisette, 
Annemarie, Mary-Lou, Alex; veel dank voor de goede sfeer en collegialiteit.  
 
Esther en Eric, dank voor het naast me willen staan vandaag. 
 
Tenslotte is het niet voor niets gebruikelijk om je ouders te bedanken. Ik ben erg blij dat jullie er 
vandaag in goede gezondheid bij aanwezig kunnen zijn om mijn promotie te vieren. 
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PhD Portfolio: summary of PhD training and teaching 
 
1. PhD training Year Workload 
(ECTS) 
General courses  
ESP03 Introduction to data-analysis 
CC02 Classical methods for data-analysis  
SNP’s and human diseases (Molmed course) 
 
2006 
2006 
2007 
 
0.9 
5.7 
1.0 
Specific courses (e.g. Research school, Medical Training) 
Biemond courses 2004, 2005, 2006, 2007, 2008, 2009 
EPNS training courses 2005, 2007, 2009 
Boerhave course on neuromuscular disorders 
Advanced Pediatric Life Support 
 
- 
- 
2007 
2008 
 
2.4 
2.1 
0.2 
1.5 
Seminars and workshops 
Voorjaarsvergadering NvKN 2005, 2006, 2007, 2008, 2009, 2010 
Werkgroep neuroneonatologie 
 
- 
2006 
 
1.0 
0.2 
Presentations 
Zellweger syndrome; voorjaarsvergadering NvKN 
Referring children for epilepsy surgery; EPNS Sweden 
Diabetes mellitus&simplified gyral pattern; voorjaarsvergadering NvKN 
Early onset diabetes mellitus and symplified gyral pattern. Doorwerth 
conference 
Genetische oorzaken van migratiestoornissen; SEIN Heemstede 
Microcephaly and simplified gyral pattern with early onset  diabetes 
mellitus; ESMRN 
Normal and abnormal cortical development; Werkgroep neuro-
neonatologie 
Cortical brain malformations; EPNS Turkey 
Long term follow up of classic lissencephaly; voorjaarsvergadering NvKN 
Migratiestoornissen door het leven heen; najaarssymposium NvKN 
 
2005 
2005 
2006 
2006 
 
2006 
2007 
 
2007 
 
2007 
2008 
2009 
 
1.0 
1.0 
1.0 
1.0 
 
1.0 
1.0 
 
1.0 
 
1.0 
1.0 
1.0 
(Inter)national conferences 
European Neurological Society, Barcelona 
EPNS Congress 2005 Göteborg Sweden, 2007 Kusadasi Turkey 
ISHN, St Andrews, Schotland  
International Doorwerth conference, UMC Radboud 
ESMRN 2004 Genoa Italy, 2007 Tübingen Germany, 2009 Zürich 
Switserland 
 
2004 
- 
2006 
2007 
- 
 
1.0 
2.0 
1.0 
1.0 
3.0 
2. Teaching 
Teacher pediatric nursing degree 2004-2008 
Cerebral cortical development for pediatricians (PAO-Sophia) 
- 
2008 
1.0 
0.5 
 
Total 
  
34.5 
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